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Abstract: The burden of cancer in the United States and abroad is comprised of 
significant morbidity, mortality, and psychological or financial harms. There remains a 
concern that the influence of published research is not maximized because of bias, lack of 
reproducibility, and suboptimal transparency. This dissertation comprises 10 
investigations of such shortcomings. As a result of these 10 studies we first found that 
oncology journal policies on reporting guidelines and trial registration could be improved 
to strengthen the transparency in published research. We found that key improvements to 
oncology interventions in trials could facilitate better translation of published results to 
daily clinical practice. An investigation of financial relationships between oncologist-
authors of influential trials and pharmaceutical drug firms uncovered pervasive, large, 
often undisclosed conflicts of interest. In a cohort of published trials, we found that 
oncologist authors misrepresented or distorted their findings to highlight favorable 
findings, even if this meant downplaying patient-centered endpoint results. We evaluated 
the potential harm from the publication of interim trial reports before patient-centered 
endpoints have accrued the necessary events to be fully powered. We reviewed a broad 
cohort of drug advertisements and found that drug firms omitted endpoints that were 
unfavorable, potentially compromising the integrity of the drug’s advertised efficacy. We 
found that noninferiority trials, which are increasingly important in oncology research, 
were poorly designed and used statistical practices which may compromise their 
robustness. We turned to systematic reviews, finding that one’s ability to reproduce the 
results of oncology meta-analyses was compromised by incomplete reporting of basic 
patient data. We found a significant risk of bias in systematic reviews cited by prominent 
cancer practice guidelines were at risk of bias. We investigated prominent cancer practice 
guidelines and found that patient values and preferences were undervalued. Altogether, 
the results of these ten studies indicate that oncology research requires a number of major 
and minor improvements to maximize its ability to work fully for the patient’s benefit.  
vi 
TABLE OF CONTENTS 
 
Chapter          Page 
 
I. INTRODUCTION ................................................................................................. 1 
 
 The Burden of Cancer ......................................................................................... 1 
 Statement of the Problem .................................................................................... 2 
 Conceptual Framework ....................................................................................... 3 
 Research Questions ............................................................................................. 4 
 Definition of Common Terms .............................................................................. 4 
 Procedures ........................................................................................................... 6 
 Significance of the Study ..................................................................................... 6 
 
II. REVIEW OF THE LITERATURE ....................................................................... 8 
  
Overview............................................................................................................. 8 
Clinical Trials ................................................................................................ 8  
 Increasing Trial Transparency ................................................................ 10 
 Audits of Trial Methods and Design....................................................... 12 
 Choosing Patient-Centered Endpoints and Outcomes ............................. 13 
 Reporting and Disclosing All Trial Information ..................................... 15 
 Summary ............................................................................................... 16 
 Systematic Reviews ..................................................................................... 16 
 Registration ........................................................................................... 17 
 Design and methods ............................................................................... 18 
 Clinical Practice Guidelines ......................................................................... 20 
 Design and Methods .............................................................................. 21 
 Bias and Reproducibility ................................................................................... 23 
 Clinical Trials .............................................................................................. 24 
 Design ................................................................................................... 24 
 Analysis and Interpretation .................................................................... 26 
 Reporting ............................................................................................... 29 
 Systematic Reviews ..................................................................................... 31 
 Design ................................................................................................... 31 
 Reporting ............................................................................................... 32 
 CPGs ........................................................................................................... 33 
 Summary ........................................................................................................... 34 
 
vii 
Chapter          Page 
 
III. ADHERENCE TO REPORTING GUIDELINES AND CLINICAL TRIAL 
REGISTRATION POLICIES IN ONCOLOGY JOURNALS: A CROSS 
SECTIONAL REVIEW .................................................................................... 35 
 
IV. TIDieR CHECKLIST EVALUATION OF CLINICAL TRIAL INTERVENTION 
REPORTING FOR RECENT FDA-APPROVED ANTICANCER 
MEDICATIONS ............................................................................................... 46 
 
V. FINANCIAL CONFLICTS OF INTEREST AMONG ONCOLOGIST 
AUTHORS OF REPORTS OF CLINICAL DRUG TRIALS ............................. 55 
 
VI. EVALUATION OF SPIN IN ONCOLOGY CLINICAL TRIALS .................... 65 
 
VII. A COMPARISON OF MATCHED INTERIM ANALYSIS PUBLICATIONS 
AND FINAL ANALYSIS PUBLICATIONS IN ONCOLOGY CLINICAL 
TRIALS ............................................................................................................ 75 
 
VIII. EVALUATION OF SELECTIVE OUTCOME REPORTING BIAS IN EFFICACY 
ENDPOINTS IN PRINT AND TELEVISION ADVERTISEMENTS FOR 
ONCOLOGY DRUGS ...................................................................................... 86 
 
IX. METHODOLOGICAL QUALITY OF ONCOLOGY NONINFERIORITY 
CLINICAL TRIALS ......................................................................................... 94 
 
X. EVALUATION OF REPRODUCIBLE RESEARCH PRACTICES IN ONCOLOGY 
SYSTEMATIC REVIEWS WITH META-ANALYSES REFERENCED BY 
NATIONAL COMPREHENSIVE CANCER NETWORK GUIDELINES .......104 
 
XI. RISK OF BIAS AND QUALITY OF REPORTING IN COLON AND RECTAL 
CANCER SYSTEMATIC REVIEWS CITED BY NATIONAL COMPREHENSIVE 
CANCER NETWORK GUIDELINES .............................................................113 
 
XII. EVALUATION OF THE NCCN GUIDELINES USING THE RIGHT 
STATEMENT AND AGREE-II INSTRUMENT: A CROSS SECTIONAL 
REVIEW ..........................................................................................................122 
 








LIST OF TABLES 
 
 
Table           Page 
 
1. Cross tabulations of oncology journals and the adherence to reporting guidelines  
and trial registration policies ................................................................................... 41 
2. Reporting of TIDieR items by included trials (n = 96)  ........................................ 51 
3. Payments to included oncologist-authors (n = 344)  ............................................. 60 
4. Characteristics of included studies and the proportion of studies with those 
characteristics that contained spin ........................................................................... 71 
5. Location, type, and frequency of spin in abstracts. Sums may exceed the total  
because some abstracts contained multiple types of spin in multiple locations ......... 72 
6. Characteristics of all interim analyses of progression-free survival (n = 33) ......... 80 
7. Characteristics of matched pairs of interim PFS and final OS analyses  
(n = 23) ................................................................................................................... 81 
8. Comparison of Hazard Ratios for PFS and OS Among Matched Pairs (n=25)...... 82 
9. Characteristics of included noninferiority trials (n = 110) .................................... 99 
10. Quality assessment of included noninferiority trials (n = 110) ..........................100 
11. Reproducible research practices of systematic reviews that underpin the National 
Comprehensive Cancer Network clinical practice guidelines for the treatment of 
cancer by site .........................................................................................................109 
12. Summary of risk of bias judgments for included systematic reviews (n = 63) ...118 
13. Adherence to RIGHT statement items overall and in each domain for all NCCN 
guidelines ...............................................................................................................127 
14. AGREE-II scores, using scaled percent adherence, in all domains and overall  
across all guidelines. ..............................................................................................129 
15. Key findings from each of the included studies for this dissertation ..................135 
16. Additional characteristics of included clinical trials. .........................................184 
17. General characteristics of systematic reviews underpinning the NCCN guidelines.185 
18. Characteristics of each index meta-analysis ......................................................186
ix 
Table           Page 
 
19. Risk of bias in all domains for individual studies ..............................................187 
20. Adherence to PRISMA items for all individual studies .....................................189 
x  
LIST OF FIGURES 
 
Figure           Page 
 
1. Study methodology for the primary and secondary objectives.............................. 37 
2. Histogram of percent of randomly sampled randomized controlled trials (RCT) that 
included a Consolidated Standards of Reporting Trials (CONSORT) flow diagram 
published in journals that adhere to the CONSORT guidelines (solid) and those that 
do not (striped) ........................................................................................................ 40 
3. Histogram of percent of randomly sampled randomized controlled trials (RCT) that 
included a trial registration number published in journals that adhere to International  
Committee of Medical Journal Editors (ICMJE) trial registration policies (solid) and 
those that do not (striped) ........................................................................................ 42 
4. Flow diagram of included and excluded studies ................................................... 49 
5. Process of identifying published clinical trials ..................................................... 57 
6. Flow diagram of included clinical trials ............................................................... 59 
7. Flow diagram of included and excluded studies ................................................... 70 
8. Flow diagram of included and excluded studies, including how studies were  
matched after initial search ...................................................................................... 78 
9. Flow diagram of included studies ........................................................................ 89 
10. Visual representation of the noninferiority margin as it relates to the expected  
effects of new treatments and active controls ........................................................... 94 
11. Flow diagram of included studies ...................................................................... 97 
12. Flow diagram of included studies .....................................................................107 
13. Comparison of reproducible research practices in systematic reviews that did  
and did not report adherence to PRISMA guidelines...............................................110 
14. Comparison of reproducible research practices in systematic reviews before  
and after uptake of PRISMA guidelines .................................................................110 







The Burden of Cancer 
 
Approximately one in two men and one in three women in the United States will 
develop some form of cancer in their lifetime1. Not all of these cancers will result in death, 
and some that may have resulted in death are able to be treated. Therefore, it is estimated 
that only one in five men and women will die as a result of cancer. Fortunately, the risk of 
death from cancer has gradually, but steadily fallen since the year 20002, which is likely 
the result of a myriad of changes to how cancer is treated, diagnosed, and prevented. 
Treatments for cancer are being approved at a rapid pace, with close to 50 new anticancer 
medications receiving Food and Drug Administration (FDA) approval each year3. Cancer 
is also being discovered more often, likely because of public health calls for increased 
cancer screening. Certain cancers, like thyroid and melanoma, which both have low 
mortality rates, affect the rate of cancer diagnosis without significantly affecting the rate 
cancer mortality, as documented by several recent studies4,5. Nonetheless, the successful 
treatment of cancer appears to be improving at a steady, consistent rate. 
 New problems in the burden of cancer are emerging as cancer treatments advance. 
In particular, a new toxicity, referred to as financial toxicity, has received recognition 
which is not the direct result of the cancer drug, nor is it listed in the FDA label. Financial 
toxicity refers to a myriad of issues related to the decreased quality of medical care related 
to financial hardship.6 These issues may manifest as the avoidance of medical care, limits 
to affordable therapies, or administration of incomplete courses of therapy. Cancer therapy 
is especially prone to financial toxicity because of the high cost and long duration of 
therapy. Many new oncology drugs are priced in the hundreds of thousands — the result 
of increased precision and thus smaller pool of patients who will receive them7. In cancer,
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however, the direct cost of a drug is not the only thing contributing to the overall cost. 
Other costs including hospital and surgical services, imaging, and radiation therapy may 
be the most expensive to patients8. New approaches to drug selection in oncology have 
included estimates of a drug’s efficacy to price ratio and increased calls to lower the direct 
costs of drugs that receive market approval9. A perfect approach has not been identified, 
and the financial burden of cancer is likely going to remain a point of discussion in decades 
to come.  
 Given the high degree of morbidity and mortality to patients with cancer, it seems 
clear that all efforts should be made to improve the treatment of cancer as quickly as 
possible. This not only includes robust funding and innovation in the treatment of cancer, 
but also improvements to the efficiency and rigor of research as it is being published. It is 
well known that all research, medical and otherwise, is prone to bias and imprecision10. It 
is fortunate that oncology is a field that is driven primarily by randomized controlled trials, 
which are often considered the most robust form of primary research11. Problems in trial 
design, translation of the findings to patient care, and reproducibility of the results are 
persistent issues which may constitute meaningful barriers to maximizing the benefit of 
research funding. These issues are central to this dissertation which comprises 10 studies 
that investigate how cancer medical research can be more rigorous and reproducible. 
 
Statement of the Problem 
 
Rigorous and reproducible medical research is a fundamental prerequisite to cancer 
treatments that improve survival and quality of life. Such evidence is vitally important 
given the significant morbidity and mortality that results from cancer every year in the 
United States1. While our understanding of cancer biology and treatment strategies has 
gradually improved, there are existing concerns about the quality of cancer medicine 
evidence12–14. These concerns are not only limited to the rationale and design of published 
research, but also apply to oncologists and drug manufacturers. To improve how cancer is 
prevented and treated moving forward, mechanisms to improve and maintain the quality 
of medical research must be implemented. A prudent starting point would be to focus on 
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the three aspects of cancer medicine evidence that exert the greatest influence on patient 
care: clinical trials, systematic reviews (SRs), and clinical practice guidelines (CPGs).  
 
Conceptual Framework for the Study 
 
The research studies described herein apply meta-research methodology. Meta-
research, also known as “research on research”, is a novel method of research that blends 
aspects of SR and observational methodology. Meta-research, as it is applied here, does 
not involved individual patients. Rather, it involves research articles, journals, practice 
guidelines, or drug advertisements. Meta-research allows one to investigate key questions 
related to how research studies are designed, conducted, reported, and shared15. The 
common goal of many meta-research studies is to improve how research results are 
translated to improve the quality of patient care. The specific procedures followed in this 
dissertation are discussed below, but in general, these procedures follow those of other 
meta-research studies: database search, article screening, data extraction, data analysis, and 
data reporting. In all cases, where feasible, the data from these studies has been made 
publicly available via the Open Science Framework (OSF), which is an online repository 
for researchers to deposit data, protocols, pre-prints (completed studies without peer 
review), and post-prints (completed studies after peer review). Such open data is consistent 
with best practices to encourage the reproducibility and rapid translation of research 
findings to clinical practice.  
Included are 10 investigations of bias, reporting, and transparency in oncology 
research studies. Five of these studies will be dedicated to clinical trials, since clinical trials 
are the most important study designs in cancer medicine for changing clinical practice. All 
FDA approvals for novel therapies must be based on at least one clinical trial. Two studies 
will be dedicated to SRs and will explore to what extent these studies are reproducible and 
transparent. One study will be dedicated to studying oncology CPGs, which are summary 
documents of all available scientific research on a given topic that are meant to guide 
patient care decisions. Two studies will be dedicated non-peer reviewed sources of 
oncology evidence: one to oncology journals and one to oncology drug advertisements. 
These last two studies gauge the extent to which oncology journals implement policies to 
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improve the quality of oncology research, and the extent to which oncology drug 




Two research questions were devised, which were purposefully broad to allow for study 
in multiple study designs and to fill gaps in knowledge in cancer research.  
 
1. To what extent is oncology cancer evidence reproducible and rigorous? 
2. What are the consequences of irreproducible or biased research?  
 
Definition of Common Terms 
  
Common terms that would otherwise be unknown to persons unfamiliar with cancer 
or medical research will be defined here. Other terms that are used in a single study or used 
sparingly in this dissertation will be defined where they are mentioned. All definitions are 
taken from the National Cancer Institute database of definitions16, unless otherwise stated. 
  
1. Clinical Trials 
a. Accelerated drug approval (AA)  
i. An official process that allows a new drug to be approved by the U.S. FDA before 
it has gone through all of the required levels of testing in humans. It is only used 
for drugs that treat serious or life-threatening diseases for which other treatments 
may not be available or may no longer be effective. A drug may be approved 
through the accelerated approval process if it has shown certain signs in clinical 
trials that it might be beneficial for patients, such as a shrinking tumor. Further 
testing of the drug is required after it has received accelerated approval and is on 
the market to confirm that it really works. 
b. Clinical Endpoints and Outcomes 
i. Overall Survival 
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1. The length of time from either the date of diagnosis or the start of treatment 
for a disease, such as cancer, that patients diagnosed with the disease are still 
alive. 
ii. Quality of life 
1. The overall enjoyment of life.  
c. Surrogate endpoints:  
i. In clinical trials, an indicator or sign used in place of another to tell if a treatment 
works. 
1. Progression-Free Survival 
a. The length of time during and after the treatment of a disease, such as 
cancer, that a patient lives with the disease but it does not get worse. 
2. Response Rate 
a. The percentage of patients whose cancer shrinks or disappears after 
treatment. 
 
SR definitions are taken from the Cochrane Handbook for Systematic Reviews of 
Interventions17, unless otherwise stated. 
 
2. Systematic Reviews 
a. PICO Question 
i. A key aspect of an SR that includes the Population(s), Intervention(s), 
Comparator(s), and Outcome(s) that will be included. Helpful in structuring the 
SR and increasing the SR findings to clinical practice. 
b. Meta-analysis 
i. An overall statistic (together with its confidence interval) that summarizes the 
effectiveness of an experimental intervention compared with a comparator 
intervention 
c. Heterogeneity 
i. Any kind of variability among studies in a systematic review, including clinical, 




 No unique definitions for CPGs are necessary and an overview of CPGs will be 




In general, each investigation in this dissertation will adhere to the following structure: 
 
1. Database search: We search PubMed (which includes MEDLINE) over a pre-specified 
time, usually 3-5 years, for articles published in oncology medical journals. Journals are 
selected from Google Scholar metrics, wherein articles are ranked by h5-index, which is a 
measure of citation rates of published articles over 5 years. The Google Scholar h5-index, 
while not perfect, is a better measure of overall journal popularity and influence of public 
articles. It improves upon Impact Factor ratings because all published articles are included 
in the h5-index. 
2. Article screening: All articles retrieved from the database search are screened by two 
investigators according to pre-specified inclusion and exclusion criteria. Each screener is 
masked to the other’s decisions, meaning each worked independently without 
collaboration, to eliminate bias. After screening, the two investigators would reconcile 
differences and achieve consensus on the cohort of included articles. Rayyan, an online 
article screening platform, was used for all screening. 
3. Data extraction: In similar fashion to article screening, two investigators would extract data 
from all included articles. Masking was maintained and discrepancies were reconciled after 
completion. We used Google Forms to extract data for most, if not all studies. 
4. Statistical analysis: For the majority of these studies, measures of central tendency and 
proportions were used to describe the data. For these analyses, Google Sheets was used. If 
more advanced statistical analysis was required, Stata 13 or 15.1 were used to analyze data.  
 
Significance of the Study 
 
It has been estimated that 75-90% of scientific research experiments are not 
reproducible, which results in tens of billions of dollars of funding in the United States 
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alone that are potentially wasteful18. Cancer medicine is one of the  highest funded, 
rapidly changing fields of medicine. A commensurate number of research studies are 
published each year19 and annual funding of cancer research is in the billions20. Whether 
or not improvements in patient care keep pace with the amount of research being 
published is contingent on multiple factors, not least of which is the quality of the 
research being published. This dissertation will study specific forms of bias that are 
common across medical research, as well as provide background information on why 
mitigating these forms of bias is important. In cancer, where patients are vulnerable and 
rely on novel and experimental therapies to save their lives, biased research design or 
outcomes could be fatal. In cancer medicine, a single clinical trial can change the 
landscape of patient care overnight. Clinical trial enrollment for cancer patients 
represents a social contract in which patients get early access to experimental therapies 
while trusting trial investigators to use their data for the common good to prevent future 
harms in other patients. If a clinical trial is not designed, reported, or interpreted in an 
unbiased manner, patient data is not used to its maximum potential and the social contract 
is breached. There is little room for error in clinical trials and all methods to understand 









 To begin, it is important to understand the background and importance of clinical 
trials, SRs, and CPGs. These types of research outputs are the subject of the majority of 
studies included in this dissertation. This overview will describe the basic function, design, 
importance, and goals of each study design. An overview of the importance of clinical 
trials, SRs, and CPGs to the advancement of cancer clinical care will be discussed. From 
there, a discussion of how bias may affect study results will be had. Within sections on 
clinical trials, SRs, and CPGs, illustrative examples of how cancer research can improve 
will be used to explain the importance of this dissertation which investigated the rigor and 




Clinical trials are fundamental to an evidence-based approach to patient care 
because many interventions have small to moderate effects sizes which may be obscured 
by chance or external factors21. The common analogy for why clinical trials are needed 
revolves around the use of a parachute when jumping out of an airplane. The risk of death 
when jumping out of an airplane is approximately 100%, with only extremely rare case 
examples of survival22. When a parachute is used, the risk of death plummets to only 1.1 
deaths in 100,000, or 0.0011%23. One does not need a clinical trial of a parachute when 
jumping out of an airplane because the effect size is very large and intuitive. However, 
there are no “parachute” interventions in medicine and a review of 80,000 medical 
practices found that only one medical intervention — extracorporeal membrane
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oxygenation in premature infants with respiratory distress — had a reliably large effect size 
on mortality, equal to an odds ratio of < 0.221. The role of a clinical trial in a medical system 
where easily identified, large effect sizes are extremely rare is plain: equalize all external 
factors to isolate a small to moderate effect size of an intervention in a given population 
under certain conditions. Clinical trials are useful in identifying interventions which 
improve patient lives one small step at a time. Well-designed clinical trials will always be 
superior forms of primary clinical research because of their ability to mitigate noise and 
identify signals.  
The major way in which clinical trials separate noise and signal is through 
randomization and blinding. Often, a trial enrolls patients according to pre-specified 
inclusion criteria. Thus, the initial cohort of patients recruited are more homogeneous 
compared to the population with the disease or condition at large. However, other, possibly 
unknown or unmeasurable, factors may still exist that may affect the results of a clinical 
trial. Randomization is an ideal method to control for these unknown or unmeasurable 
factors24. If done properly, randomization starts the trial off with groups that look alike in 
all known and unknown ways. Blinding is equally important to the rigor of a clinical trial.25 
Trial patients, investigators, or assessors may be blinded, and when all three are blinded, 
the trial is “triple-blind”. If a group is blinded, it means they are unaware of the intervention 
being received or given. Knowledge of the intervention may affect patient response, 
behavior, and attitudes toward an intervention. Similarly, investigator knowledge of an 
intervention may lead to biased assessments. This was the case in a placebo-controlled trial 
of multiple sclerosis patients, where only the unblinded investigator assessments found a 
significant effect of the intervention26. Last, when trial assessors — a third-party group 
separated from the investigators that are most often used in situations where blinding is 
impossible (e.g., intravenous vs. oral medication) — are not blinded, they may assess trial 
outcomes differently27. It may be said that randomization establishes an unbiased 
foundation for the trial, while blinding is instrumental in maintaining that foundation until 
the trial ends.  
The advantages that randomization and blinding provide for identifying small to 
moderate effect sizes interventions, and as a result clinical trials have boomed in popularity 
in the era of evidence-based medicine28. Randomization and blinding should be considered 
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the bare minimum for a clinical trial to be considered rigorous, and myriad other factors 
may affect a trial outcome10. As clinical trial popularity has increased, so has our 
expectation for their methods and reporting. Failure to employ the highest-quality methods 
may lead to results that are larger or smaller than they truly are. That is to say, every 
intervention has either no effect, positive effect, or negative effect. What is being 
determined in a clinical trial is the presence, size, and direction of the effect. Since a clinical 
trial is limited by pragmatism (e.g., limitations to the number of enrolled patients) and 
cannot precisely ascertain the truth, every clinical trial must be seen as a snapshot in time 
of an intervention’s effectiveness. The next steps in advancing clinical trials are to 
maximize their rigor and usefulness in clinical practice by proactively mitigating and 
identifying sources of bias. This will help ensure that every snapshot of an intervention is 
as accurate and truthful as possible. It has been understood that maximizing trial 
effectiveness requires 1) a mechanism to increase transparency; 2) an audit of trial methods 
and design; 3) the choice of patient-centered endpoints; and 4) reporting and disclosing all 
trial information. 
 
Increasing Trial Transparency 
  
The concept of trial registration was borne out of efforts to maximize altruism and 
trust in clinical research.29 The impetus for these efforts revolves around the fact that 
clinical research involves human participants who contribute their time and data in 
exchange for access to cutting-edge drugs and advancements in clinical care. Many in the 
scientific community see the inclusion of patients in clinical trials as a social contract: 
patients contribute their data with the understanding that their data will be used and 
reported in an ethical manner, regardless of trial results30. It is plainly understood that 
patients have a right to access and make decisions about their data, be it in a clinical trial 
or elsewhere, but individual patient data are often not available to the public or the patient 
participants31. Before trial registration, there was no way to track what clinical trials had 
been started around the world. Without a way to track which trials have been started, some 
trials that enrolled patients and that generated data may go undetected and unpublished. In 
2005, to increase transparency, promote honesty, and combat conflicts of interest in clinical 
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trials, the International Committee of Medical Journal Editors — the most widely 
recognized coalition of medical journals — declared prospective trial registration to be a 
requirement for publication moving forward.29 Following that declaration, in 2007 the 
Food and Drug Administration Amendments Act (FDAAA) made clinical trial registration 
a legal requirement for any trial that enrolled patients in the United States and tested FDA-
regulated interventions.32  
Trial registries employ a number of useful practices to monitor trial progress and 
evolution. As of 2016, there were 17 documented trial registries, some named for countries 
that founded them (e.g., Australian New Zealand Clinical Trials Registry) and some 
deliberately named to recruit an international cohort of trials (e.g., International Standard 
Randomised Controlled Trial Number registry).33 ClinicalTrials.gov (CT.gov) is the most 
popular registry, and the one most useful to discuss clinical trial features. CT.gov is a free, 
publicly-available website that houses time-stamped entries and changes to individual trial 
registrations. In CT.gov, studies are labeled as initiated, ongoing, completed, or unknown. 
Results may be posted when available. In addition, the time-stamps are attached to every 
line item, allowing the public to review a history of changes for everything from the title 
to the investigation sites to the endpoints being measured (and their order). The result is a 
database that complements official study protocols and provides a means of detecting 
where changes that result in bias may have entered a trial.  
The two goals of trial registration, as outlined by the directors of CT.gov were to 
1) “establish a publicly accessible and searchable database for disseminating a minimum 
set of structured information about all ongoing and completed trials”, and 2) “provide 
access to date-stamped protocol details throughout the study lifecycle”.33 Overall, trial 
registration has been successful at accomplishing its two key goals, but not without some 
noticeable areas in need of improvement. With respect to goal one, CT.gov houses 358,767 
individual trial registrations from all 50 states and 219 countries, as of November 2020.34 
One may search and filter by a number of pertinent clinical factors, including, but not 
limited to, disease or condition, intervention, eligibility criteria, and study locations. 
Thousands of research studies33 have been conducted that use CT.gov, either for primary 
research to audit the completeness of registration reporting35, detect bias in published 
trials36, or for inclusion of unpublished data in an SR. The administrators of CT.gov self-
12 
 
identified several areas of improvement, including incomplete registrations, unidentified 
duplicate registrations across databases, out-of-date registrations (e.g., those without 
follow up from authors), and retroactive registration after trial start, which may obscure 
early changes in trial design and blind the public to possible bias33.  
Goal two includes access to the date of trial registration broadly, and the time-
stamped primary outcome measure entries with sufficient detail to allow for detection of 
unacknowledged changes.33 This goal is vitally important to prevent two major forms of 
bias which may distort the portfolio of published research: 1) publication bias and 2) 
selective outcome reporting bias. Publication bias refers to the selective publication of 
research studies that reach favorable conclusions, typically those that are statistically 
significant. Selective outcome reporting bias refers to the selective inclusion, exclusion, 
alteration, or reordering of study endpoints, often in the pursuit of conveying favorable 
study results.  
 
Audits of Trial Methods and Design 
  
With the advent of the evidence-based medicine movement in the 1980s has come 
an emphasis to conduct meta-research. Meta-research is simple in its aims: to audit swaths 
of research to improve how we perform, communicate, verify, evaluate, and reward 
research37. Meta-research may encompass a wide range of observational, interventional, 
and theoretical designs. Some meta-research studies generate models to ask critical 
questions about the utility of popular research designs38. Some may ask whether the control 
arm in a clinical trial is considered standard of care39, since a suboptimal control arm may 
not capture the true magnitude of benefit that a novel intervention adds to a field. Another 
meta-research study may ask whether conflicts of interests are disclosed according to rules 
and policies set forth by medical journals or CPG panels40,41. Last, a meta-research study 
may evaluate the risks of bias in a cohort of research studies with common features42,43. 
Despite the diversity of meta-research studies, they all share one common goal: optimizing 
scientific research.  
 There is a strong need for meta-research in cancer. Currently, oncology research is 
being conducted at a breakneck pace unlike anything seen in history. CPGs often require 
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semi-annual updates given the number of practice-changing trials that are published44. 
However, there has been growing concern about whether the oncology community is able 
to self-police itself and reject research that is flawed or suboptimal45. It would seem that 
growing social pressure to cure cancer46, paired with the daily loss of life in an oncologist’s 
practice, and ample money from pharmaceutical companies in the form of direct payments 
to physicians41,47 has led to a low-bar for Food and Drug Administration drug approval3 
and guideline recommendations48. Oncology clinical trials often have significant 
methodological shortcomings, including inadequate use of patient crossover (when patients 
in the control arm move to the intervention arm)49, suboptimal control arms39, poor 
statistical assumptions50, misrepresenting and distorting research findings51, and biased 
interpretation of research findings52. Meta-research studies are responsible for all of these 
findings and will continue to be important to understand how best to optimize oncology 
trials in the future.  
 
Choosing Patient-Centered Endpoints and Outcomes 
  
In clinical research, the goal is not to simply conduct a study and derive an outcome 
— that outcome must mean something for patients. It is the goal of clinical research to test 
what is meaningful, not simply measurable53. Patient-centered outcomes (e.g., measured 
variables, like fatigue score) and endpoints (e.g., measured parameters, like change in 
fatigue score over 6 weeks) can be wide-ranging and are best identified using the help of 
patients and other stakeholders. The inclusion of patients into these decisions about patient-
centered endpoints has been the mission of groups such as COMET (Core Outcome 
Measures in Effectiveness Trials)54, PCORI (Patient-Centered Outcomes Research 
Institute)55, and SPOR (Strategy for Patient-Oriented Research)56. Patient-centered 
endpoints may be pragmatic, like increased exercise capacity in a patient with heart failure, 
or could be absolute, like reduction in death due to heart failure. Regardless, all patient-
centered endpoints have one thing in common: they matter to patients.  
In oncology, there are really only two endpoints that are commonly measured that 
are patient-centered: Overall Survival (OS) and Quality of Life (QoL). The rest of 
commonly measured variables in oncology trials (all defined in the Introduction), such as 
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progression-free survival (PFS), are surrogate endpoints and not wholly patient-centered. 
The main argument using surrogate endpoints is to save time in clinical trials, since often 
these endpoints can be measured before a patient dies or follows up to evaluate quality of 
life. This argument has been largely refuted, but persists nonetheless57. It has been 
suggested that slowing tumor growth, part of what is measured with PFS, is valuable to 
patients, but this has not been empirically proven. The few studies that asked patients 
whether PFS matters to them were synthesized recently and found to be significantly 
flawed, since they did not define PFS properly to patients58. PFS is a composite endpoint 
that measures the time to 1) growth of a known tumor by 20%, 2) development of new 
tumor lesions, 3) death of the patient - whichever happens first59. The first two 
measurements are measured using regular computed tomography scans in trial patients, 
with the third being assessed at regular intervals using patient follow up and contact. It can 
be theorized that growth of a tumor or development of new lesions is meaningful to 
patients, but this assumes a patent can feel their tumor grow. In many cases, the patient 
cannot tell when their tumor grows at all, which explains why lung cancer patients present 
with advanced disease so often60. In reality, the assessment of PFS is largely subjective, 
since tumors often grow before a patient dies (removing the possibility of death being the 
event of interest in PFS), and there is no evidence to suggest that 20% growth is what 
matters to patients. All of these factors notwithstanding, PFS is the most common endpoint 
that leads to FDA approval in oncology, signaling that pharmaceutical companies, trial 
authors, and regulators are content with its measurement3.  
 The use of PFS and other surrogate endpoints for drug approval is not the only 
reason why they are not patient-centered endpoints. A reasonable person may see the flaws 
with PFS measurement, for example, and still see value in it if it predicts improvement in 
patient-centered outcomes, like OS. This hypothesis has been refuted time and time again. 
In an updated SR, it was found that surrogate endpoints do not predict OS61,62 in the 
majority of cancers. Moreover, different SRs showed that surrogate endpoints do not 
predict improved QoL in cancer patients63,64. For oncology research to accurately predict 
patient outcomes in the real-world, improvements to trial design must be made, chief 




Reporting and Disclosing All Trial Information 
 
For clinical trials to maximize its effectiveness, all individual patient and aggregate 
trial-level data must be made publicly available. The reason for this is simple: the history 
of medical research has shown that conscious and unconscious bias in how data is sorted, 
analyzed, and presented may affect trial results and conclusions. Data sharing is now 
considered an ethical requirement for clinical trials by the ICMJE, similar to trial 
registration65. The ethical and pragmatic benefits of trial data sharing include improved 
accuracy of trial results66, advancements in scientific discovery via secondary analyses67, 
and accelerated scientific progress68. Beyond these commonly understood reasons, there is 
also a strong argument that the patients who contribute data to the trial are the true owners 
of the data, similar to how patients own their data in everyday clinical encounters30.  
 Previous research has suggested that clinical trial authors are willing to share trial 
data publicly, but barriers still persist that may prevent complete adherence69. These 
barriers, for example, may include fear of scrutiny from third-parties who aim to re-analyze 
study results or lack of familiarity with how data must be formatted or how to use data 
repositories. Another significant barrier is that sharing one’s data does not positively affect 
career advancement, but the uncovering of accidental (or intentional) flaws in a dataset 
may negatively affect career advancement. From the point of view of a trial author, absent 
external compulsions from a funding source or journal, there is little incentive to share 
one’s data. Overcoming these barriers requires innovative approaches, such as incentive 
programs that counteract negative pressures to sharing data70 or alterations to how 
academic advancement is achieved.  
 In oncology, the availability of data sets is complicated by the overbearing 
influence of the pharmaceutical industry in leading clinical trials. Pharmaceutical 
companies maintain proprietary control of the individual patient data that results from their 
clinical trials. The result is that data is only available upon request of the company. Despite 
endorsing a commitment to sharing anonymized individual patient data in 2014, the 
pharmaceutical industry has been found to rarely share data, due to the severe restrictions 
for which trial data may be shared31. A recent analysis of the availability of industry-
sponsored trial data found that only 9/61 (15%) identified trials were eligible for data 
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sharing two years after trial completion. The main reasons for data not being available were 
that the pharmaceutical company did not have a data sharing policy or process and that 
trials were still ongoing. These barriers signify that commitments to data sharing may be 
toothless if no consequences or incentives exist to reinforce them. 
  
Summary 
Overall, clinical trials are the best primary research method to identify which 
interventions are effective and which are not. The backbone of a rigorous clinical trial is 
randomization and blinding. Additional measures must be taken to cement trials as 
unbiased, useful research studies, however. Without transparent declaration of one's 
methods before study initiation, bias may seep in and affect results. Without choosing a 
patient-centered endpoint, the results may not matter. Finally, without publication of 
independent patient data in a public repository, results may not be completely trustworthy 




SRs are studies that aim to “synthesize all empirical evidence that fits pre-specified 
eligibility criteria in order to answer a specific research question.”17 The key feature of SRs 
that distinguish them from other forms of research are that they use systematic research 
methods, which can be accomplished by combining multiple database searches with 
reviews of the unpublished literature. The benefit of SRs is the ability to derive summary 
effects by combining all retrieved research data, and from these summary effects, identify 
more robust answers to key clinical questions. For example, the popular SR of antenatal 
corticosteroids for mothers delivering premature infants was able to empirically show that 
administration of steroids saved infant lives and did not adversely harm the mother or 
child71. Prior to the publication of this SR, there was conflicting evidence about the efficacy 
and safety to mother and child of antenatal steroids. Today, administration of antenatal 
steroids is common practice, unquestioned, and has improved outcomes for premature 
infants. This SR was so influential that it has been immortalized as the logo for the 
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Cochrane Collaboration — an international group dedicated to conducting and publishing 
high-quality SRs on key clinical topics.  
 Just as with clinical trials, the benefit of SRs may be undercut by poor methods and 
design. One may argue that biased SRs are more harmful than biased clinical trials, since 
clinical trials are a form of primary research and may represent a single data point, whereas 
SRs are designed to resolve discrepancies in primary research and derive evidence-based 
summary effects. The means by which one ensures SRs are free from bias are largely 
similar to clinical trials: transparent registration, robust design and methods, and complete 
and availability reporting of all data. This section will address these topics and provide a 




Registering an SR offers similar benefits as what were discussed in the Trial 
Registration section above. That is, prospective SR registration allows one to not only 
claim their SR idea sooner than one could if they waited to publish their paper, but it also 
provides the public a time-stamped history of changes that can improve transparency in the 
SR process. Currently, the most commonly used SR registry is PROSPERO (International 
Prospective Register of SRs)72. Despite a growing number of SRs being registered in 
PROSPERO, it was recently shown that SR registration is much less common than clinical 
trial registration, with only 15.2% of SRs included in a recent study being registered73. The 
number of SRs whose registration was not up-to-date was staggering, with 85% not 
containing up-to-date information. The best use of an SR registry includes updating the 
information as an SR evolves. It may be the case that the proposed analysis is not possible, 
due to limitations in the primary research studies or unforeseen problems by the SR authors. 
It is likely that the lack of attention that SR registration has received compared to clinical 
trial registration is the source of the underuse of registries like PROSPERO. For ICMJE-
member journals, trial registration is a condition for publication, but no such impetus exists 
for SRs29. Movements to improve the registration of SRs follow the same line of reasoning 




Design and methods 
  
One reason that SR registration is so important is because of the flexibility of the 
analyses. Statistically, SRs may be considered more complex than the average clinical trial, 
and there is a commensurate decrease in understanding of SR methods, which has 
prompted some researchers to publish step-by-step guides to understanding SR74–76. For 
those wishing to conduct an SR, it is recommended to adhere to the Cochrane Handbook 
of SRs17 when determining study methods, and the PRISMA Statement (Preferred 
Reporting Items for SRs and Meta-Analyses)77 when writing a manuscript. In basic terms, 
an SR consists of 4 sections: 1) literature search, 2) article screening, 3) data extraction, 
and 4) data analysis.  
 An SR literature search should be comprehensive and broad enough as to not miss 
any potentially relevant studies. It is recommended to search at least two different research 
databases, with the most common being PubMed (which includes MEDLINE) and 
EMBASE77. It is recommended to conduct the search with the help of a trained research 
librarian, since librarians are experts in database search syntax and optimization. In 
addition to searching at least two research databases, it is recommended to search “gray 
literature”, also known as unpublished or yet-to-be published literature, and to augment 
one’s search of the published literature by handsearching relevant medical journals or the 
citation lists of articles retrieved from the database search78. Searching gray literature 
mitigates the possibility of publication bias affecting the SR results. Publication bias occurs 
when only statistically significant results are published, which may exaggerate summary 
effects of interventions. Augmenting a search with handsearching methods mitigates the 
possibility that relevant articles are excluded because of suboptimal search terms or 
database indexing.  
 Article screening is relatively straightforward and involves at least two authors 
reviewing all articles retrieved from the literature search79. The best manner by which to 
screen articles is to keep all authors involved working separately without knowledge of the 
others’ decisions. In doing so, bias may be prevented from affecting the inclusion or 
exclusion of studies. The authors judge each article according to prespecified inclusion 
criteria, which is commonly organized in the form of a PICO (population, intervention, 
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comparator, outcome) question80. An example of a basic PICO question is randomized 
trials testing whether pembrolizumab [I] improves survival [O] compared to standard 
chemotherapy [C] in patients with lung cancer [P]. More advanced or narrow PICO 
questions are often constructed to improve the directness of an SR. A PICO question that 
is too broad may lead to unsatisfactory heterogeneity between studies. Heterogeneity is the 
degree to which patients, primary study methods, or primary study results vary from one 
other81. A heterogeneity statistic is often listed within a forest plot — the visual 
representation of meta-analytic results — and an assumption of whether heterogeneity is 
expected to exist is made prior to analysis. If heterogeneity is expected, the effects model 
for the meta-analysis may change. A balance between a PICO question that is broad and 
narrow enough to be clinically meaningful is the basis for a robust SR.  
Data extraction follows a similar method to article screening and often includes at 
least two authors working separately without knowledge of the decisions of others82. What 
data is extracted may differ from SR to SR and is based on what information is necessary 
to answer the research questions that were posed. Data extraction must be comprehensive 
to allow for robust primary, subgroup, and sensitivity analyses, while refined enough so as 
to not distract from the key questions to be answered. A basic formula that would follow 
the PICO question posed above would be to extract the number of patients, the dose and 
administration schedule of pembrolizumab, the precise standard of care administered to 
control patients, the disease severity for included patients, whether other co-interventions 
were given (e.g., other medications), the efficacy outcomes (survival), and any safety data. 
In addition to data that is extracted to answer the research question, it is highly 
recommended that SR authors assess the included studies for risks of bias that may affect 
study results. For clinical trials, the use of the Cochrane Risk of Bias version 2 tool83 is 
recommended, and for observational studies, the Risk Of Bias In Non-randomized Studies 
of Interventions tool is most appropriate84. The risk of bias of primary studies included in 
an SR may be the driver of a study’s effect and is essential for understanding the results of 
an SR.  
 SR analyses come in three major forms: primary, subgroup, and sensitivity74. SRs 
are not powered for a primary outcome like clinical trials. In other words, the ability for an 
SR to truly detect an effect of an intervention is not contingent on the accrual of patient 
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events or included studies. Rather, SRs define a primary outcome, which is akin to a 
primary question. In our PICO question above, OS would be the primary outcome and 
other outcomes, like safety analyses, would be secondary because they are more peripheral 
relative to our PICO question. Subgroup analyses divide included studies, or patients 
therein, into two or more groups to compare whether results differ. Variation in results may 
indicate that the overall effect is driven by the grouping variable that divides the cohort 
into its groups and the subgroup interaction analysis is used to statistically determine 
whether a difference exists between subgroups85. Sensitivity analyses are used to test the 
robustness of the data and are wide-ranging in their types86. The goal of a sensitivity 
analysis is to determine whether one or more studies was responsible for the SR summary 
effect. If the results of the SR are affected by a sensitivity analysis, then the overall results 
are considered fragile, unstable, and subject to question. Some common examples of 
sensitivity analyses include: removing one study at a time from the meta-analysis and re-
analyzing results, removal of studies with high risk of bias, and removing studies based on 
study design (e.g., observational studies). Altogether, primary, subgroup, and sensitivity 
analyses are crucial to understanding the degree to which results are trustworthy, reliable, 
and applicable to the entire population of patients in question.  
  
Clinical Practice Guidelines 
  
CPGs are consensus statements, developed by a group of multidisciplinary experts, 
which aim to guide healthcare practice and patient care in an evidence-based manner87. 
CPGs are often referenced by physicians seeking guidance on key aspects of patient care, 
insurance companies determining which interventions will be paid for, and patients seeking 
more information about their disease. Hundreds of CPGs exist, many of which overlap in 
their scope and topics, and are regularly updated as new evidence is published. CPGs are 
of the utmost importance to modern clinical practice, since they represent common ground 
for all stakeholders to gather and understand patient care. Because of the importance of 
CPGs, the Institute of Medicine (now the National Academy of Medicine) has published a 
lengthy document outlining best practices for CPG development and dissemination88. 
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Several key methods must be implemented to ensure that CPGs are useful and robust, 
capable of identifying the most evidence-based treatments for common diseases.  
To illustrate the extent of the problem in oncology that would have gone unnoticed 
if not for meta-research, one needs not look further than the National Comprehensive 
Cancer Network (NCCN) CPGs. The NCCN guidelines are the gold-standard for oncology 
practice in the United States, so much so that the NCCN guidelines are one of 5 
compendiums for the Centers for Medicare and Medicaid (CMS) database89. In other 
words, if the NCCN recommends a drug, CMS is obligated to pay for it. The NCCN most 
often references clinical trials as its basis for its recommendations. This system works best 
for patients if the NCCN guidelines are evidence-based and free from potential bias. There 
is strong evidence from meta-research studies that NCCN authors hold large, highly-
relevant conflicts of interest with drug manufacturers whose products are included in the 
NCCN guidelines41. There is additional evidence that rampant off-label use (i.e., non-FDA 
approved use) of drugs is recommended by NCCN authors48. That means that an oncologist 
can reasonably prescribe a drug to a patient without FDA approval and CMS, using tax 
dollars, is compelled to pay for it. Adding to all of this, the status quo of how oncologists 
are paid is by “cost-plus reimbursement” which pays oncology practices who purchase 
drugs from a manufacturer a percentage of the cost of the drug that is prescribed. This 
reimbursement procedure gives an incentive to prescribe more costly drugs90. Last, it has 
been empirically shown that when oncologists maintain conflicts of interest with a drug 
company, the oncologist is more likely to prescribe that company’s drugs and more 
expensive drugs in general91–93. None of these facts would be understood without the use 
of meta-research methods. 
 
Design and Methods 
  
The structure, methodology, and reporting of CPGs are best outlined by the 
Reporting Items for Practice Guidelines in Healthcare (RIGHT) statement94 and the 
Appraisal of Guidelines, Research and Evaluation (AGREE-II) guidelines95. RIGHT and 
AGREE-II are considered the premier sources for those seeking to conduct or evaluate 
CPGs. These two documents outline the key CPG items that need to be reported and key 
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methodological considerations that would ensure the CPG results and recommendations 
are robust. Even if these guidelines are not explicitly followed by CPG working groups, 
one may still find a high-degree of overlap between CPGs that are considered robust and 
the recommendations outlined by the RIGHT and AGREE-II documents.  
 The major reason why CPGs are considered to be the gold standard references for 
clinical practice is that they are based on an SR of the literature, evidence-based methods 
for rating the quality of evidence and applicability of interventions, and written by groups 
with access to experts in the field. The same principles apply to CPG authors that apply to 
SR authors: the best means to derive evidence-based recommendations is to use a 
systematic search of the published and unpublished literature to identify all relevant data. 
CPG development groups often have a team of librarians or search experts who conduct 
literature searches. These results are aggregated and interpreted by the clinical experts. 
These experts have a difficult task of interpreting literature that may be imprecise, indirect, 
or suffer from other risks of bias. Recall that many interventions in medicine are of small 
or modest effect sizes, which opens the possibility that favorable and unfavorable results 
for an intervention may coexist in the literature. Making sense of this tangled web of data 
is made easier using the GRADE (Grading of Recommendations, Assessment, 
Development and Evaluations) method of rating evidence96.  
 The GRADE method is simple: one starts by assuming that all data is high-quality 
and is downgraded to moderate, low, or very low levels based on key factors. These key 
factors cover a multitude of nuanced methodological shortcomings, but broadly, the 
GRADE method downgrades evidence for 1) imprecision, 2) indirectness, 3) 
inconsistency, and 4) risk of bias96. Imprecision refers to data that shows a wide range of 
variability, often due to insufficient sample size to obtain a robust result97. Indirectness 
refers to data that is somewhat relevant to the PICO question posed, but certain aspects are 
tangential98. An example of data that is indirect is a trial of a relevant intervention against 
the relevant comparator, but in a population that differs from the one of interest. 
Reasonable conclusions may be drawn about the intervention’s effectiveness based on 
clinical gestalt, but nonetheless the answer is unknown. Inconsistency refers to data sets 
that compete with one another, as in the case of two trials where one shows a significant 
effect in favor of the intervention and one shows no such effect99. Risk of bias is best 
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identified using robust tools83,84,100 mentioned in the SR section above, and may reflect a 
range of methodological flaws that can undermine trustworthy results101. Levels of 
evidence are often shown as a numerical grade - 1 for high-quality with increasing numbers 
representing a step down in methodological quality.  
 These alphabetical scores for levels of evidence are often combined with numerical 
scores for clinical recommendation grade, as is done in the European Society of Medical 
Oncology (ESMO) guidelines102. The clinical recommendation grade is essentially the 
CPG authors declaring how assured they are that a therapy or practice should be 
incorporated into clinical practice. This combination of alphanumeric scores is a shorthand 
for whether evidence is robust and whether the data indicates the practice should be 
implemented. A variety of combinations may be used, such as 1A, which indicates high-
quality evidence that an intervention should be used, and 1D which indicates high-quality 
evidence that a practice should be avoided. There is significantly more flexibility in how 
CPG authors assign clinical recommendations than in how they assign levels of evidence 
GRADE scores. CPG authors may use a combination of level of evidence, clinical gestalt, 
and patient values and preferences to justify a clinical recommendation. It goes without 
saying that the best means by which to ensure the process of deriving CPG 
recommendations is to form a multidisciplinary team of experts who are free from undue 
external influences and fully equipped to make the right recommendations. Cases where 
external influences on CPGs have occurred have been disastrous and likely resulted in 
patient harm103, especially because some prominent CPGs are used to guide insurance 
coverage and reimbursement. 
 
Bias and Reproducibility 
 
 Now that a clear understanding of the background and importance of clinical trials, 
SRs, and CPGs is understood, it is important to know what forms of bias may affect these 
three forms of research output. The rigor and reproducibility of oncology evidence is 
directly affected by suboptimal methods, interpretation, reporting, and dissemination of 
research. This section will aim to define common terms, explore consequences of various 
forms of bias, and demonstrate real-world consequences of these biases. A general 
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The most appropriate manner by which one may structure a discussion on bias in 
the design of clinical trials is via the PICO framework discussed previously. Therefore, the 
first area of interest is the Population that is enrolled in a clinical trial. Clinical trials are 
also known as “controlled trials” because of their highly rigid and structured set of rules 
and inclusion criteria. These rules and criteria are meant to reduce any noise or error in the 
measurements of the efficacy of a cancer therapy, but have led to trial populations being 
different in terms of age, gender, type and location of cancer, severity of disease, and 
postoperative treatments104–107. The criteria are also meant to increase the rate of trial 
enrollment, since younger and healthier patients are more likely to comply with cancer trial 
protocols that require regular follow up108. On the contrary, it is no surprise that the strict 
rules leading to younger and healthier patients in cancer clinical trials has led many to 
question how the trial efficacy translates to real-world effectiveness. This lack of 
translation was evident with sorafenib for the treatment of hepatocellular carcinoma after 
primary resection. In the trial, sorafenib had a 2.8-month survival advantage over placebo, 
but the patients had more vitality and earlier-stage liver disease than real world patients. In 
the follow up, propensity-score matched analysis of patients in the real-world, the effect of 
sorafenib was erased, likely because the patients who received sorafenib in the real world 
were older and sicker than the trial participant.  
With respect to cancer trial interventions, there are few questions about the dosage 
or mode of administration. A more fundamental question was recently raised about why 
certain drugs are being studied in the first place. The natural progression of a novel cancer 
therapy is to first test it in a Phase 1 trial to establish the safety and most appropriate dose, 
then move to Phase 2 where efficacy of a drug is established based on a drug’s ability to 
halt cancer growth or eradicate cancerous cells. Only after Phase 1 and 2 trials are favorable 
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drugs moved to Phase 3, where survival and quality of life are tested. A recent search of 
New England Journal of Medicine, Journal of Clinical Oncology, Lancet, and Lancet: 
Oncology — the four most prominent publishers of cancer clinical trials — found that 
“negative” Phase 3 trials of novel cancer therapies published in 2016 were not supported 
by Phase 2 evidence half of the time109. In other words, companies proceeded to Phase 3 
even if the Phase 2 data was negative or inconclusive. The result was a nonsignificant and 
unfavorable result in Phase 3. The choice to proceed to Phase 3 is postulated to be based 
on either the “sunk cost bias”,  in which companies have pursued a drug further to try and 
compensate for potential losses, or the gamesmanship of Phase 3 trials109. In particular, this 
gamesmanship takes the form of the fact that Phase 3 trials enroll more patients, and are 
therefore more statistically powerful and able to detect smaller differences than a Phase 2 
trial. So, companies may pursue Phase 3 testing knowing that a smaller difference will be 
identified and can be used to lobby for FDA approval. The overall result may be that drugs 
with clinically insignificant benefits are approved because of statistical gamesmanship, not 
the drug’s true value.  
 Oncology clinical trial control arms are a more contentious area of research. To 
understand the scope of the problem, it is important to understand how oncology trials 
function globally. The United States drug market is the most lucrative in the world110, and 
it is therefore the most sought after by for-profit companies. Demonstrating efficacy across 
the globe is important for drug approval and use in other countries. It is common for 
modern oncology trials to enroll patients globally111. Given the cost of these novel cancer 
drugs, it is unlikely that anyone that lives in a low- or middle-income country will be able 
to afford the trial drug after it is on the open market. Access to that drug for trial participants 
is clearly beneficial if the drug is effective. The caveat is that these low- and middle-income 
countries also cannot afford recently approved cancer drugs that may be standard of care 
at the time of the novel trial. That means that unless the for-profit company buys and 
donates the standard of care drug that is used as a control arm in low- and middle-income 
trial centers, those trial centers are instructed to use the best available control arm drug at 
their disposal. This was empirically studied recently and it was found that 17% of new 
FDA-approved drugs between 2013 and 2018 were based on a suboptimal control arm39. 
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The implication is that approximately 1 in 5 new drugs approved in the United States, the 
perceived efficacy may be lower than what is true.  
Finally, oncology clinical trial outcomes are the most robust source of confusion 
and bias. There are, broadly, two types of endpoints in oncology and medical research: 
clinical endpoints and surrogate endpoints. Clinical endpoints directly measure patient 
outcomes, and some examples include survival, quality of life, or major adverse cardiac 
events (in the case of cardiovascular trials). Surrogate endpoints indirectly measure clinical 
endpoints and examples include delay in tumor growth, decreased tumor burden, or 
changes in a lab value (e.g., cholesterol). Many drugs have anticancer activity, and may 
delay tumor growth or decrease tumor size, but do not improve survival. This is difficult 
to understand because many consider shrinking a tumor as a fundamentally helpful thing 
for patients. Indeed, it is when it can provide symptomatic relief to patients. However, 
many patients do not present with symptoms of their tumor being too large and causing 
pain. For example, the most common presenting symptom for lung cancer is cough112, and 
lung cancer often presents in advanced stages, sometimes with metastatic disease113. 
Surrogate endpoints that measure delay in tumor growth set arbitrary growth criteria that 
have no basis in patient symptoms, pain, or discomfort114. A delay in tumor growth may 
not be truly valuable to patients unless it corresponds with improvements in survival. As it 
turns out, repeated analyses show that such surrogate endpoints do not correlate with 
survival or quality of life, as would be expected if symptomatic relief were 
conferred61,62,115. Nonetheless, surrogate endpoints are heavily valued in oncology clinical 
trials and are most often the basis for FDA approval of novel therapies3.  
 
Analysis and Interpretation 
 
Sample size calculations are fundamental to the analysis and interpretation of a 
clinical trial. A sample size calculation consists of 3 items: the estimated effect size, the 
type 1 error rate (i.e., alpha), and the type 2 error rate (i.e., beta). The estimated effect size 
should ideally be based on previous literature and may come from an observational study, 
phase 2 trial, or any other robust piece of literature that supports the estimated effect that 
one would expect to see for the intervention. The alpha percentage is often defaulted at 0.5, 
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or 5%, to represent a one in twenty chance that the observed effect in the trial would be 
that large if the intervention were truly ineffective. In other words, imagine a trial in which 
a novel cancer therapy reduced the absolute risk of death by 20%, P = .05. Since we start 
with the null hypothesis assumption that the intervention has no effect, it would not be 
expected to show an effect that large more than 5% of the time if it were truly ineffective. 
Therefore, all else being equal, the fact that it demonstrated a large effect indicates that it 
is a truly effective drug. The type 2 error rate, or beta, is colloquially referred to as the 
“false negative rate”, or the rate at which we would fail to identify an effect that truly exists. 
Beta is important because 1 - beta gives us the study power, which is the probability that 
the study has of identifying a true effect when it exists. The effect size, alpha, and beta are 
used to generate a sample size that is necessary to conduct the trial under the statistical 
assumptions laid out.  
Modern oncology trials funded by for-profit companies have the resources to recruit 
more patients than trials of previous decades. It is well known in scientific research that a 
larger sample size is required to identify statistically significant small effect sizes. A recent 
study by Ocana and Tannock reviewed trials approved by the FDA for novel cancer 
therapies and found that in some the observed effect was smaller than the estimated effect 
in the sample size calculation. The implication is that the observed effect is smaller than 
what the authors considered clinically significant enough to include in a sample size 
calculation, yet because the observed effect was statistically significant, the trial was 
“positive”. Another paper reviewed the mean effect size of novel cancer therapies and 
found that the average cancer drug improves survival by 2.4 months116.  
 
Hazard ratios are the default effect size used in the majority of oncology clinical 
trials because hazard ratios are a measure of instantaneous risk to an individual, rather than 
an estimate of risk to a group as is seen with odds ratios. Hazard ratios neatly fit into the 
structure of oncology trials, which rely heavily on survival analyses and Kaplan-Meier 
curves. A hazard ratio is difficult to interpret and translate to clinical benefit, since it does 
not capture the overall, longitudinal risk to a patient117–119. Additionally, hazard ratios are 
calculated using models that are difficult to understand and rely on a set of assumptions 
that, when violated, render hazard ratio estimates untrustworthy. The key assumption worth 
28 
 
discussing further is the assumption that censoring of a trial participant is unrelated to the 
prognosis of that individual in the trial.  
Censoring has recently become a hot topic in oncology research. Censoring in a 
clinical trial happens when an individual experiences the outcome event or they are lost to 
follow up120. A censored participant is represented by tick marks on a survival curve. 
Imbalances in censoring may occur for multiple reasons, but the most dangerous reason is 
due to physician knowledge of the control arm patients. Some side effects in oncology are 
notably more common in some drugs or drug class than others121. If an oncologist notices 
a side effect associated with the control arm, they may heighten their clinical investigation 
of the patient leading to earlier detection of an event of interest (e.g., tumor growth) in the 
control arm. As surrogate endpoints are so popular and common, the majority of new trials 
are subjected to this bias. An empirical analysis of differential censoring found that 
censoring was more common in the control arm early in trials, which is indicative of 
heightened clinical investigation122.  
Another driver of heightened clinical investigation early in clinical trials is the fact 
that crossover is built into trial designs. Crossover occurs when a patient in one arm crosses 
over to receive the therapy from the other arm49. In oncology trials, this crossover occurs 
unidirectionally from the control arm to the intervention. Not all oncology trials are 
completely blinded, either because one arm has oral medications and the other has 
intravenous, but also because of the aforementioned common side effects in a certain class 
of drugs. A physician who knows the trial is comparing a novel immunotherapy to an older 
chemotherapy, and may not only be able to tell which therapy a patient has received, but 
also favor the novel intervention and want a patient to receive that therapy. In such cases, 
crossover may be a sought-after phenomenon by a physician. Crossover can taint the 
analysis of clinical trials because a patient is often analyzed in the group they were 
assigned, regardless of whether they crossed over123,124. So, if patients in the control arm 
are moved to the intervention, it may prolong their life and obscure the true effect of an 
intervention and result in a false-negative or diminished effect size. This crossover may be 
okay if a drug has already established its baseline efficacy in a previous trial, but many 
novel drugs, without baseline proof of efficacy allow crossover. In such cases, regulators, 
oncologists, and patients may not know the true effect size going forward. The proper and 
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improper use of crossover has been thoroughly discussed by experts in the field to provide 
a framework for future trial to follow125. 
 Last, the use of interim analyses in oncology trials may subject trials to biased 
interpretations and analysis. An interim analysis is essentially an “early look” at the trial 
data, and if the data is favorable enough, the trial may be stopped early for benefit. 
Similarly, if the data is unfavorable enough the trial may be stopped early for harm126. 
Strict statistical criteria are used to keep trials free from bias in traditional interim 
analyses127. In oncology trials interim analyses have transformed into an analysis of 
surrogate endpoint data alone. Most oncology clinical trials have 2 primary endpoints, each 
with their own sample size estimation, and enrollment occurs continuously until both 
endpoints have accrued enough events. One of these primary endpoints is a surrogate 
endpoint, for which events accrue more quickly, and the other is often OS, for which events 
accrue slowly. An oncology trial will have fully matured data for the surrogate endpoint 
months before OS, and it is common for trials of novel oncology drugs to publish the results 
of their interim analysis of surrogate endpoint data months before the OS data has fully 
accrued events. This was studied outside of oncology and it was found that the conclusions 
of interim analyses changed 21% of the time128. In oncology, there are open questions about 
whether interim results with surrogate endpoints will translate to OS benefit, and whether 





Several key reporting biases have been well documented across medical research. 
The first one worth understanding is publication bias. Publication bias occurs when trials 
that obtain unfavorable, often not statistically significant results, are published at a lower 
rate than trials that obtain favorable, often statistically significant results.129 There are two 
main drivers of publication bias — author-driven and journal driven. Author-driven 
publication bias occurs when authors are unsatisfied or uninterested in the results of their 
study and decide to not pursue publication. Journal-driven publication bias occurs when 
journals reject papers that do not include statistically significant results, perhaps because 
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these results are not attractive to readers. The effect of publication bias is a portfolio of 
published research that is overwhelmingly favorable to the intervention. The seminal paper 
on publication bias compared the portfolio of results for antidepressants in the published 
literature and FDA drug efficacy reviews, where submission of all clinical data is 
compulsory.129 Authors of this paper found 74 studies submitted to the FDA, of which 
31%, including 3,449 patients’ data, were not published in medical journals. In the 
published literature, 94% of antidepressant trials were “positive”, whereas only 51% of 
studies submitted to the FDA were “positive”. The implication is a biased portfolio of 
research available to everyday physicians and readers, and downstream effects that may 
occur when these studies are aggregated in meta-analyses or CPGs.  
Selective outcome reporting bias is another form of bias that affects the portfolio 
of medical evidence. Selective outcome reporting occurs when authors of medical research 
papers include, exclude, or change study endpoints on the basis of statistical 
significance130. There have been massive gains in the understanding and monitoring of 
selective outcome reporting bias, thanks in large part to the advent of clinical trial 
registries34, federal policy that requires prospective trial registration131, and the open data 
movement132. Without these advancements, medical research would be subjected to 
investigators’ or study sponsors’ desires to publish a positive and wholly favorable study. 
The downstream effects of selective outcome reporting bias include changes to patient care 
based on the perception of highly favorable results, exaggeration of meta-analysis effect 
sizes, and distrust of scientific research. The prevalence of selective outcome reporting bias 
has been empirically studied across medicine133–135, including hematology36 and 
oncology136. 
Spin is a subtype of selective outcome reporting bias, and is subtler and more 
subjective. Spin is defined as “use of specific reporting strategies, from whatever motive, 
to highlight that the experimental treatment is beneficial, despite a statistically 
nonsignificant difference for the primary outcome, or to distract the reader from 
statistically nonsignificant results”137. The impact of spin goes beyond medical research 
papers. Evidence of spin has been found in press releases138 and even peer review 
comments sent to the author139. The effect of spin on physicians was evaluated in a group 
of 300 oncologists, of whom half were randomized to the spin group and the other was 
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randomized to the no spin group52. In the spin group, 30 abstracts with at least one type of 
spin were given to oncologists to read. The types of spin include selective outcome 
reporting, omission of unfavorable results from the discussion, and emphasis on a subgroup 
that performed well. In the no spin group, these 30 abstracts were rewritten by the study 
authors to have no spin or distortions, then given to each oncologist to read. The group that 
read the abstracts with spin were more likely to rate the intervention as more beneficial, 
say they would read the whole article, and rate the trial as less rigorous. The implication is 
clear: misrepresented and distorted research findings in medical research affect how 
physicians perceive the efficacy of drugs that are studied. 
 The common thread for how to prevent all reporting biases is to emphasize open 
data, pre-registered protocols, and standardized reporting guidelines. If all trials were 
registered with their planned endpoints, evidence of publication and selective outcome 
reporting bias is easy to identify. If standardization to how studies are reported is 
emphasized, spin would become less common. In all cases, studies would be independently 
reproducible if data and statistical analysis plans were made available at the time of 
publication. The Open Science movement132 is predicated on equity for patients, the public, 
and medical researchers in terms of access to data that impacts how clinical decision 






The success of an SR begins with a robust and comprehensive database search 
based on a well-defined PICO question. Bias in an SR occurs when the search neither 
maximizes its sensitivity and specificity17. SRs that do not search multiple, relevant 
databases are unlikely to identify all relevant studies. SRs that do not search for 
unpublished data may not generate reliable results78. Unpublished data, or gray literature, 
is more likely to have smaller or null effect sizes because of publication bias. Inclusion of 
only the published literature may result in exaggerated effect sizes in a direction that is 
favorable to the intervention. SRs that do not include all languages may or may not generate 
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unreliable results. There is a debate about whether or not including only English-language 
studies is appropriate, with advocates of including English-language articles highlighting 
the fact that non-English studies are more likely to be at a higher risk of bias due to financial 
restrictions of low- and middle-income countries140. This does not seem to be an axiom and 
it is likely that the effect of language bias is sporadic, though still present. To that effect, 
the Cochrane collaboration recommends minimizing language bias as best as possible 
within the bounds of budget and time restraints17. 
 A particularly common and unrecognized form of bias in SR searches centers on 
what is known as citation bias. Citation bias occurs when authors of SRs try to bolster their 
search returns by hand-searching the reference lists of relevant articles identified in the SR 
search141. This may seem logical until one understands that the manner in which studies 
are cited is often biased. Cited studies are more likely to confirm the results of the study 
doing the citing, and cited studies are subjected to publication bias, meaning they are more 
likely to have statistically significant results. Therefore, the practice of identifying new 
studies from the reference lists of included studies may be seen as a method to reduce bias, 
but may in fact be increasing the bias in an SR. The prevalence of citation bias in the SRs 
in the field of otolaryngology was recently studied and it was found that  
72.4% (390/539) hand-searched reference lists of included articles with 58.5% (228/390) 




In a similar fashion to clinical trials, SRs are subject to publication bias, selective 
outcome reporting bias, and spin. The manner by which each bias is mitigated is similar to 
clinical trials as well: pre-registration, publicly available protocols with statistical analysis 
plans, and guidelines for how data should be reported and interpreted. Unfortunately, the 
rate of pre-registration of SRs is far lower than that of clinical trials73. The availability of 
protocols is low, with some estimates finding that just under half of SRs have public 
protocols142, while others finding closer to one-third143. One can imagine the effect that 
lack of pre-registration and public protocols would have on the published SR literature, 
and indeed, a recent meta-analysis of studies investigating selective outcome reporting bias 
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found that 38% (184/485) included, excluded, or omitted outcomes82. It is likely that this 
number is a lower end estimate because it is only possible to study selective outcome 
reporting if a protocol or preregistration is available. Publication bias has been quantified, 
with past studies finding that the SRs in general medical journals differ from those in the 
Cochrane collaboration journal, which requires publication regardless of results144,145. 
Spin, otherwise known as the distortion or misrepresentation of research findings, was 
recently studied in the abstracts SRs of breast cancer146, orthopedic147, and glaucoma148 
interventions — each study finding a significant amount of spin that may affect the 
interpretation of SR results.  
 
Clinical Practice Guidelines 
 
 At a fundamental level, CPGs are an SR. All relevant literature is retrieved for a 
certain topic, but unlike normal SRs, CPGs rely on an expert panel to issue clinical practice 
recommendations based on the available evidence. CPGs may or may not synthesize results 
from included articles, but more often issue qualitative recommendations based on the 
preponderance of evidence gathered88. It is imperative that CPGs are based on a robust, 
systematic database search, that authors are experts in evidence synthesis, and that experts 
are free from any bias that could affect their recommendations. Beyond those basic tenets 
of CPG development, other, more nuanced, methodological items should be considered. 
These additional items are best summarized by the AGREE-II (Appraisal of Guidelines for 
Research and Evaluation version 2) tool, which is commonly used to assess the 
methodological quality of CPGs. The AGREE-II instrument asks whether a CPG 1) defines 
its scope and purpose; 2) outlines stakeholder involvement; 3) has high methodological 
quality; 4) clearly presents results and recommendations; 5) is applicable to clinical 
practice; 6) is free from external conflicts of interest. In oncology, assessments using 
AGREE-II have consistently shown that oncology CPGs do not sufficiently involve key 
stakeholders, including patients, nor are they free from conflicts of interest149–151.  
 Without patient and other non-physician stakeholder involvement, it is unlikely that 
CPGs will consistently make recommendations that align with public interest. For 
example, most novel oncology drugs are so costly that a new term has been coined in 
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oncology: financial toxicity6. Financial toxicity is unlike other drug toxicities, which occur 
when someone takes a drug. Financial toxicity precludes someone from taking a drug 
because the cost is so burdensome that the individual cannot afford it. Thus, it may be that 
patients and other relevant stakeholders would prefer an older drug that is more cost-
effective, because a full course of an older drug may be more effective than half a course 
of a newer drug. Some have questioned whether financial conflicts of interest play a role 
in the clinical recommendations of oncology CPG authors41. Evidence suggests that 
oncology CPG authors have extensive financial COI with companies who develop novel 
cancer drugs41. Some would suggest that these conflicts are to be desired since a close 
working relationship with industry is working to serve the patient's best interest152. 
However, ample evidence suggests that financial conflicts of interest not only affect 
guideline recommendations153, but also physician prescribing behavior154 and 




 Clinical trials, SRs, and CPGs are vital to medical decision making in oncology. A 
strong understanding of clinical trials, SRs, and CPGs is necessary to appreciate the 
findings of this dissertation. Furthermore, a baseline understanding of bias is important 
since many of the studies included in this dissertation discuss the prevalence, influence, 
and implications of bias from the perspective of research translation to clinical practice. 
Without improvements in the rigor and reproducibility of oncology evidence, which 
include improvements in study design, stakeholder involvement, and bias mitigation, it is 
unlikely that future oncology evidence will maximize its potential to improve patient 





ADHERENCE TO REPORTING GUIDELINES AND CLINICAL TRIAL 
REGISTRATION POLICIES IN ONCOLOGY JOURNALS: A CROSS SECTIONAL 
REVIEW 
 
This work was previously published in the British Medical Journal: Evidence Based 
Medicine with the following citation:  
Wayant C, Moore G, Hoelscher M, Cook C, Vassar M. Adherence to reporting guidelines 
and clinical trial registration policies in oncology journals: a cross-sectional review. 





Poor methodological quality and incomplete reporting of published research affects 
clinical decision making 156–158 and contributes to research waste 159. Reporting guidelines 
(RGs) offer one solution by promoting transparency and ensuring that key methodological 
safeguards are fully reported 160. In oncology, recent studies have shown evidence of poor 
reporting quality of phase II and III trials 161,162. Moreover, a survey of members from the 
European Organization for Research and Treatment of Cancer found that the frequency of 
adverse event reporting fell short of members’ expectations 162. To address such situations, 
correct implementation of the Consolidated Standards of Reporting Trials (CONSORT) 
checklist by clinical trialists would ensure that all harms and unexpected effects 
encountered by the treatment group are reported in oncology trials (CONSORT Item 19) 
163. Indeed, the CONSORT statement, like other RGs has been shown to improve the 
quality of research when incorporated into study design and reporting.164,165
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The registration of clinical trials is another mechanism intended to promote 
transparency and improve methodological standards. Two recent studies demonstrated 
small improvements over time in the quality of trial registration, but conclude that more 
improvement is necessary with respect to important items such as clearly defined primary 
outcomes.166,167 Discrepancies between outcomes listed in the trial registry record and 
those reported in the published trial have been noted across many medical specialties, 
providing indirect evidence for selective reporting bias. This bias occurs when researchers 
preferentially include (or exclude) outcomes based on statistical significance (or a lack 
thereof) 82,168. The International Committee of Medical Journal Editors (ICMJE) and the 
World Health Organization (WHO) have instituted policies to improve clinical trial 
reporting and registration. The US government has made prospective clinical trial 
registration a legal mandate 169, and similar regulations have been implemented in Europe 
170. In January 2017, the US National Institutes of Health (NIH) began requiring 
registration of all NIH-funded randomized trials in ClinicalTrials.gov (the US clinical trial 
registry) prior to patient enrollment and reporting of summary results after trial completion 
171.  
In this study, we first evaluated the published guidance (e.g., instructions for 
authors) provided by a cohort of highly ranked oncology journals to authors regarding the 
use of RGs for common study types. We also examined these journals’ policies on clinical 
trial registration. We then evaluated whether this guidance has led to improvements in 
reporting and registration.  
 
Methods 
The primary outcome of this study was to examine the adherence to RGs and trial 
registration policies of 21 oncology journals. The secondary outcome was to investigate 
whether adherence to the CONSORT statement and ICMJE trial registration policies 
affects reporting practices in oncology. Our exploratory outcome was a description of the 
rates of adherence to oncology-specific RGs (e.g., REMARK for tumor marker prognostic 
studies).  
We surveyed Google Scholar and identified the top 20 oncology journals, sorted by 
h5-index. We also included JAMA Oncology because its impact factor places it in the top 
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20 oncology journals, but Google rankings do not yet reflect that status. We conducted a 
cross-sectional review of the oncology journals’ policies and instructions for authors 
concerning guideline adherence and trial registration requirements. This study did not meet 
the regulatory definition of human subject research, so it was not subject to Institutional 
Review Board oversight. We applied relevant SAMPL guidelines for reporting descriptive 
statistics 172.  
Before initiating the study, all authors met to outline the study design. A study 
protocol was developed based on our previous investigations 173,174. A pilot test was done 
on the first 5 journals to identify any flaws in the protocol and to establish uniformity in 
data extraction. Follow-up meetings were held periodically throughout the data extraction 
process to resolve discrepancies. CW, MH, and CC performed web-based searches for each 
journal and searched the 
instructions for authors 
page for relevant 
information. A third author 
(GM) validated all data. 
Each author was blinded to 
the ratings of the others. 
The methodology for the 
following Primary and 
Secondary outcomes is 
visual depicted in Figure 1. 
 
Primary Outcome 
For each journal, we determined whether it adhered to ICMJE Uniform 
Requirements for Manuscripts (URM), Animal Research: Reporting of In Vivo 
Experiments (ARRIVE), Case Reports (CARE), CONSORT, Meta-Analysis of 
Observational Studies in Epidemiology (MOOSE), Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA), Quality of Reporting of Meta-
analyses (QUOROM), Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE), or Standards of Reporting Diagnostic Accuracy Studies 
Figure 1. Study methodology for the primary and secondary objectives. 
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(STARD). Additionally, we extracted whether or not a journal mentioned 
ClinicalTrials.gov, WHO trial registries, or both. If a journal mentioned trial registration 
without naming a specific registry, we coded that journal as “generic trial registration.”  
Definitions were constructed a priori by CW and MV for the coding process based 
on previous literature definitions 173,174. For each of the RGs and registries, adherence by 
each journal was classified as “compulsory/required,” “recommended,” or “not 
mentioned.” For cases in which it was unclear whether the journal followed a specific 
guideline or registry, adherence was rated as “unclear.” Keywords such as “must,” “need,” 
or “manuscripts will not be considered for publication unless” were categorized as 
compulsory/required. Similarly, keywords such as “should,” “encouraged,” and “prefer” 
were categorized as recommended.  
After data extraction, MH and CC reviewed each journal’s website to determine 
which of the common study types relating to extracted RGs (systematic reviews/meta-
analyses, clinical trials, diagnostic accuracy studies, case reports, epidemiological studies, 
and animal studies) were accepted. Next, MH and CC emailed the editors-in-chief of the 
included journals for confirmation regarding the extracted study type. We sent two 
reminder emails at 1-week intervals to ensure best practices in eliciting email response 175. 
We cross-referenced the journals’ accepted article types to the data that we extracted from 
journal websites. If a journal did not publish a particular type of study, then it was not 
considered in comparing accepted study types and RG adherence. For example, ARRIVE 




Next, CW performed a PubMed search using publication type “randomized 
controlled trial” for all included journals during a 5-year period (January 1, 2012, to 
December 31, 2016). This search strategy has been shown to have over 93% sensitivity 
and specificity for retrieving RCTs 176. All RCTs were divided into groups based on 
whether or not the journal adhered to CONSORT guidelines and whether or not they 
endorsed ICMJE trial registration policies. CW then randomly sampled 30 RCTs from each 
journal. If a journal did not publish at least 40 RCTs during the 5-year study period, it was 
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excluded. Odds ratios and confidence intervals were calculated based on the results of the 
data extraction using STATA 13.1. 
 
Exploratory Outcome 
A single author (CW) surveyed each journal’s website to descriptively analyze the 
rate of adherence to oncology-specific RGs. A list of these guidelines can be found on the 
EQUATOR Network’s website 177.  
All authors met after completing data extraction and analysis to resolve any final 
discrepancies in the scoring of the journal data.  
 
Results 
Our study comprised 21 oncology journals. Table 1 shows all extracted data. Only 
1 (4.8%) journal was found to not adhere to any RG, while 5 (23.8%) did not adhere to any 
trial registration policies. The ICMJE-URM was mentioned by 15 (71.4%) journals, and 
the EQUATOR Network was mentioned by 3 (14.3%) journals. We recorded an editor 




Reporting Guideline Adherence 
The CONSORT statement was mentioned by 16 journals: 11/21 (52.4%) required 
adherence, and 5/21 (23.8%) recommended adherence. ARRIVE was mentioned by 11 
journals: 1/20 (5.0%) required adherence, and 11/20 (55.0%) recommended adherence. 
STARD was mentioned by 8 journals: 4/19 (21.1%) required adherence, and 4/19 (21.1%) 
recommended adherence. PRISMA was mentioned by 8 journals: 3/21 (14.3%) required 
adherence, and 5/21 (23.8%) recommended adherence. STROBE was mentioned by 7 
journals: 5/21 (23.8%) required adherence, and 2/21 (9.5%) recommended adherence. 
MOOSE was mentioned twice and was recommended both times. QUORUM and CARE 






Five (23.8%) journals did not mention trial registration at all. Ten journals 
mentioned trial registration through ClinicalTrials.gov: 3/21 (14.3%) required registration, 
and 7/21 (33.3%) recommended it. Six journals mentioned WHO trial registration: 4/21 
(19.0%) required registration, and 2/21 (9.5%) recommended it. Generic trial registration 
was mentioned by 11 journals: 8/21 (38.1%) required generic registration and 3/21 (14.3%) 
recommended it. 
 
 Secondary Outcome 
 
Our PubMed search yielded 2614 results and 13 eligible journals, defined as those 
publishing more than 40 RCTs in the 5-year period studied. Journal specific publication 
rates of a CONSORT Flow Diagram and trial registry number are available via the Open 
Science Framework (osf.io/7g6td). 
 
CONSORT Guidelines 
Of the 13 journals, 10 adhere to CONSORT guidelines and 3 do not (Figure 2). The 
RCTs published in the 10 journals that adhere to CONSORT included a flow diagram 
70.3% (211/300) of the time. The 3 that do not adhere to CONSORT included a flow 
diagram 57.8% (52/90) of the time. This finding indicates that journal adherence to 
CONSORT increases the likelihood of an author adhering to its key items (OR=1.73, 95% 




Figure 2. Histogram of percent of 
randomly sampled randomized 
controlled trials (RCT) that 
included a Consolidated Standards 
of Reporting Trials (CONSORT) 
flow diagram published in journals 
that adhere to the CONSORT 
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Table 1. Cross tabulations of oncology journals and the adherence to reporting guidelines and trial registration policies 
Key: 1 (required), 2 (recommended), 3 (unclear), 4 (not mentioned), N/A (does not accept the corresponding study type). 
ARRIVE, Animal Research: Reporting of In Vivo Experiments; CARE, Case Report; CONSORT, Consolidated Standards of Reporting 
Trials; ICMJE, International Committee of Medical Journal Editors; MOOSE, Meta-Analysis of Observational Studies in Epidemiology; 
NA, not applicable; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; QUOROM, Quality of Reporting 
of Meta-analyses; STARD, Standards of Reporting Diagnostic Accuracy Studies; STROBE, Strengthening the Reporting of 
Observational Studies in Epidemiology. 
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ICMJE Trial Registration Policies 
Nine of the 13 journals endorsed ICMJE trial registration policies and 4 did not 
(Figure 3). The RCTs published in the 9 journals that endorsed ICMJE registration policies 
included a trial registration number 67.4% (182/270) of the time. The RCTs published in 
the other 4 journals included a trial registration number 67.5% (81/120) of the time. No 
association existed between endorsement of ICMJE and reporting of a trial registry number 




Six of the included oncology journals adhered to REMARK Guidelines (Table 1). 
No other mention of oncology-specific guidelines was found.  
 
 
Figure 3. Histogram of percent of randomly sampled randomized controlled trials (RCT) that included a trial registration 
number published in journals that adhere to International Committee of Medical Journal Editors (ICMJE) trial 
registration policies (solid) and those that do not (striped). 
 
Discussion 
  Oncology journals support the use of reporting guidelines more often than journals 
in other medical specialties. Only one journal in our sample did not adhere to any RGs. 
Recent investigations have found no adherence to RGs in 48% (32/67) of hematology 
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journals173, 41% (11/27) of emergency medicine174, and 41% (15/37) of critical care 
journals.178  
Specific guidelines such as CONSORT and PRISMA still show a need for greater 
endorsement since several journals do not mention these guidelines. Evidence suggests that 
adherence to CONSORT and PRISMA improves some aspects of study methodology in 
oncology. These studies also called into question important items that remain 
underreported 179–181. Additional studies corroborate these findings in other medical 
specialties 182,183 Specifically, key items such funding source, proper adherence to study 
protocol, sample size calculation, adverse events, and description of the trial's design have 
been found to be underreported 162,179,184,185. The same trends have been observed in 
oncology SRs; however, these studies have also noted that risk of bias evaluations are 
infrequently reported 180 
Calls have been made in the past for increased transparency in clinical trial 
reporting for the sake of patient outcomes and research integrity 186. RGs were designed to 
increase scientific transparency and integrity. For example, CONSORT requires trial 
registration and the reporting of the registration number, which may prevent the selective 
reporting of outcomes upon publication. A beneficial aspect of RGs for peer reviewers and 
editors includes the ease by which the methodological rigor of a trial may be evaluated. 
This is particularly beneficial for junior authors and reviewers who wish to familiarize 
themselves with aspects of high-quality study designs. The submission of a guideline 
checklist along with a manuscript may also decrease the time burden for reviewers and 
editors who choose to investigate the methodological quality of a manuscript. 
Our secondary objective was to determine if journal endorsement of a guideline or 
policy affected the design and reporting of an RCT. Our results demonstrate that the journal 
adherence to CONSORT guidelines increased the likelihood of authors publishing a 
CONSORT flow diagram. This finding indicates that oncology journal adherence to 
CONSORT has a positive effect on reporting practices within oncology trials. And while 
publication of a participant flow diagram may fail to predict adherence to other CONSORT 
items, our finding nonetheless demonstrates that good reporting practices are more likely 
to occur in CONSORT-endorsing oncology journals. 
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With regard to trial registration, our results demonstrate no association between 
oncology journal endorsement of ICMJE clinical trial registration policies and author 
publication of a registry number. The rates of publication of a registry number were similar 
in ICMJE-endorsing and non-ICMJE-endorsing journals (67.5% and 67.4%, respectively). 
We recognize a need for improvement, not only because one-third of the analyzed trials 
did not direct the readership to the registration page, but also because journals that endorsed 
the ICMJE trial registration policy failed to distinguish themselves from non-endorsing 
journals. Here, oncology journal policy can help steer clinical trials in a more transparent 
direction by enforcing the registration of clinical trials and the reporting of the registry 
number in published manuscripts. 
Some areas of medicine, such as oncology, have study designs that are unique and 
require their own specific guidance with regard to methods and reporting. Therefore, our 
exploratory outcome was to determine the rates of adherence to oncology-specific RGs. 
We found that 6 journals adhered to REMARK Guidelines for tumor marker prognostic 
studies, making it the most popular and only oncology-specific RG within our journal 
cohort. The rate of adherence to REMARK is encouraging, given the unique study design 
for which it was created, and the fact that not all journals within our sample accept tumor 
marker prognostic studies. This finding reflects the overall theme that oncology journals 
adhere to RGs at a higher rate than journals in other specialties. 
For journals that do not currently adhere to RGs or registration policies, a first step 
may be to simply refer authors to the EQUATOR Network. The EQUATOR Network is 
the premier clearinghouse for RGs; it was established to aid authors and reviewers in the 
reporting and evaluation of scientific research, and it is committed to strengthening the 
integrity of scientific research 187. The network has produced algorithms to aid researchers 
who are unfamiliar with RGs to determine which one is most suited for their study design. 
The network also displays RGs for popular study designs on its homepage to help mitigate 
the time burden of choosing the correct guideline. Only 3 journals in our sample referred 
authors to the EQUATOR Network’s website. 
The EQUATOR Network is currently publicizing and organizing its first project 
dedicated to a single medical specialty. The EQUATOR Network Oncology Project is 
designed to increase awareness, address barriers to adherence, and augment the use of RGs 
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in the oncology literature 188. The future goal of the project is to establish an expert advisory 
group composed of multiple stakeholders in oncology that share the common goal of using 
RGs, in part, to increase the quality of oncology research. The EQUATOR Network 
Oncology Project is currently in the early stages of development, and its present and future 
plans can be found on the EQUATOR Network’s website. 
Other methods beyond RGs that are designed to increase research transparency 
have also been implemented. The BMJ and BMJ Open both require a declaration of 
transparency on behalf of all primary authors of clinical trials, with the aim of reducing the 
incidence of selective reporting bias, which is frequently found in both oncology and 
hematology journals 36,189. Additionally, most journals require a declaration of any conflict 
of interest that the authors may have, with the aim of increasing the integrity and objectivity 
of published research.  
 
Limitations 
One limitation of our analysis with respect to our secondary objective is that the 
inclusion of a flow diagram may fail to predict a trial’s adherence to other CONSORT 
statement items. Recent studies have demonstrated variable adherence to CONSORT 
statement items.190,191 Therefore, our finding that manuscripts in CONSORT-adhering 
journals more often publish a participant flow diagram may not be generalizable to all 
CONSORT statement items. 
 
Conclusion 
To conclude, RG adherence in oncology journals is better overall compared with 
other medical specialties that have been investigated, but nonetheless, adherence to 
individual RGs needs improvement. We have demonstrated that mentioning CONSORT 
increases the likelihood of author adherence. The benefits of RG adherence have been 
demonstrated as well as some solutions to potential barriers to uptake and adherence. 
Ongoing efforts are being made to improve the quality of oncology research, and we 
encourage support of these efforts, which may begin with a reference to RGs in the 





TIDieR CHECKLIST EVALUATION OF CLINICAL TRIAL INTERVENTION 
REPORTING FOR RECENT FDA-APPROVED ANTICANCER MEDICATIONS 
 
This work was previously published in the British Medical Journal: Evidence Based 
Medicine with the following citation:  
Wayant C, Bindernagel R, Vassar M. TIDieR checklist evaluation of clinical trial 
intervention reporting for recent FDA-approved anticancer medications. BMJ Evid 





 The ability to replicate and effectively implement new healthcare interventions is 
essential to advancements in patient care. The ability to replicate and implement clinical 
trial interventions is especially important, since trial methodology lends itself to more 
trustworthy, replicable results192. However, in the past, clinical trials have been shown to 
exhibit low-quality methods193,194 and low-quality reporting195,196, which may compromise 
a physician’s ability to critically appraise trial results and decide whether the intervention 
is suitable for their practice. Owing to the poor overall methodological and reporting 
quality of clinical trials, much of the focus for improving clinical trials centered on items 
such as proper randomization and blinding197–199. Much less attention has been dedicated 
to the reporting of clinical trial interventions200. What has conspicuously not been discussed 
is the actual quality of reporting of clinical trial interventions. Absent high-quality 
reporting of all aspects of healthcare inventions, implementing interventions effectively 
becomes difficult. More concerning, however, is that physicians may be incapable of 
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assessing how evidence from highly regimented clinical trials may translate to real-world 
patient care.  
In a recent analysis of cancer chemotherapy trial interventions, it was found that 
only 11% (30/262) reported all key intervention elements201. The most common elements 
not reported were specific pre-medications and dose-adjustment protocols. Such findings 
are a cause for concern, especially since newly-approved cancer medications are 
expensive202 and may only extend patient survival by a median of 2.1 months116. Moreover, 
many FDA (Food and Drug Administration) oncology drug approvals are now based on 
non-comparative studies with a primary endpoint that is a surrogate for OS3,203. Surrogate 
endpoints may exaggerate the real-world effectiveness of these novel drugs204, so the need 
for clearly and comprehensively described interventions is vital to translating new data to 
clinical practice.  
Given the influence that clearly described healthcare interventions can have on the 
quality of patient care, and the consequence of poorly described interventions, we aim to 
evaluate the completeness of intervention reporting in pivotal oncology clinical trials. Our 
selected cohort of oncology clinical trials consists of trials which formed the basis for novel 
FDA drug approvals. Our primary research questions are how well-described are these 




 We extracted all FDA hematology/oncology drug approvals for anticancer 
medications from 2017 and 2018 from the FDA website205. Using the clinical trial registry 
identifier included in these approvals or a PubMed search, we matched the approvals to 
published clinical trials. If the trial registry listed associated publications, we individually 
reviewed each publication to determine which, if any, contained data that could be matched 
to the FDA approval summary. If none of the associated publications matched, a PubMed 
search was used to identify relevant trials. Trials were matched to an FDA approval on the 
basis of PICO (population, intervention, comparison, outcome), sample size, and reported 
efficacy data. For example, if the FDA approval summary stated that a phase 3 trial with 
200 patients and a primary endpoint of OS was conducted, we searched for trials that 
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matched these criteria, and others if necessary. If no trials were able to be matched, the 
drug and its approval were excluded. We only included studies of anticancer medications 
(e.g., solid tumors, leukemia, lymphoma) and excluded any interventions for benign 
hematologic diseases (e.g., sickle cell anemia). 
 The matched and included published trials were assessed using the TIDieR 
(Template for Intervention Description and Replication) checklist206. Along with the 
published trial, all supplemental documents (e.g., protocol, appendices) were investigated. 
The TIDieR checklist was designed using best-practice, robust Delphi methods by experts 
in the field of research methods and reporting. The 12 TIDieR checklist items cover the 
full breadth of intervention reporting: from materials used in the intervention to 
assessments of treatment compliance and fidelity. A full list of checklist items is available 
alongside our protocol via the Open Science Framework207. Two authors (CW, RB) 
extracted all data for all TIDieR checklist items for all included published trials using a 
standardized Google Form created to reflect the 12 TIDieR checklist items. In addition to 
the TIDieR checklist items, we extracted data related to the design of the trial (e.g., 
randomization, blinding, study phase) as well as whether a trial protocol was available. We 
defined a protocol as a document that describes the background, rationale, objectives, 
design, methodology, statistical considerations, and organization of a clinical research 
project. Thus, supplemental methods sections were not considered a protocol for the 
purpose of data analysis, but could be considered when evaluating adherence to TIDieR. 
After investigation of all published documents with the TIDieR checklist, we reviewed 
drug labels for each included drug approval. Information gathered from the drug labels did 
not contribute to TIDieR adherence, since TIDieR is designed to assess the reporting of 
published trial interventions. Instead, data gathered from the drug label was gathered to 
determine whether additional information is presented to the FDA that is not presented to 
the public in a journal article. 
 We scored each TIDieR item on a three-point Likert scale with the following 
categories: 0 (not reported), 1 (partially reported), 2 (fully reported). We then summed the 
scale score for each of the 12 TIDieR items to generate a composite scale score ranging 
from 0 (poor reporting) to 24 (full reporting) for each included trial. We followed the 
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guidance of Yamato, et al208, who previously showed that this composite scale score may 
be used to determine the overall quality of intervention reporting. 
 The primary outcome of this study was the completeness of reporting of pivotal 
oncology drug trial interventions that formed the basis for recent FDA approvals. 
Secondary analyses include evaluating whether clinical trials with accessible protocols 
exhibited higher-quality reporting and comparing subgroups of trials. Trials were stratified 
by design, journal, clinical phase, sample size, drug class, and by novelty in class. 
 For the calculation of summary statistics, medians, and interquartile ranges (IQR) 
we used Google Sheets. Our percent adherence rates for TIDieR items reflect a 
denominator of 192, which corresponds to 2 (full TIDieR Item reporting) multiplied by 96 
(number of included trials). Thus, a hypothetical item may be partially reported by all 
clinical trials (each scored as 1 for partial reporting), but the overall percent adherence 
would be 50% (96/192). To avoid misleading statistical reporting, we report percent 
adherence rates as well as the number of trials that fully report, partially report, or did not 
report an item. We prespecified a multiple regression model to investigate the association 
between journal, funding source, and protocol availability on increased TIDieR composite 
score of clinical trial intervention reporting. However, our sample of trials aggregated 
heavily into industry funding and only 3 journals, rendering our multiple regression 
analysis difficult. Instead, we used the nonparametric k-sample test of equality of medians 
to investigate whether publication of a protocol results in higher median TIDieR composite 
scores. We used a nonparametric test because our data was not normally distributed upon 
visual inspection of a histogram and Shapiro-Wilk test of normality. Stata 15.1 was used 
for all analyses. We prespecified an alpha threshold of .05 for statistical significance. 
 
Results 
We identified 121 new listings on 
the FDA hematology/oncology FDA 
approvals and safety notifications page205, 
of which 36 were excluded (Figure 4). The 
85 included listings were all for anticancer 
medications and were underpinned 
 
Figure 4. Flow diagram of included and excluded studies. 
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by a total of 96 clinical trials published in peer-reviewed journals. The 96 clinical trials 
were most often published in New England Journal of Medicine (n = 40, 41.7%), Lancet: 
Oncology (n = 23, 24.0%), and the Journal of Clinical Oncology (n = 12, 12.5%). Included 
trials were most often funded solely by industry (n = 83, 86.5%), followed by mixed 
funding sources (n = 9 with partial industry, n = 1 without partial industry). Trials were 
most often randomized (n = 60, 62.5%), open label (n = 68, 70.8%), and phase III (n = 56, 
58.3%). See Table 16 for more trial characteristics. 
 Overall, the median TIDieR composite score was 17 (IQR 2), corresponding to 
between 8 and 9 (out of 12) fully reported TIDieR items. No trials reported all TIDieR 
items. Seven TIDieR items had greater than 90% adherence across all clinical trials (Table 
2), with 2 items showing 100% adherence: Item 1, name of intervention, and Item 2, 
rationale for the intervention. Three items were poorly (<5%, each) or moderately (<50%) 
reported: Item 5, intervention provider (including training and expertise), Item 7, types of 
institutions where clinical trial was conducted (including infrastructure and relevant 
features), and Item 11, if and how intervention compliance was assessed. Subgroup 
comparisons of TIDieR compliance are available via the Open Science Framework207. 
There was no difference between subgroups. The median TIDieR composite score when 
drug labels were included rose to 18 (IQR 1). 
Qualitatively, for the Items 5, 7, 11 that showed poor to moderate adherence 
(<50%), we identified key action items to improve the quality of intervention reporting. 
For Item 5, which relates expertise, background and any specific training given to 
intervention providers, we found a paucity of data. Mostly, protocols would provide a 
generic statement of “trial personnel” that administered study medications, but failed to 
mention if these personnel were the investigators, pharmacists, or others. Patient-self 
administration was scored as partial reporting since there was little detail about training of 
patients to self-administer. For example, “patients randomized to the duvelisib arm self-
administered 25 mg capsules twice daily”209 exemplifies statements related to patient self-
administration. For Item 7, which relates to the description of types of institutions that 
functioned as trial centers, including infrastructure and relevant features, all clinical trials 
were scored as “not reported”. Despite nearly all clinical trials listing trial centers by name, 
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neither the type of institution, nor the capabilities and infrastructure of these centers were 
described. 
Item Full reporting 
Partial 
reporting No reporting 
Overall 
score (%) 
1. Name the intervention. 96 0 0 192/192 (100%) 
2. Rationale for the intervention. 96 0 0 192/192 (100%) 
3. Materials used in intervention (e.g., dose and 
formulation). 92 4 0 
188/192 
(97.9%) 
4. Procedures of intervention (e.g., administration 
procedure). 91 5 0 
187/192 
(97.4%) 
5. Expertise, background and any specific training 
given to intervention providers. 0 7 89 
7/192 
(3.6%) 
6. Mode of delivery of the intervention (e.g., 
oral/intravenous, alone/group). 11 82 0 
104/192 
(54.2%) 
7. Types of trial locations, including infrastructure or 
relevant features. 0 0 96 
0/192 
(0.0%) 
8. Number of times the intervention was delivered and 
over what period of time including the number of 
sessions, their schedule, and their duration, intensity or 
dose. 
94 2 0 190/192 (99.0%) 
9. Plans for individual personalization of treatment 
(e.g., dose reductions). 86 5 5 
177/192 
(92.2%) 
10. Study-level modifications to intervention planned 
(e.g., induction and maintenance). 60 33 0 
153/192 
(79.7%) 
11. How intervention compliance is assessed. 11 37 48 59/192 (30.7%) 
12. How well was the intervention delivered (e.g., 
treatment delays, discontinuations). 93 0 3 
186/192 
(96.9%) 
Table 2. Reporting of TIDieR items by included trials (n = 96). 
For Item 11, which relates to whether compliance to the intervention was assessed, 
we found little information past accountability of study drugs (e.g., accounting for number 
of pills dispensed and used at follow up). According to the TIDieR checklist206, 
assessments of intervention adherence require more than simple assessments of drug 
quantity consumed — they also relate to how the drugs were consumed. For example, 
“subjects will keep a daily diary to record dosing compliance, which will also be assessed 
at each clinic visit by means of a capsule count in the returned bottle. Late doses (i.e., 4 or 
more hours after scheduled time) should be noted in the diary. Doses that are late by more 
than 12 hours should be skipped and recorded in the dosing diary as missed.”210 was scored 
as full reporting; whereas, “the study personnel will account for all investigational products 
dispensed to and returned from the subject”211 was scored as partial reporting because it 
can be inferred that drug quantity accountability was assessed.  
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The k-sample test of equality of medians indicated that the publication of a protocol 
resulted in significantly higher TIDieR composite scores (𝜒2 (1) = 32.0, P < .001). Median 
TIDieR composite score in studies with a protocol (n = 62) was 18 (IQR 1) versus 16 (IQR 
1.75) for trials without a protocol (n = 34).  
  
Discussion 
 The results of this investigation reveal stark differences in the quality of reporting 
of TIDieR checklist items in pivotal oncology trials. All of the included clinical trials 
formed the basis for new FDA hematology/oncology drug approvals, and all exhibited 
strengths and weaknesses, as it relates to the reporting of the interventions. On one hand, 
all clinical trials listed the drug name and dose and the rationale for the intervention (Items 
1 and 2). Included clinical trials also frequently described the number of times the 
intervention was delivered (including description of treatment cycles) (Item 8), any rules 
for individual modifications to the intervention (Item 9), and the number of treatment 
discontinuations or delays (Item 12). Seemingly, all of these items would be expected in 
an oncology clinical trial, but a previous study of the reporting of oncology interventions 
suggests that these items cannot always be assumed present201. Overall, because the 
included oncology clinical trials reported items homogeneously — a high proportion did 
or did not report specific items — we believe that targeted improvements will strengthen 
all future clinical trials.  Namely, we recommend including a description of trial center 
infrastructure and capabilities (rather than just the name), describing who is administering 
the interventions (including special training or instructions given), and describing how 
intervention compliance will be assessed. We further recommend the publication of a study 
protocol, since better adherence to TIDieR was shown (equivalent to a median of 1 more 
item, of 12, reported) and inclusion of a protocol should presumably require little effort if 
one was written for the trial. Last, we recommend that journals scrutinize their reporting 
requirements for interventions, since FDA drug labels included more information than 
published reports. All of these recommendations may be enforced by new journal, 
regulatory agency, or trial registry requirements for intervention reporting.  
 Many previous studies have noted that cancer outcomes differ based on where 
patients receive treatment212–214. A recent risk-adjusted observational study of Medicare 
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beneficiaries showing a significant reduction in OS for patients treated at community 
hospitals compared to National Cancer Institute, academic centers, and free-standing 
cancer hospitals exempt from prospective payment systems215. Historically, most clinical 
trials are conducted at academic centers216, which may hinder the translation of clinical 
trial outcomes to community settings, where most cancer patients receive treatment217,218. 
Moreover, there may be selection bias regarding patients enrolled in trials that underpin 
FDA approvals, since these trials are conducted at academic centers and the patients 
included may differ from those treated in the community. While it is true that the translation 
of care from clinical trials to real-world settings and from academic to community centers 
is multifactorial, one small mechanism to clarify contextual factors that contributed to trial 
outcomes (and how these outcomes may be expected to translate to other locations) is to 
describe the infrastructure and capabilities of the trial center. For example, in accordance 
with the TIDieR checklist recommendations, a clinical trial may report the countries of 
participating centers, types of hospitals that participated, whether care is publicly or 
privately funded, volume of hospital activity, or the availability of certain facilities or 
equipment (as relevant)206. Similar to the reporting of trial center infrastructure, explicitly 
reporting who was involved in administering clinical trial interventions, including any 
training or prior expertise, may be helpful in translating clinical trial intervention outcomes 
to the real-world.  
 Novel cancer immunotherapies, such as CTLA-4, PD-1, and PD-L1 inhibitors, have 
previously been shown to improve cancer patient survival, but often result in high rates of 
immune-related adverse events219,220. Moreover, it has been reported that immune-related 
adverse events may continue to progress even after withdrawal of immunotherapy221. 
Despite an understanding of immune-related adverse events, a recent SR noted that the 
reporting of immune-related adverse events in clinical trials was suboptimal, although 
better in trials published more recently and in higher impact factor journals, such as those 
included in our study219. Nonetheless, our results indicate that while included trials 
contained details about how many patients discontinued or delayed the intervention, very 
little information was given on the methods of assessing compliance. For example, whether 
outpatient trial participants were required to keep a detailed diary of how many doses were 
taken, delayed, or missed. Further, the quality of these doses, since many trials include 
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detailed instructions as to how each dose is to be taken (e.g., with food). Given the rate of 
adverse events, it may be expected for deviations from the protocol to occur beyond dose 
delays or dose discontinuations. The chief reason for detailed compliance information is to 
determine whether or not treatment effects are likely to be affected by how well patients 
complied to study procedures, and also to show readers how compliance was encouraged. 
We recommend future trial authors detail how compliance is to be assessed for the 
intervention, rather than just the rates of adverse events. 
This study has several strengths and limitations. For strengths, we used double data 
extraction to mitigate bias in the data collection process. We further restricted our analysis 
to high-profile oncology clinical trials published, and thus our cohort of studies may 
represent the highest level of reporting of oncology interventions. However, because our 
sample represents a very unique cohort of oncology clinical trials, the results of this 
investigation may not be generalizable. The trials in our sample were remarkably 
homogeneous — TIDieR items were either reported or not by almost all studies. Thus, our 
recommendations to improve the quality of reporting of oncology clinical trials may 
require validation in a different cohort of oncology trials. Last, this study was not designed 
to incorporate oncologist beliefs and attitudes regarding deficits in TIDieR reporting.  
In conclusion, we found that key TIDieR items were reported in nearly all included 
clinical trial interventions (each of which formed the basis for an FDA drug approval). 
These highly-reported items include the dose and treatment regimen for the intervention 
and decision rules for individual treatment modifications. However, key items were under-
reported that may be useful to oncologists in the community, such as rates of compliance, 
the infrastructure of the participating trial centers, and the training or expertise for 
intervention providers. We recommend journals and regulatory agencies adopt and enforce 
the reporting of all pertinent aspects of clinical trial interventions. Trial registration sites, 
such as clinicaltrials.gov, may further be restructured to request information required by 
the TIDieR checklist. We further recommend adherence to TIDieR and the publication of 
a complete study protocol, since the inclusion of a protocol was significantly associated 





FINANCIAL CONFLICTS OF INTEREST AMONG ONCOLOGIST AUTHORS OF 
REPORTS OF CLINICAL DRUG TRIALS 
 
An abbreviated version of this work was previously published in JAMA Oncology as a 
research letter with the following citation:  
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Oncologist Authors of Reports of Clinical Drug Trials. JAMA Oncol. Published 
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In medicine, a conflict of interest may affect patient care in many ways.222 In 
clinical care, a physician’s receipt of payments from a pharmaceutical company may 
interfere with one’s ability to objectively treat patients. Even small payments, such as 
meals, increase the likelihood that a physician will prescribe a company’s drugs.223 In 
clinical research, conflicts of interest can undermine the legitimacy of data reporting. A 
recent Cochrane SR found that industry-sponsored trials were more likely to report 
favorable efficacy results and present conclusions that were inconsistent with the study’s 
results than non-industry funded trials.224 Conflicts of interest, thus, compromise the 
quality of patient care and public trust in the medical profession.  
Concerns about physician financial conflicts of interest (FCOI) led to the passage 
of the Physician Payments Sunshine Act and the creation of the Open Payments Database 
(hereafter referred to as Open Payments).225,226 Open Payments aims to increase the 
transparency of financial relationships between physicians and industry by making all 
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pharmaceutical industry payments to physicians of $10 or more publicly available. A recent 
investigation using 2015 Open Payments data found that approximately 48% of United 
States physicians received payments totaling $2.4 billion from pharmaceutical 
companies.227 In oncology, physician FCOI disclosures are particularly important because 
of the need to bring lifesaving drugs to market while simultaneously ensuring their efficacy 
and safety. Previous oncology investigations have shown that FCOI disclosures may be 
inadequate among clinical trialists,228 editors,229 and CPG authors153; however, a focused 
investigation of FCOI for clinical trialists who undertook the trials that led to FDA drug 
approval is warranted. These trials represent the driving force in oncology and rapidly 
change the trajectory of cancer care. These trials also generate high impact factor 
publications, prestige for authors, revenue for the pharmaceutical companies, and 
newsworthy headlines.  
Therefore, the primary objective of this cross-sectional analysis of FDA-approved 
oncology drug trials is to quantify the frequency and amount of industry-author financial 
relationships. The secondary analysis is to identify the frequency of undisclosed author 
FCOIs and determine if an increase in General payments resulted in the year following 
publication. We conducted pre-planned subgroup analyses, stratifying our data by journal 
and industry sponsor. 
 
Methods 
This study was not subject to institutional review board oversight because it did not 
meet the regulatory definition of human subject research as defined in 45 CFR 46.102(d) 
and (f) of the Department of Health and Human Services’ Code of Federal Regulations.230 
One of us (CW) searched the FDA Hematology/Oncology (Cancer) Approvals & 
Safety Notifications web page for oncology drug approvals between January 1, 2016 and 
August 30, 2017 (the start date of our study). The focus of this investigation was to assess 
the FCOIs for authors of drug trials for malignant diseases. We excluded any trials of drugs 
for benign diseases (e.g., sickle cell disease) and any trial of a diagnostic tool/test. FDA 
approvals cite clinical trial number(s) rather than a published report; therefore, we 
identified the published manuscript with the endpoints that formed the basis of each FDA 
approval. If the FDA approval did not report the clinical trial number(s), we searched the 
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press releases for the 
pharmaceutical companies 
that sponsored the drug trial 
for the clinical trial 
number(s). If the press 
releases did not report the 
clinical trial number(s), we 
searched ClinicalTrials.gov 
using PICO (Population, 
Intervention, Comparison, 
Outcome) keywords. The 
process by which we identified clinical trial numbers for drug approvals is detailed in 
Figure 5. If an FDA approval was based on the pooled analysis of multiple clinical trials, 
we included all underlying trials.  
After identifying the published reports, we only included those that were published 
after September 2013 which corresponds with the earliest month and year of payments 
catalogued in Open Payments. From the published reports, one of us (CW) extracted the 
following items: title, journal, date of trial registration (considered the start of the financial 
relationship for that trial), date of publication (considered the end of the financial 
relationship for that trial), drug for which the approval was based, industry sponsor, author 
names, author affiliations, and author disclosure statements. Only United States physicians 
(MD or DO) were included in this analysis, since other degrees (e.g., PhD) and authors 
from other countries are not catalogued in Open Payments.  
Three of us (CW, CM, and PS) then proceeded to search the Open Payments 
Database for each author’s FCOIs. CM and PS extracted all data first, then CW validated 
the data by extracting data a second time for comparison. CW was blinded to the data 
extracted by CM and PS. We used a combination of author name, location of institution, 
and medical specialty to correctly identify authors. From the Open Payments Database, we 
extracted all payments from the industry sponsor starting with the year of trial start date to 
the year of publication, and recorded any time authors disputed a payment. Any disputed 
payments were subtracted from the final payment amount. We also extracted data from any 
Figure 5. Process of identifying published clinical trials. 
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subsidiaries of a pharmaceutical company. We chose to do so because the parent company 
stands to profit from a successful subsidiary-sponsored trial. Additionally, we extracted the 
General Payments (minus food/beverage payments) for the year following trial publication 
to examine the continuation of the industry-author financial relationship after publication 
of a high-impact trial.  
 
The Open Payments Database categorized payments into four categories: 
 
1) General: These include consulting fees, speaking fees, honoraria, gifts, 
entertainment, food and beverage, travel and lodging, and education. 
2) Research payments: Payments associated with a research study, including basic and 
applied research, and product development. 
3) Associated research payments: Funding for a research project or study where the 
physician is named as a principal investigator.  
4) Ownership: Ownership and investment interest in companies, which describes both 
the actual dollar amount invested and the value of the ownership or investment 
interest. 
 
We cross-referenced author disclosure statements from the published report with 
the payments received from the industry sponsor of the drug. A disclosure statement was 
considered inaccurate if an author did not completely disclose the financial relationship 
depicted in Open Payments. For example, if an author disclosed only grant funding from 
the sponsor of their trial, but received speaking, consulting, or honoraria fees. Authors 
commonly reported only “personal fees” and we were unable to uniformly determine if this 
referred to grants, research payments, or personal payments. Therefore, as long as the 
personal fees were from the sponsoring company, we were forced to consider this 
sufficient. We did not encounter any Ownership payments; therefore, the Results and 
Tables exclude this category.  
Sums, means, and medians, were calculated using Microsoft Excel. We made violin 
plots using RStudio and the package ggplot2 for visual representation of the distribution of 





Between January 1, 2016 and August 30, 2017, we 
identified 56 FDA hematology/oncology approvals. 
Ten approvals were excluded from this analysis. The 
remaining 46 approvals were based on 61 clinical 
trial numbers, of which 43 were included for 
analysis (for exclusions see Figure 6). These 43 
clinical trial numbers were each successfully linked 
with a published trial. In all, 1,007 authors were included. From these 1,007 total authors 
we identified 344 United States physicians to be included for our primary analysis (Figure 
6). There was a median of 11 United States physicians per manuscript (IQR 7.5 - 20). All 
manuscripts identified were published in one of six journals: JAMA Oncology, Journal of 
Clinical Oncology (JCO), New England Journal of Medicine (NEJM), The Lancet, The 
Lancet: Oncology, The Lancet: Haematology. All six journals adhere to the International 
Committee of Medical Journal Editors (ICMJE) policy regarding FCOI and require authors 
to fill out a disclosure form prior to manuscript submission.  
 
Primary Objective 
Of 344 authors, 263 (76.5%) accepted at least one payment, 196 (57.0%) accepted 
more than $100,000, 48 (14.0%) accepted more than $1,000,000, eight (2.3%) accepted 
more than $5,000,000, and two (0.6%) accepted more than $10,000,000. The largest 
amount of money received during the course of a clinical trial was $25,661,335 from 
Novartis. The median total payments to authors was $195,321 (IQR $532 - $597,628) with 
a cumulative total of $216,627,353.  
For General payments, authors accepted a median of $2,828 (IQR $0 - $19,628), 
and a total of $6,318,031. For Research payments, authors accepted a total of $513,885 
(median of $0). For Associated Research payments, authors received a median of $164,644 
(IQR $0 - $551,926) and a total of $209,795,437 (Table 3). 
  
 












(IQR) $2,828 ($0 - $19,628) 0 ($0 - $0) $164,644 ($0 - $551,926) 
Mean (SD) $18,336 ($107,087) $1,494 ($10,841) $609,870 ($1,843,467) 




(IQR) $1,170 ($0 - $20,506) $0 ($0 - $0) $81,591 ($0 - $518,546) 
Mean (SD) $19,544 ($128,467) $1,173 ($5,500) $563,049 ($1,900,634) 




(IQR) $3,783 ($58 - $18,793) $0 ($0 - $0) 
$292,273 ($44,909 - 
$667,547) 
Mean (SD) $15,861 ($28,249) $2,188 ($17,457) $709,472 ($1,719,681) 
Sum $1,744,762 $240,678 $78,041,888 
Table 3. Payments to included oncologist-authors (n = 344). 
 
Secondary Objective 
Of 344 authors, 110 (31.9%) did not fully disclose their FCOI from the trial’s 
sponsor. Of these 110 authors, 79 (71.8%) accepted more than $100,000, 17 (15.5%) 
accepted more than $1,000,000, and 4 (3.6%) accepted more than $5,000,000. The greatest 
amount of undisclosed payments accepted during one clinical trial was $15,363,234 from 
Novartis. For General payments, non-disclosing authors accepted a median of $3,783 (IQR 
$58 - $18,793), and a total of $1,741,186. For Research payments, non-disclosing authors 
accepted a total of $240,678 (median $0, IQR $0 - $0). For Associated Research payments, 
non-disclosing authors accepted a median of $292,273 (IQR $44,909 - $667,547), and a 
total of $78,041,888.  
Twenty-nine authors published trials between 2013 and 2015. These authors were 
assessed for an increase in General payments (minus food/beverage) the year following 
publication of their manuscripts. Thirteen (44.8%) received more General payments (minus 
food/beverage) in the year following than their average amount received in the years 
previous. The mean year-after increase was $7,770. Thirteen (44.8%) received no 
payments during and after the completion of their trial. Three (10.4%) received less than 








The 43 trials reported on 23 unique oncology drugs and were published with 
financial support from 19 unique sponsors (or combinations, thereof). Merck (n = 70), 
Hoffman-La Roche/Genentech (n = 49), and Bristol-Myers Squibb (n = 45) funded the 
most authors. The sponsors with the highest proportion of authors with undisclosed FCOI 
were Pfizer (9/16, 56.3%), Eisai (6/12, 50.0%), and Tesaro (3/6, 50%). Data for each 




Authors published most often in The Lancet: Oncology (n = 115), New England 
Journal of Medicine (n = 100), and The Lancet (n = 70). The journals with the highest 
proportion of authors with undisclosed FCOI were New England Journal of Medicine 
(46/100, 46.0%), The Lancet (26/70, 37.1%), and The Lancet: Haematology (11/30, 
36.7%). Authors published in New England Journal of Medicine had the highest median 
undisclosed General payments, while authors in The Lancet had the highest median 
Associated Research payments.  
 
Discussion 
Our study found that approximately one in three oncology authors failed to 
adequately disclose industry financial conflicts of interest (FCOIs). Moreover, the median 
undisclosed payments exceeded the median disclosed payments for General and Research 
payments. Further, we demonstrated that physicians who published high-profile oncology 
drug trials received more General Payments (e.g., honoraria, consulting fees, 
travel/lodging) in the year following publication. These findings are consistent with what 
has been shown in the oncology literature.47,153,231  
Historically, opinions regarding FCOIs in medical research have differed. Most 
parties would agree that the relationship between industry and physicians has benefited 
patients with cancer through the development of drugs that improve survival and quality 
of life. At the same time, there is widespread concern that the pharmaceutical industry’s 
role in medical practice unduly influences professional behavior and judgement.152,232  
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These concerns are likely to grow since industry continues to fund an increasingly large 
proportion of medical research.233  
Some skeptics question whether the emphasis on FCOI disclosures misses the mark 
of preventing bias, arguing that it is the receipt of payments that increases the risk for 
bias.234 To them, there is less value in requiring FCOI disclosures, since disclosure cannot 
retroactively prevent bias. The might also question whether all payments from industry 
should be called “conflicts”, since aligning with industry represents a “confluence” of 
physician interests to better serve patients.235  
Countering such skepticism, there is credible evidence that industry-sponsored 
studies are more likely to report favorable efficacy results224 and that oncologists who 
receive industry payments are more likely to prescribe industry drugs.92 Further, 
proponents of FCOI disclosure argue that a lack of disclosure can signal potential bias, and 
allow the reader an opportunity to draw conclusions regarding the validity of the study 
results. They would further argue that simply disclosing payments is not enough, and that 
stricter standards and regulations should be applied to industry-author financial 
relationships.232  
At minimum, these stricter standards and tighter regulations would include cross-
referencing an author’s voluntary FCOI disclosure with Open Payments data. Open 
Payments Database is organized to make searching for authors and their payments easy 
and quick. To explain the utility of this practice, consider a scenario from our dataset. A 
physician authored three trials for pembrolizumab: one for the treatment of gastric cancer; 
two for the treatment of head and neck squamous cell carcinoma. In the author’s first 
publication he declared no competing FCOIs. In his next two publications he reported a 
financial relationship with Merck. He received payments in years prior to his first 
publication, all the way through his last publication. 
Scenarios like this example were common in our analysis and suggest that authors 
are willing to disclose FCOIs, but occasionally do not for unknown reasons. Moreover, it 
may reflect inertia in conforming to standards for FCOI disclosure. However, as also shown 
in the example, the inertia can be overcome, since he did eventually disclose his FCOIs. 
The original causes for undisclosed FCOIs must be identified and addressed to continue 
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progress towards complete transparency in FCOI disclosures. Ignoring the barriers to FCOI 
disclosure is not an option, since financial bias can affect the conduct of clinical trials.236  
We recommend that journals, trial sponsors, and authors review the Open Payments 
Database for each clinical trial they conduct or publish. Though, for these parties to commit 
to this practice, the database must be recognized as accurate. Anecdotally, some have 
recently given accounts of discrepancies in the database, but these accounts focus on 
misattributed General Payments, such as meals.237 Furthermore, when larger issues arose 
soon after the creation of the database, the Centers for Medicare and Medicaid Services 
took drastic measures to resolve and prevent future errors,238,239 making it unlikely that a 
six-figure research payment to an author could be misattributed. Such large payments were 
common among oncologists in our analysis. The current nature of oncology research relies 
on expert opinion and experts who frequently work alongside industry in clinical research, 
and one would expect such relationships to have a financial component.240 These payments 
do not, and should not, prevent the publication of a clinical trial; but, failure to disclose 
these payments raises suspicion for bias. 
As the pharmaceutical industry’s involvement in medical research has grown, the 
medical community has directed increasing attention to the issue of financial bias.41,241 
Now, complete FCOI disclosure is often seen as a minimum obligation. In light of this 
investigation’s findings, a critical next question is: which parties, if any, are responsible 
for ensuring complete disclosures of FCOIs? Currently, physicians, industry, and journals 
seem to work separately in handling the disclosure of FCOIs, but it appears to us that 
complete disclosure will require these parties to work in concert. 
Trialists must learn to prioritize disclosure complete disclosure of FCOIs so that it 
becomes second nature, akin to recruiting participants. Pharmaceutical companies should 
require authors they fund to completely disclose all FCOIs in all trial-related publications. 
Such a policy could be emphasized prior to entering a financial relationship and include 
this requirement in any mutually approved contract. Journals should act to educate and 
require peer reviewers to cross-reference an author’s voluntary FCOI disclosure with Open 
Payments data. Cross-referencing author disclosures and payments could be expedited by 
requiring authors to submit a link to their Open Payments information. Then, any 
discrepancies could be included in peer reviewer comments to authors and authors could 
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be required to respond. If all three parties buy in, undisclosed FCOIs could be eliminated 
either by completely disclosing them or clarifying any rare instance of a misattributed 
payment.  
The limitations of our study include potential inaccuracies of the Open Payments 
Database and human errors in data extraction. Even though most physicians are listed with 
middle initials, specialty, and location, not all physicians have this information. In such 
cases, it is possible that we were led to extract data from the wrong physician. All efforts 
were taken to mitigate this possibility, including data extraction and verification from three 
authors. 
To conclude, we found that close to one in three physician authors of FDA-
approved drug trials failed to completely disclose FCOIs. Three parties — authors, 
sponsors, and journals — share in the responsibility for correcting this problem. Each plays 
a key role in addressing concerns for financial bias in high-impact oncology clinical trials. 
We argue that, so long as industry plays a role in funding oncology clinical trials, complete 
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When authors misrepresent, distort, or otherwise selectively feature specific 
research data they introduce “spin” to the literature. The prevalence of spin has been 
quantified in a recent SR, which found that a median of 56.8% of trials contain some form 
of spin242. The effect of spin has been demonstrated in a two-arm, parallel group 
randomized trial involving 300 oncologists who were asked to evaluate a trial abstract with 
a nonsignificant primary endpoint52. Half were assigned to read an abstract with an overly 
optimistic conclusion about the intervention, while the other half read an abstract that 
concluded no benefit of the intervention. Oncologists who received the abstract with the 
overly optimistic conclusion rated the intervention as more effective, the trial as less 
rigorous, and were more likely to read the full text of the trial. 
In 2016, a trial was published that examined the effect of adjuvant sunitinib on 
advanced stage renal cell carcinoma post nephrectomy.  This trial, which formed the basis 
for FDA approval, used improvements in a surrogate endpoint (disease-free survival) as 
evidence of drug efficacy, and relegated the collinear Kaplan-Meier curves for OS to the 
Supplement.243 Despite OS being the secondary endpoint, the eight year follow-up data 
and hazard ratio of 1.01 (95% CI, 0.72 to 1.44) was highly suggestive of no survival benefit. 
Indeed, a letter in reply to this trial was written to emphasize that the goal of cancer therapy
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 is to extend survival and mitigate adverse events, neither of which was shown in this trial 
of sunitinib244. Some have described the FDA approval of sunitinib as “regulatory 
capture”245, which occurs when parties with high-stakes interest in a policy decision 
overpower other parties with less interest to achieve an intended outcome. We have an 
additional concern: how certain research data can be highlighted or omitted in order to shift 
perceptions of a drug’s efficacy. In this case, by not mentioning the nonsignificant OS data 
in the abstract and placing the Kaplan-Meier graph in the Supplement, the authors of the 
sunitinib study framed their printed study around a statistically significant surrogate 
endpoint and omitted visual evidence of the nonsignificant survival benefit. 
There are many forms of spin in the reporting of medical research findings, but at 
its core spin is an attempt to beautify or omit unfavorable results.242 Abstracts may be most 
susceptible to spin because of the limited word counts enforced by journals. Further, the 
consequences of spin in abstracts may be more severe. There is evidence that many 
physicians only read the abstract of most research articles246–248. Moreover, institutions in 
low- or middle-income countries may not have the resources to access the full text of 
articles. Thus, abstracts must be accurate synopses of full manuscripts and avoid 
misleading conclusions about drug efficacy. In oncology, spin occurs in the abstracts as 
well as the full text of manuscripts185,249. Trial authors may omit toxicity results or 
selectively report endpoints based on statistical significance. And while all areas of 
medicine including oncology are susceptible to spin, we argue that the oncology literature 
may be most susceptible due, in part, to the presence of surrogate endpoints that are 
designed to predict clinical benefits to patients. 
Surrogate endpoints are often acceptable in oncology trials250, even for FDA 
approval.3 However, OS is considered the ideal survival endpoint in oncology trials owing 
to its objectivity and relevance to patients.251 But, OS requires increased sample size and 
follow-up duration, which may delay the approval or development of new therapies.252 
Owing to these factors, surrogate endpoints have increased in popularity as primary 
endpoints since they often require fewer patients and less time to measure.250 Despite their 
popularity, surrogate endpoints are often imperfect measures of OS and frequently have 
larger effect sizes.253 The fact that surrogate endpoints are often imperfect measures of 
treatment effectiveness, they may show discordant results and OS may be required to 
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clarify treatment utility in practice. However, because OS is more often statistically 
nonsignificant, authors may be tempted to spin toward the surrogate endpoints that tend to 
have larger effect sizes. 
Regardless of which endpoint is primary and which is secondary, selectively 
emphasizing a secondary endpoint or subgroup analysis means authors are emphasizing 
fragile, underpowered results. Since surrogate endpoints and OS are almost equally 
acceptable in clinical trials, oncologist-authors may feel comfortable focusing on 
whichever of these endpoints is statistically significant. Therefore, the primary objective 
of this novel investigation is to evaluate the frequency and manifestations of spin in 
oncology clinical trials that measured a surrogate endpoint and OS. 
 
Methods 
We searched PubMed on March 30, 2018 to identify clinical trials published in 
2017 reporting at least one key surrogate endpoint and OS published in ten key journals. 
The exact search strategy is publicly available via the Open Science Framework.254 The six 
key surrogate endpoints were PFS, disease-free survival, objective response rate, complete 
response, time to progression, and time to treatment failure. These surrogate endpoints 
were selected based on the Food and Drug Administration’s (FDA) “Guidance for Industry: 
Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics” document.255 
The following journals were searched: Journal of Clinical Oncology, The Lancet: 
Oncology, JAMA Oncology, Cancer, Annals of Oncology, Journal of the National Cancer 
Institute, British Journal of Cancer, European Journal of Cancer, New England Journal 
of Medicine, and The Lancet. Search results were added to a PubMed collection and 
uploaded to Rayyan256. 
One of us (CW) screened all articles for inclusion. To be included an article had to 
meet the following criteria: randomized clinical trial with a head to head comparison, 
measure both a surrogate endpoint from the FDA “Guidance to Industry” list and OS, and 
conduct a superiority analysis. We excluded articles that were not clinical trials, clinical 
trials with an incompatible design (e.g., cluster, crossover, single arm), pooled analyses, 
noninferiority analyses, and trials of non-oncologic interventions published in the included 
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general medical journals. Three of us (CW, DM, and KV) extracted data for all included 
trials. 
 
Definition of Spin 
Our definition of spin was based on Boutron, et al.,137 which states that spin is the 
“use of specific reporting strategies, from whatever motive, to highlight that the 
experimental treatment is beneficial, despite a statistically nonsignificant difference for the 
primary outcome, or to distract the reader from statistically nonsignificant results.” We 
modified this definition to include all trials regardless of the statistical significance of the 
primary endpoint. Doing so allowed us to capture evidence of spin in abstract conclusions 
when a surrogate endpoint (primary endpoint) was statistically significant and OS 
(secondary endpoint) was nonsignificant. 
 
Objectives 
Our primary objective was to assess the frequency and manifestations of spin in 
oncology clinical trials that report both a surrogate endpoint and OS. Spin was assessed 
within a trial (i.e., emphasizing a subgroup analysis when the primary analysis is 
nonsignificant) and outside a trial (i.e., selective outcome reporting bias - adding, 
subtracting, or changing the order of trial endpoints compared to a trial registry before 
publication). In the former (within a trial), primary trial endpoints would match the registry, 
but they would be reported out of order or with different emphasis. In the latter (selective 
outcome reporting bias), trial endpoints would not match the registry. Our secondary 
objective is to compare trials with OS as the primary endpoint and with OS as the secondary 
endpoint.  
 
Spin in the abstract title and results 
We considered there to be evidence of spin if a study title suggested treatment 
effectiveness where none exists. For example, if a title began with “First line use of…”, 
despite showing no significant benefit of the intervention, this may be spin and mislead 
readers about the study conclusions. We considered there to be spin in abstract results when 
a trial emphasized statistically significant results out of order (e.g. subgroup before overall 
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analysis, secondary endpoint before primary endpoint), reported a per-protocol analysis 
when intention-to-treat was prespecified, or used “trend statements” in the description of 
statistical significance (e.g., “trend toward significance”). We did not consider it to be spin 
if a trial omitted a secondary endpoint (including OS) from the abstract results section, 
since this could be interpreted as the standard reporting of results. 
 
Spin in the abstract conclusions 
We considered there to be evidence of spin when a trial interpreted statistically 
nonsignificant results as showing treatment equivalence or comparable effectiveness, 
focused on a significant subgroup or within-group comparison, used unjustified, optimistic 
statements in the description of outcomes, emphasized subgroups or modified treatment 
populations, distracted from nonsignificant findings by stating that the nonsignificant 
results were due a trial design issue (e.g., underpowered), or claimed treatment benefit from 
a statistically significant surrogate endpoint when OS was nonsignificant. We considered 
using only a surrogate endpoint as evidence of treatment benefit as spin because surrogate 
endpoints have been shown to be poor predictors of OS.61 Abstract conclusions frequently 
state that the primary, surrogate endpoint was met while maintaining a focus on patient-
important endpoints, such as OS. A clear statement that OS data was nonsignificant was 
not required. In phase 2 trials or interim analyses of phase 3 trials, we did not consider 




Summary statistics (frequencies and proportions) were calculated using Google 
Sheets. We used Stata 15.1 (Stata Corp, LLC; College Station, TX) and Fisher’s exact test 





Of the 620 articles retrieved, 124 
were included. Articles were excluded 
mostly for not being oncology trials 
published in general medical journals, 
being nonrandomized (including single-
arm trials), or for not measuring both a 
surrogate from the FDA guidance 
document and OS. Figure 7 itemizes all exclusions.  
Table 4 itemizes characteristics of the included trials and describes the proportion 
of trials with spin associated with each characteristic. Overall, in the 124 trials there were 
126 primary endpoints: 71 were surrogate endpoints and 55 were OS. In five trials, OS and 
a surrogate endpoint were co-primary endpoints, while in nine trials the surrogate endpoint 
and OS were co-secondary endpoints. The most common surrogate endpoints measured 
were PFS (n = 46), followed by disease-free survival (n = 17), and overall response rate (n 
= 3). The primary endpoint was clearly described in 86.3% (107/124) of abstracts. In the 
majority of cases, the primary endpoint was not statistically significant (79/126; 62.7%, 
95%CI 54.0%-70.7%).  
We found evidence of spin in 46 of 124 (37.1%, 95%CI 29.1%-45.9%) of trial 
abstracts (Table 5). There was no evidence of spin in trial titles. Spin was present in 19 
(15.3%, 95%CI 9.9%-22.4%) abstract results and 40 (32.3%, 95%CI 24.7%-40.9%) 
abstract conclusions. Of the 118 trials that reported a trial registration number, 10 (8.5%, 
95%CI 4.7%-14.9%) selectively reported their endpoints. Sixteen (12.9%, 95%CI 8.1%-
19.9%) RCTs had spin in both the abstract results and conclusions.  
When OS was a primary endpoint there was evidence of spin 29.1% (16/55; 95%CI 
18.8%-42.1%) of the time. OS was statistically significant in 3 of these trials; however, 
evidence of spin in each trial was due to selective reporting bias, which indicates that 




Figure 7. Flow diagram of included and excluded studies. 
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Characteristic Total No. (%) 
No. With Spin 
(%) 
Primary endpoint  
Overall survival 46 (37.1) 13 (28.2) 
Surrogate endpoint 60 (48.4) 24 (52.2) 
Both 9 (7.3) 3 (6.5) 
Neither (e.g., both secondary endpoints) 9 (7.3) 6 (13.0) 
Journal  
Journal of Clinical Oncology 31 (25.0) 16 (34.8) 
Lancet Oncology 30 (24.2) 5 (10.9) 
Annals of Oncology 19 (15.3) 10 (21.7) 
New England Journal of Medicine 16 (12.9) 4 (8.7) 
JAMA Oncology 9 (7.3) 3 (6.5) 
British Journal of Cancer 8 (6.5) 5 (10.9) 
Cancer 6 (4.8) 3 (6.5) 
Lancet 4 (3.2) 0 (0.0) 
Journal of the National Cancer Institute 1 (0.8) 0 (0.0) 
Control arm  
Active drug only 85 (68.5) 31 (67.4) 
Active + Placebo 22 (17.7) 4 (8.7) 
Placebo 12 (9.7) 9 (19.6) 
Other 4 (3.2) 1 (2.2) 
Surgery 1 (0.8) 1 (2.2) 
Funding source  
Industry 68 (54.8) 22 (47.8) 
Mixed (with Industry) 25 (20.2) 13 (28.3) 
Public (e.g., government) 24 (19.4) 6 (13.0) 
Private (e.g., foundation) 4 (3.2) 2 (4.3) 
Hospital 1 (0.8) 1 (2.2) 
Not mentioned 1 (0.8) 1 (2.2) 
Other 1 (0.8) 1 (2.2) 
Table 4. Characteristics of included studies and the proportion of studies with those characteristics that contained spin. 
 
Thus, when OS was the primary endpoint, spin was primarily used to distract from 
the nonsignificant OS data. When OS was a secondary endpoint there was evidence of spin 
43.5% (30/69; 95%CI 32.4%-55.2%) of the time. OS was statistically significant in 2 of 
these trials, meaning authors were most likely to frame their conclusions around 
statistically significant surrogate endpoint data, rather than patient important outcomes. 
There was no significant difference in the rates of spin when OS was a primary or 
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secondary endpoint (p = .13), indicating that evidence of spin was used for different reasons 
depending on which endpoint is primary and which is statistically significant.  
Location and type of spin No. (%) 
Total abstracts with evidence of spin 46 (37.1)  
Abstracts with spin in the title 0 (0.0) 
Abstracts with spin in the results* 19 (15.3) 
 
Focus on statistically significant subgroup analysis 6 
Use of suggestive language (e.g., trend toward significance) 5 
Omit statistically nonsignificant OS primary endpoint data 4 
Focus on hazard ratio, omit confidence interval and p-value 2 
Focus on statistical significance, ignoring small effect size 1 
Other 5 
Abstracts with spin in the conclusions* 40 (32.3) 
 
Recommend use of drug based on surrogate endpoint alone 17 
Emphasis on statistically significant subgroup analysis 5 
Interpreting a nonsignificant P value as showing noninferiority 5 
Focus on flaws in trial design rather than nonsignificant results 4 
Use of suggestive language (e.g., trend toward significance) 3 
Focus on statistical significance, ignoring small effect size 1 
Other 9 
Table 5. Location, type, and frequency of spin in abstracts. Sums may exceed the total because some abstracts 
contained multiple types of spin in multiple locations.  
 
Spin in the abstract results was most often due to authors emphasizing a statistically 
significant subgroup analysis (n = 6). Five trials used rhetoric to spin their data, 4 
emphasized a statistically significant secondary endpoint, and 2 reported only a ratio of 
events that favored the intervention and omitted the confidence interval or p-value that 
would have shown that the intervention effect was not statistically significant.  
Spin in the abstract conclusions was most often due to authors using a statistically 
significant surrogate endpoint to highlight the efficacy of their intervention, without 
caution because of nonsignificant OS data (n = 17). All of the included trials had mature 
OS data. Five trials emphasized a statistically significant subgroup analysis, 5 wrongly 
interpreted a nonsignificant p-value as showing equivalence between the experimental and 
control groups, and 4 distracted from nonsignificant findings by critiquing their trial 
design. Nine trials were classified as having “Other” evidence of spin, and in these cases 
the authors either claimed that the intervention was beneficial, despite reporting no 
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significant endpoints, or claimed to accomplish another objective that was not established 




Our results show that spin is prevalent in the abstracts of oncology clinical trials 
that measure OS and a surrogate endpoint. The conclusion sections of abstracts were most 
prone to contain spin. OS was more often a secondary endpoint. As a secondary endpoint, 
OS was statistically significant only twice; therefore, authors frequently concluded a 
treatment was effective based on significant surrogate endpoint data alone. And while it is 
not spin to discuss statistically significant surrogate endpoints when they are the primary 
endpoint of a trial, we considered it to be spin to ignore nonsignificant OS data and 
conclude that a treatment is definitively effective based on a surrogate endpoint alone. 
These results are in line with previous investigations of spin both in oncology189,249,257 and 
the overall medical literature137,242,258, indicating that spin continues to affect the accurate 
interpretation of trial results by physicians. The implication of this finding is that 
misrepresented, distorted research findings are being purported as true to oncologists. 
Misrepresented or distorted research findings affect oncologist beliefs about drug 
efficacy. The SPIIN randomized trial demonstrated that oncologists believe drugs are more 
effective if the clinical trial abstract has spin in the conclusions.52 Furthermore, oncologists 
are also more likely to read the full text of a clinical trial that has spin in the abstract. The 
reading habits of oncologists indicate that the effects of spin may be compounded since 
investigations of spin in the full text of trials have demonstrated that spin occurs at a similar 
rate.137 It is known that internists often read only study abstracts, either to quickly learn or 
to screen out uninteresting results.246 If these findings hold true for oncologists, trial authors 
may be incentivized to spin nonsignificant results, since spin leads to more interest among 
readers, and may improve the chances of favorable peer reviews and publication.   
The tendency for trial authors to emphasize statistically significant surrogate 
endpoints when OS is nonsignificant is not surprising. Surrogate endpoints are increasingly 
important to the field of oncology and often are the basis for new drugs approvals under 
the FDA Accelerated Approval pathway.3 Clinical trial authors may believe that the 
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intervention drug is truly effective, even without OS data. Optimism bias toward new 
oncology interventions has been described previously.257 However, when OS data is 
mature, available, and nonsignificant it may be difficult for authors to conclude that their 
drug is beneficial. Even if OS is a secondary endpoint, concluding that a treatment is 
beneficial may be difficult when only significant surrogate endpoint data are available at 
the time.  
When authors deemphasize available OS data, there may be consequences for 
patients. Patients receiving adjuvant sunitinib may, like the oncologist-authors and the 
FDA reviewers, believe the drug is more effective than it truly is. Surrogate endpoints are 
useful when they predict OS early and accurately, but surrogate endpoints are incapable of 
completely replacing OS. Caution may be warranted in a trial that has statistically 
significant surrogate endpoint data and nonsignificant OS data, regardless of which 
endpoint is primary or secondary, since OS is what the surrogate endpoint is trying to 
predict.  
To conclude, this investigation of spin in the abstracts of oncology clinical trials 
measuring OS and a surrogate endpoint shows that spin is common. Further, as a secondary 
endpoint, OS was statistically significant twice, raising questions about trial design and the 
utility of OS as a secondary endpoint. Nevertheless, authors frequently conclude a 
treatment is effective based on only statistically significant surrogate endpoint data. Spin 
was most common in the conclusion sections of abstracts, where authors interpret their 
results. The consequences of spin may include confusion about the true efficacy of a drug 
for patients and the dissemination of distorted conclusions to oncologists. 
This study is limited by the 1-year cross section that was chosen for analysis. It is 
possible that our results do not reflect the reporting of oncology trials outside the chosen 
time frame, including clinical trials that were published in 2018 and later. Readers should 
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In medical research, hype is the early excitement surrounding promising 
interventions, despite a lack of substantial supporting evidence.259 Hype often opposes 
reason, but it is common, such as when cancer drugs are heralded as “game changers” 
despite having been evaluated only in animals and not having received Food and Drug 
Administration (FDA) approval. Journalists often perpetuate such hype, though physicians 
also may be responsible.45 Cancer researchers perpetuate hype by casting unfavorable 
(nonsignificant) results in a favorable light.185,249 This dangerous practice leads physicians 
to overstate a drug’s efficacy.52 
 We argue that hype affects the oncology community in particular owing to the 
prevalence of surrogate endpoints. The popularity of surrogate endpoints among oncology 
trial sponsors and investigators has been met with caution from others in the medical 
community.260–262 This skepticism exists because surrogate endpoints often fail to predict 
the clinical endpoints that are most important to patients: OS and quality of life.61,250,263 
Nevertheless, most new drugs that receive accelerated approval from the FDA are analyzed 
using surrogate endpoints,61 and the market price for drugs approved based on surrogate 
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endpoints does not differ from the price of drugs approved based on OS.264 When drugs 
granted accelerated approval report the required follow-up data, it is frequently for another 
surrogate endpoint, which can generate hype.3 The current process for drug approvals 
means that formal assessments of OS may be delayed until after the drug has been widely 
used in patient care. 
 One increasingly popular surrogate endpoint for OS is PFS. PFS is a composite 
endpoint that combines assessments of tumor progression and death from any cause.255 In 
oncology studies, the strength of association between PFS and OS varies and depends on 
tumor type, tumor stage, and drug intervention.265,266 A recent study showed that effect 
sizes are significantly larger for PFS than for OS.253 PFS requires less time and fewer 
patients to achieve statistical power. Thus, although oncology trials often report both PFS 
and OS, they may publish the mature PFS data apart from the mature OS data. Publishing 
interim trials with only mature PFS data apart from the confirmatory analyses of OS may 
promote hype.  
 In this investigation, we analyzed the hype generated by oncology clinical trials 
that published interim analyses. We investigated whether significant differences existed 
between interim and final analyses, with respect to the Altmetric score and journal 
prominence. We restricted our sample to trials that assessed both PFS and OS, because a 
recent analysis of interim results excluded these trials.128  
 
Methods 
First, we searched PubMed, including Medline, on January 18, 2018, using the 
following search strategy: (((interim) OR immature) OR not mature) AND (overall survival 
AND progression free survival) AND Clinical Trial[ptyp] AND ("2005/01/01"[PDat] : 
"2015/12/31"[PDat]). We placed no restriction on included journals. All records were 
gathered in a PubMed collection. 
Next, we exported this collection of 393 records to Rayyan.256 We excluded any 
record that was not a randomized clinical trial, trial protocols, trials that did not assess both 
PFS and OS, and any record not available in English. To be included, a randomized clinical 
trial must have reported mature PFS data and denoted their OS data as immature. We 
further included any trials in which OS not denoted as immature but in which the 
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prespecified number of deaths had not occurred. If we identified a trial reporting final or 
updated OS results, we attempted to identify the interim analysis with PFS data. 
To match interim analyses with their corresponding final analyses, we used a 
combination of a PubMed search using the PICO (population, intervention, comparator, 
outcome) format, review of clinical trial registries, and emails to corresponding authors. If 
an author did not respond to our email, we sent 2 additional emails at 1-week intervals.  
One of us (CW) independently extracted the following data from each interim and 
final analysis: title, year of publication, journal, intervention drug, comparator drug(s), 
whether a PFS benefit was demonstrated, median survival times and hazard ratio, cancer, 
cancer setting, trial funding source, trial design (e.g., superiority or noninferiority), whether 
an interim analysis was prespecified, and number of required PFS and OS events to achieve 
statistical power. All data were extracted via a piloted and validated Google Form. We 
retrieved the Altmetric score for each interim and final analysis using the “Altmetric it” 
bookmarklet, which identified the Altmetric score for each trial from PubMed. 
To compare the interim and final analyses, we identified whether a PFS or OS 
benefit was demonstrated. Authors reported hazard ratios (HR) with confidence intervals 
most often. We calculated the ratio of hazard ratios (rHR) between PFS and OS (HR-PFS 
/ HR-OS) to determine whether the HR effect size favored PFS or OS. This method was 
derived from a recent analysis of PFS and OS HR effect sizes.253 As needed, the direction 
of effect was stabilized so that an HR less than 1.0 favored the intervention. This 
convention means that an rHR of less than 1.0 indicates a larger effect size for PFS 
compared to OS.  
We further asked whether the publication of an interim analysis, apart from its final 
OS analysis, was justified based on the strength of the correlation between PFS and OS. 
To answer that question, we searched the literature to determine the strength of the 
correlation between the two endpoints for the specific tumor, tumor setting, and drug class. 
We began by referencing an SR of the correlation between surrogate endpoints and OS in 
oncology.61 For any tumors, tumor settings, or drug classes that were not included, we 
searched PubMed (Medline) using the PICO format. We considered a strength of 
correlation of r ≤ 0.7 to be low, 0.7 < r < 0.85 to be medium, and r ≥ 0.85 to be high, based 
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on Prasad et al.’s SR, which adapted the Institute of Quality and Efficiency in Health Care’s 
convention for trial-level correlation.61,267 
  We used the Wilcoxon signed-rank test for matched pairs to compare differences 
in continuous variables and Fisher’s exact test to compare differences in categorical 
variables. For our rHR analysis, visual inspection of the histogram and results from the 
Shapiro-Wilk test of normality indicated that the data were not normally distributed. 
Therefore, we report a median rHR and use this median to determine the median-effect size 
difference between PFS and OS. We used Stata 13.1 for all statistical analyses. 
 
Results 
Our search of PubMed retrieved 393 records. Figure 8 itemizes the 360 excluded 
records. We identified 27 interim analyses with mature PFS data, and we found an 
additional 6 via final analyses with mature OS data from our search. Of the 33 interim 
analyses with mature PFS data identified, only 25 could be paired with a final analysis. We 
excluded 2 of these matched pairs, because their final analyses were either in an abstract 
or in-press in a journal without an impact factor. The eight unmatched interim analyses 
have not yet published mature OS data. Therefore, 23 matched pairs were included. Unless 
otherwise specified, our results are for the 23 interim analyses with a final analysis pairing.  
 
Figure 8. Flow diagram of included and excluded studies, including how studies were matched after initial search. 
All interim analyses (n = 33) were prespecified and conducted in accordance with 
that trial’s protocol. A statistically significant PFS benefit occurred in 93.9% (31/33) of 
interim analyses. At long-term follow up, the PFS effect size decreased in 8 trials (2 became 
nonsignificant), increased in 5 trials, and remained the same in 1. Eleven trials did not 
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report updated PFS data. A statistically significant benefit in OS occurred only 8 times, 
although 12 trials allowed crossover and 2 administered additional therapies to patients 
after progression. In the 2 interim analyses with a statistically nonsignificant PFS benefit, 
a statistically significant OS benefit occurred in 1 of them. That trial compared concurrent 
and sequential alternating gefitinib in previously untreated metastatic non-small cell lung 
cancer.268 Across all studies (n = 33), to achieve statistical power, the median number of 
required patient events was 282.50 (interquartile range [IQR] 191.50–380.25) for interim 
PFS analyses and 385 (IQR 245–492) for final OS analyses.  
Among matched pairs (n = 23), interim analyses were published in more prominent 
journals compared to final analyses (Table 6). Specifically, interim analyses were more 
likely to be published in the top 5 general medicine journals (e.g., New England Journal of 
Medicine, The Lancet) but not more likely to be published in the top 5 oncology journals 
(e.g., Journal of Clinical Oncology, The Lancet: Oncology). Interim analyses were 
published in journals with an impact factor of ≥ 20 more often, but this difference was not 
statistically significant. The median impact factor was 44 (IQR 24–72) for journals 
publishing interim analyses versus 24 (IQR 11–34) for journals publishing final analyses. 
Only 2 interim analyses were published in journals with an impact factor less than 10, 
compared to 6 final analyses; 1 final analysis was published as an abstract, and 1 was an 
in-press manuscript. The impact factor increased once and remained the same 3 times from 
interim to final publication. 
Interim analyses also had higher Altmetric scores than final analyses. The median 
Altmetric score was 28 (IQR 13.25-82.25) for interim analyses versus 18 (5-46) for final 
analyses (p = .002). Of the 2 final analyses that had no Altmetric scores or impact factors, 
1 was an abstract and 1 was an in-press manuscript in ESMO: Open. The Altmetric score 
increased 3 times and remained the same 1 time from interim to final analyses. 
We were able to compare PFS and OS effect sizes in 24 trials. The PFS effect size 
was larger than the OS effect in 21 of 24 (87.5%) trials. When comparing the interim 
analyses with mature PFS data and the final analyses with mature OS data, the median rHR 
was 0.69 (0.51–0.86), corresponding to a median 31% larger effect size for PFS compared 
to OS (Table 7). The rHR was the same in immunotherapy trials (n = 8) where traditional 
80 
 
PFS is not yet a validated surrogate endpoint [0.69 (IQR 0.66-0.82)]. The effect size for 
PFS was larger than OS in all matched pairs of immunotherapy trials. 
 
Characteristics n (%) 
Reason for Interim Analysis 33 (100) 
 
Impact Factor ≥20 29 (87.9) 
Top 5 General Medical* 18 (54.5) 
Top 5 Oncology** 11 (33.3) 
Altmetric Score [Median (IQR)] 50 (10 - 129) 
PFS Benefit 
 Significant 31 (93.9) 
 Nonsignificant 2 (6.1) 
Funding 
 
Industry Alone 27 (81.8) 
Industry Partly 2 (6.1) 
Government 1 (3.0) 
Non-Profit 1 (3.0) 
None Listed 2 (6.1) 
Design 
 
Superiority 32 (97.0) 
Noninferiority 1 (3.0) 
Phase II 3 (9.1) 
Phase II/III 1 (3.0) 
Phase III 29 (87.9) 
Control Group 
 
Active 13 (39.4) 
Placebo 6 (18.2) 
Placebo Plus Active 13 (39.4) 
Surgery 1 (3.0) 
Number of PFS Events [Median (IQR)] 287 (193 - 384) 
Strength of Correlation Between PFS & OS 
 
High (r ≥ 0.85) 3 (9.1) 
Medium 0.7 < r < 0.85) 5 (15.2) 
Low r ≤ 0.7 22 (66.7) 
Unknown 3 (9.1) 







Interim (PFS) Final (OS) Difference (p-value) 
Journal Prominence* 
 
Impact Factor ≥20, n (%) 21 (91.3) 15 (65.2) 0.07 
Top 5 General Medical, n (%) 14 (60.9)) 3 (13.0) <0.01 
Top 5 Oncology, n (%) 8 (34.7) 13 (56.5)) 0.26 
Both Interim & Final in Impact 
≥20 Journal 
 13 (56.5)  
Altmetric Score* [Median (IQR)] 28 (13.25 - 82.25) 18 (5 - 46) <0.01 
Interim PFS (+) [n=15], Final OS (-) [n = 14]* 
 Impact Factor ≥20, n (%) 12 (80.0) 5 (35.7) <0.03 
Altmetric Score [Median (IQR)] 16.5 (7.25 - 43.25) 7 (1.5 - 17.25) <0.05 
Interim PFS (+), Final OS (+) [n = 8] 
 Impact Factor ≥20, n (%) 8 (100) 8 (100) n/a 
Altmetric Score [Median (IQR)] 137 (82 - 161) 42 (33 - 84) <0.05 




Journal of Clinical 
Oncology n/a 
Altmetric Score 77 60 n/a 
Interim PFS (-), Final OS (+) [n = 1] 
 Journal Annals of Oncology ESMO Open n/a 
Altmetric Score 6 n/a n/a 
Table 7. Characteristics of matched pairs of interim PFS and final OS analyses (n = 23). *Two were excluded from 
overall matched pair analysis due to publication as an abstract or for being in-press in a journal without an Impact 
Factor. The in-press matched pair is included in the stratified analysis but its Impact Factor is shown as "n/a".                 
 
In 19 of the 25 total matched pairs, there was a low (r ≤ 0.7) or unknown strength 
of correlation between PFS and OS (Table 8). In 3 cases, the strength of correlation was 
medium (0.7 < r < 0.85). In 3 other cases, the strength of correlation was high (r ≥ 0.85). 
For the 8 interim analyses that had yet to report final OS data, the strength of correlation 
between PFS and OS was low in 5 and medium in 3. All 8 unmatched interim analyses 
were published in New England Journal of Medicine (n = 3), The Lancet: Oncology (n = 
2), Journal of Clinical Oncology (n = 2), or The Lancet (n = 1). 
Overall, New England Journal of Medicine published the most interim analyses of 
PFS (n = 9), all of which were statistically significant. Only 2 nonsignificant interim 
analyses of PFS were published — 1 in The Lancet: Oncology and 1 in Annals of Oncology. 
For final analyses of OS, The Lancet: Oncology published the most (n = 7), of which 5 













Type of Cancer Strength of Correlation 
PFS (+) 
OS (-) 
n = 16 
Yardley, 
2013 Everolimus 
0.38 (0.31 - 
0.48) 
0.89 (0.73 - 
1.10) 0.43 Breast Low 
Schmittel, 
2006 Irinotecan no HR 
0.75 (0.54 - 
1.03) n/a Small-cell lung Medium 
Brufsky, 
2012 Bevacizumab 
0.49 (0.33 - 
0.74) 
1.01 (0.85 - 







0.82 (0.72 - 
0.94) 
0.99 (0.85 - 
1.16) 0.83 Ovarian Unknown 
Aghajanian, 
2012 Bevacizumab 
0.48 (0.39 - 
0.61) 








2.3 (1.08 - 
4.94) 
0.91 (0.70 
to 1.14) 2.54 Ovarian Low 
Escudier, 
2007 Bevacizumab 
0.63 (0.52 - 
0.75) 
0.91 (0.76 - 
1.10) 0.69 Renal Low 
Pavel, 2011 Everolimus 0.77 (0.59 - 1) 
1.17 (0.92 - 
1.49) 0.66 Neuroendocrine Low 
Nordlinger, 
2008 FOLFOX4 
0.73 (0.55 - 
0.97) 
0.88 (0.68 - 
1.14) 0.83 Colorectal High 
Bolla, 2005 Post-op irradiation 
0.49 (0.41 - 
0.59) 
1.18 (0.91 - 
1.53) 0.42 Prostate Unknown 
Motzer, 2008 Everolimus 0.3 (0.22 - 0.40) 
0.87 (0.65 - 
1.15) 0.34 Renal Low 
San-Miguel, 
2014 Panobinostat 
0.63 (0.52 - 
0.76) 
0.94 (0.78 - 




0.57 (0.45 - 
0.73) 
0.86 (0.67-
1.10) 0.66 Melanoma Low Pembrolizumab 
[10mg/kg arm] 
0.50 (0.39 - 
0.64) 
0.74 (0.57-
0.96) 0.68 Melanoma 
Perren, 2011 Bevacizumab 0.81 (0.70 - 0.94) 
0·99 (0.85 - 
1.14) 0.82 Ovarian Unknown 
Ledermann, 
2012 Olaparib 
0.35 (0.25 - 
0.49) 
0.73 (0.55 - 
0.96) 0.48 Ovarian Unknown 
PFS (+) 
OS (+) 
n = 8 
Ryan, 2013 Abiraterone 0.53 (0.45 - 0.62) 
0.81 (0.70-
0.93) 0.65 Prostate Unknown 
Choueiri, 
2015 Cabozantinib 
0.58 (0.45 - 
0.75) 
0.66 (0.53 - 
0.83) 0.88 Renal Low 
Stewart, 
2015 Carfilzomib 
0.69 (0.57 - 
0.83) 
0.79 (0.67 - 
0.95) 0.87 Multiple myeloma Medium 
Long, 2014 Trametinib 0.75 (0.57 - 0.99) 
0.71 (0.55 - 
0.92) 1.06 Melanoma High 
Larkin, 2014 Cobimetinib 0.51 (0.39 - 0.68) 
0.7 (0.55 - 
0.90) 0.73 Melanoma High 
Baselga, 
2012 Pertuzumab 
0.62 (0.51 - 
0.75) 
0.66 (0.52 - 
0.84) 0.94 Breast Low 
Escudier, 
2007 Sorafenib 
0.44 (0.35 - 
0.55) 
0.88 (0.74 - 
1.04) 0.50 Renal Low 
Krop, 2014 Trastuzumab 0.53 (0.42 - 0.66) 
0.68 (0.54 - 
0.85) 0.78 Breast Low 
PFS (-) 
OS (-) Weber, 2015 Nivolumab 
0.82 (0.32 - 
2.05) 
0.95 (0.73 - 





0.71 (0.42 - 
1.20) 




Table 8. Comparison of Hazard Ratios for PFS and OS Among Matched Pairs (n=25). A hazard ratio (HR) less than one favors the 




 Our results demonstrate that interim analyses with mature PFS data generate hype 
in oncology. Compared to final analyses, interim analyses are more likely to be published 
83 
 
in top-5 general medical journals and more likely to have higher Altmetric scores. Two 
factors help to explain these differences. PFS was more likely to be statistically significant 
and have a larger effect size. Additionally, two recent investigations show that interim 
analyses in oncology are associated with exaggerated effect sizes and that PFS effect sizes 
are larger than OS effect sizes.253,269 Another investigation found that for FDA-approved 
drugs, the post-approval trials frequently have smaller treatment effects compared to their 
matched pre-approval trials.270 Lastly, Woloshin, et al found that one-fifth of final analyses 
fail to agree with the conclusions of the interim analyses.128 This last study suggests that 
no significant difference exists between interim and final publications regarding journal 
prominence and Altmetric score. Our results show the opposite.  
We believe that hype in the oncology literature is easier to generate than in the 
overall medical literature for several reasons. First, most current FDA approvals are for 
oncology drugs.271 Also, social and governmental pressure creates a sense of urgency 
among the oncology community to make cancer therapies available to patients.46 
Moreover, a large treatment effect often causes excitement, especially given the knowledge 
that recently approved cancer drugs improve OS by a median of only 2 months.116 
Nevertheless, our results should not discourage the analysis of surrogate endpoints. Instead, 
they should encourage the proper presentation of surrogate endpoint results.  
The publication of interim analyses with only mature PFS data apart from 
confirmatory OS analyses must be cautioned. We have demonstrated that the PFS effect 
sizes are frequently exaggerated, compared to the final OS analyses, and that OS fails to 
confirm a significant PFS benefit in most cases. On the contrary, recent investigations of 
the correlation between PFS and OS in PD-1 inhibitor immunotherapy trials showed the 
opposite – that PFS effect sizes were smaller compared to OS effect sizes272. Moreover, in 
two cases — one investigating bevacizumab in ovarian cancer and one investigating 
perioperative FOLFOX4 in metastatic colorectal cancer — the significant PFS effect from 
the interim analyses became nonsignificant at follow-up273,274. The clinical relevancy of 
inhibited tumor growth, which likely contributes to the exaggerated PFS effect size, is 
relevant to patients only if the OS benefit follows. Our data show that the mature PFS data 
in interim analyses were more often statistically significant than subsequent OS data. 
Crossover was allowed after disease progression in 12 of the included trials and 2 trials 
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administered additional interventions — which may mask true OS benefits. Whether 
crossover after disease progression is an acceptable feature of trial design has been debated 
recently49,123,124.  
We further demonstrated that the incidence of publishing interim analyses 
separately from their final confirmatory analyses has steadily increased. Numerous 
manuscripts have called for caution when interpreting surrogate endpoint data.61,250,252,260–
262 Our results support this cautionary call: only 3 of the 33 included interim analyses 
showed that PFS strongly correlated with OS. For any cancer, cancer setting, or drug 
intervention without a validated correlation of PFS and OS, the interim publication of PFS 
data without accompanying OS data is not just unreliable, but likely to generate hype. We, 
therefore, recommend caution when reading interim analyses with only PFS data, since the 
effect size and clinical benefit may not be corroborated by future OS data. 
Analyses of surrogate endpoints likely affects clinical decision making. A recent 
review of FDA drugs that received accelerated approval in the last 25 years showed that 
all were approved based on a surrogate endpoint and that most received regular approval 
based on another surrogate endpoint.3 The strength of correlation between surrogate 
endpoints and OS could be high for many of these drugs, but it is more likely that the OS 
effect size is small or null. To be certain, adding even 2 months to a patient’s life cannot 
be discounted and is incredibly important, but patients often expect much more when 
choosing between treatment options.275 One must question how the perceived survival 
benefit demonstrated by surrogate endpoints affects physician and patient expectations 
around treatment decisions. 
The limitation of our study is that our results are not generalizable to all surrogate 
endpoints, because they may correlate with OS differently and may be published apart from 
OS analyses more or less frequently. Further, the magnitude of difference in Altmetric 
scores between interim and final analyses may be biased, because the final analyses were 
published more recently. However, only 6 final analyses were published in 2017 or later, 
and 1 was in-press at the time of analysis and thus excluded. Of the 5 that were included, 
3 had Altmetric scores well above the median (69, 60, and 43). We are therefore confident 
that the bias due to time of publication is minimal. 
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To conclude, we do not discourage the use of surrogate endpoints in oncology. They 
are valuable and serve a useful purpose. We do, however, encourage the proper 
presentation of surrogate endpoint results in oncology. PFS effect sizes are frequently 
larger than OS effect sizes, and PFS is infrequently validated as a surrogate endpoint for 
OS. We recommend caution when encountering an oncology trial with only immature OS 
data, because we have demonstrated that such interim analyses may generate unsupported 
and inappropriate hype. When these interim analyses are published, the journals should 





EVALUATION OF SELECTIVE OUTCOME REPORTING BIAS IN EFFICACY 
ENDPOINTS IN PRINT AND TELEVISION ADVERTISEMENTS FOR ONCOLOGY 
DRUGS 
 
This work was previously published in the Journal of General Internal Medicine with 
the following citation:  
Wayant C, Aran G, Johnson BS, Vassar M. Evaluation of Selective Outcome Reporting 
Bias in Efficacy Endpoints in Print and Television Advertisements for Oncology 




Industry-sponsored television and print advertisements targeted to consumers and 
health care providers (HCPs) compose a multibillion dollar industry in the United States.276 
Consequently, the benefits and harms of these advertisements have been strongly debated, 
with much of the discussion focusing on consumers.277,278 Advocates of direct-to-consumer 
advertisements argue that they function as public service announcements that empower 
patients with information, lead to doctor-patient conversations, and facilitate the initiation 
of treatment.279–281 Opponents argue that direct-to-consumer advertisements may mislead 
patients,282,283 exaggerate potential drug benefits,284,285 omit quality of life,286 and increase 
health care spending.279,280 In cancer medicine, drug advertisements have been the subject 
of particularly intense debate,286–288 especially given the often high toxicity289 and cost290 
associated with new cancer medications. The controversial nature of oncology drug 
advertisements, paired with their prevalence in the lives of HCPs and consumers, raises the 
critical question of whether the clinical data in oncology drug advertisements are 
transparent, straightforward, and unbiased.
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One threat to the accurate presentation of clinical data is selective outcome 
reporting bias, which occurs when published study endpoints do not match those 
prespecified in a trial registry or protocol.291 Trial endpoints may be added, removed, or 
reordered for several reasons. Some of these reasons, such as poor study accrual,292 are 
ethical and understandable. However, in other cases, selectively reporting endpoints can 
be dangerous and may affect perceptions of drug efficacy through the omission or demotion 
of statistically nonsignificant results. A recent analysis of hematology clinical trials found 
that endpoints were often selectively reported to highlight statistically significant results,36 
and a Cochrane SR found that selective outcome reporting bias in clinical trials affected 
the conclusions of a “substantial proportion of Cochrane reviews.”293 To avoid misleading 
readers, authors of medical research studies should accurately report data for all endpoints 
prespecified in their protocol, regardless of statistical significance.  
While much is known about the selective reporting of trial endpoints between 
protocols and published reports, little, if anything, is known about the selective reporting 
of trial endpoints between published reports and drug advertisements. Because 
advertisements represent a snapshot of a drug’s evidence profile, they may be slanted 
toward selective reporting of endpoints previously analyzed in published trials. The 
primary objective of the current study was to investigate the rates of selective outcome 
reporting bias of efficacy endpoints at two junctures: in published cancer clinical trials and 
in television and print advertisements for anticancer medications. The rationale for this 
investigation was that selective outcome reporting bias has been shown to be a consistent 
issue in the biomedical literature,36,136,293,294 and print or television advertisements may 
unintentionally inflate perceptions of the benefits of oncology drugs.  
 
Methods 
Consistent with a recent investigation of health care advertisements,295 we used the 
AdPharm database to identify oncology drug advertisements uploaded within an 18-month 
span between March 1, 2017, and September 1, 2018. AdPharm is an online database that 
is updated daily with advertisements for health care or pharmaceutical products. Each entry 
in AdPharm contains basic information about the advertisement, including the target 
audience or country of origin. AdPharm does not track or list the number of viewers of an 
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advertisement. Advertisements were included in the study if they were for an anticancer 
drug and if they included quantitative data, were in English, and were marketed to 
consumers or HCPs.  
After screening all advertisements, CW and GA extracted data in a duplicate and 
masked fashion. The following items were extracted from print and television 
advertisements: market audience, air or print date, efficacy endpoints, data for efficacy 
endpoints, design features of the clinical trial that generated the data, any citation for a 
published trial, and, in the case of a consumer-directed advertisement, any mention of 
speaking with an HCP.  
To compare advertisement endpoints with journal-published endpoints, we used the 
citations in the advertisements or a PubMed search to identify a matching trial. We used 
keywords and Boolean operators to search for and identify matching trials, if no citation 
was included. Trials were matched on the basis of intervention, co-intervention, control, 
sample size, and cancer type. After identifying matched trials, we extracted the efficacy 
endpoints reported, data for those endpoints, and the date of article publication. Our 
analysis of selective reporting bias between published articles and advertisements consisted 
of determining which endpoints were included in the published paper and which were 
included in the advertisements. When an endpoint was excluded from the advertisement, 
we then determined whether or not that endpoint was statistically significant using the 
published statistics (e.g., confidence intervals or alpha level). Similarly, we investigated 
selective outcome reporting between the retrieved published papers and their trial 
registrations. We chose to use trial registrations, rather than protocols, because trial 
registrations are time-stamped and show a history of changes, which supports an accurate 
analysis of any endpoint changes or updates. 
This is a novel study of selective outcome reporting in drug advertisements. As 
such, there is no effect size on which to base a power calculation. Therefore, we provide a 
range of included studies required for sufficient power using standard effect size 
measurements (Cohen’s d = 0.2, 0.5, 0.8). These effect size measurements were converted 
to odds ratios for our power calculation, based on the paper by Chen, et al296. We 
prespecified a type I error rate of 0.5 and type II error rate of 0.2. The range of included 
advertisements required ranged from 485 (odds ratio = 1.68, Cohen’s d = 0.2) to 89 (odds 
89 
 
ratio = 3.47, Cohen’s d = 0.5) to 45 (odds ratio = 6.71, Cohen’s d = 0.8). We used gpower 
3.1 for all power calculations.  
We used Stata 15.1 for all analyses except E-values, for which we relied on the 
formula described by VanderWeele and Ding.297 E-values were used to assess the degree 
of unmeasured confounding in our analyses. For the two primary endpoints of selective 
outcome reporting bias of efficacy endpoints in published papers and in advertisements, 
we calculated unadjusted risk ratios (uRR) and 95% confidence intervals (CIs) to compare 
the rates of advertising significant and nonsignificant endpoints. We analyzed all 
advertisements together, as well as consumer- and physician-directed advertisements 
separately. In all analyses of selective outcome reporting bias, we excluded endpoints from 
single-arm trials, immature OS data, and endpoints that could not be located in the 
published paper. We define “immature” data as data that have not accrued the prespecified 
number of patient events to achieve study power. 
 
Results 
We identified 490 
advertisements in total, of which 
74 were included in initially 
(Figure 9). Advertisements were 
excluded for not describing a 
drug treatment (n = 249), not 
including quantitative data (n = 88), and not being in English (n = 79). The vast majority 
of print advertisements (n = 66) were in clinical magazines and designed to target HCPs (n 
= 55, 83.3%). Print advertisements pertained to 34 unique drugs designed to treat 21 unique 
malignancies. The drugs that were the most commonly advertised in print were 
pembrolizumab (n = 8), palbociclib (n = 6), and ribociclib (n = 5). All television 
advertisements (n = 8) were directed to consumers and were related to four unique drugs 
and two unique malignancies. Palbociclib was the most commonly television-advertised 
drug (n = 3), followed by pembrolizumab (n = 2), nivolumab (n = 2), and abemaciclib (n 
= 1). The only malignancies represented were non-small-cell lung and breast cancers (both 
n = 4). 




Registration to Publication 
Forty-eight clinical trials were identified that supported the 74 included 
advertisements. All 48 trials reported a trial registration number. Seven trials were 
registered after the start of subject enrollment, although one trial began in 1999 before 
ClinicalTrials.gov registration. Besides the six trials that were registered after they began 
(excluding the trial that began in 1999), an additional six studies deviated from the 
registered primary endpoints in ways that may have affected the integrity of the trial. For 
all six, primary endpoints were added to the registry after the start of the study. In one 
study, an endpoint was demoted from primary to secondary in the published report. With 
regard to registered secondary endpoints, 16 trials deviated from the registry, with 13 
adding secondary endpoints during the trial period. One study promoted a registered 
secondary endpoint to a primary endpoint in the publication, one removed a secondary 
endpoint from its registry, and one did not list or report a registered secondary endpoint in 
the paper. Overall, 41/48 (85.4%) trials were registered prior to study enrollment and 41/48 
(85.4%) did not deviate from the registered primary endpoints. 
 
 
Publication to Advertisement 
After excluding advertisements supported by single arm trials (n = 8), we next 
compared the efficacy endpoints cited in the 66 remaining advertisements to the 40 
remaining clinical trials supporting them. Of the 539 endpoints eligible for inclusion in 
advertisements, we excluded 175 endpoints for being from single-arm trials (n = 100), for 
including immature time to event data (n = 51), or for not including a statistical analysis in 
the published paper (n = 24). Five trials were cited for advertisements directed to 
consumers and physicians. 
Across all included advertisements (n = 66), statistically significant endpoints were 
more likely to be reported than nonsignificant endpoints (uRR 1.26; 95% CI 1.14—1.40). 
Primary endpoints were reported 97.8% (92/94) of the time. Secondary endpoints were 
reported much less frequently (66/270, 24.4%). Overall, half (33/66, 50.0%) of 
advertisements included data for immature endpoints.  
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Among advertisements directed to HCPs (n = 47), if an endpoint was statistically 
significant, it was more likely to be reported in the advertisement (uRR 1.36; 95% CI 1.20–
1.54). For consumer-directed advertisements, there was no significant difference (uRR 
1.01; 95% CI, 0.85–1.21). 
 
Discussion 
 This study is a novel investigation of selective outcome reporting in drug 
advertisements marketed to consumers and health care providers. We found that 
statistically significant endpoints were more likely to be reported than nonsignficant 
endpoints. This finding was mostly driven by physician-directed advertisements, which 
were more prevalent and where the difference was also significant. Because previous 
studies investigating selective outcome reporting in drug advertisements do not exist, it is 
not possible to compare our results within the context of previous literature. In this study, 
we also evaluated selective outcome reporting between trial registrations and the published 
trial reports, which is the conventional manner for the investigation of selective outcome 
reporting 134,291,298. There is ample evidence that industry-funded studies are more likely to 
report more favorable results in published papers224,299,300. Our results indicate that the 
degree of selective outcome reporting was higher between published trial reports and 
advertisements than between the trial registrations and their publications. These findings 
raise important questions about perceptions of drug efficacy. Moreover, many included 
endpoints were surrogate endpoints, which may  or may not correlate with improved 
survival in cancer patients62 and are more likely to be statistically significant204. Some 
cancer trialists have argued that OS should be routinely collected and reported, owing to 
the importance that patients with cancer place on decreased mortality53.  
Our study found that advertisements were often aired or printed before final OS 
data were available, which may introduce uncertainty and may raise the risk of reporting 
false-positive results to the public 301. Previous studies have found that only negligible 
correlations exist between surrogate outcomes and OS for many types of cancer 62. Further, 
the results from surrogate outcomes—published as interim analyses before OS data are 
mature—often do not result in improvements in OS 204. Thus, we believe that the surrogate 
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outcomes reported in media advertisements have the potential to overstate the efficacy 
benefit that will eventually be found when OS data become available. 
To our knowledge, the Food and Drug Administration (FDA) does not offer 
guidance on reporting surrogate endpoints and OS in oncology drug advertisements. 
Existing draft guidance for advertising efficacy endpoints focuses on the reporting of 
absolute or relative statistics.302 This gap in FDA guidance may be relevant to patients if 
advertisements only report surrogate endpoints. A recent review found that there are no 
high-quality data supporting the idea that patients understand surrogate endpoints and their 
shortcomings.58 The lack of guidance and patient misunderstanding may multiply issues 
with oncology drug advertisements. Namely, we have shown that nonsignificant endpoints 
and immature OS data are often excluded from oncology drug advertisements, resulting in 
a higher degree of significant surrogate endpoints, which patients may not fully understand. 
One must weigh the benefits and harms of oncology drug advertisements as seen in 
this study. The advertisements that we assessed often excluded nonsignificant endpoints, 
yet drug advertisement proponents argue that advertisements, any selective reporting aside, 
initiate a patient-physician conversation.279–281 Because of the paucity of research into the 
effects of selective outcome reporting in drug advertisements, we cannot address how the 
omission of nonsignificant endpoints affects patients’ perceptions of drug efficacy. It is 
even more difficult to assess the effect of these advertisements on physicians, who in theory 
should be well versed in clinical endpoints and should have read the clinical trials 
associated with advertised drugs. However, we believe our study raises questions that could 
be answered using robust methodologies, following the example of other forms of bias 52. 
Our study is limited because we were not able to assign an appropriate weight to 
each advertisement based on audience size. The television advertisements, which were all 
marketed to consumers, likely had a larger audience than the print ads, which were mostly 
marketed to HCPs and published in clinical journals. So, while most advertisements 
included in this study were marketed to HCPs, these advertisements were likely seen by 
fewer people. Moreover, it is difficult to determine whether selective outcome reporting in 
patient-directed advertisements (where it exists) has the same effect as in physician-
directed advertisements. We may reasonably assume a higher degree of health literacy 
among physicians; therefore, selective reporting of endpoints in advertisements directed to 
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physicians may not carry similar weight as for advertisements directed to patients. Last, 
the computed E-values for this study show that unobserved confounding may affect our 
results (i.e., that some factor other than the significance of endpoints may drive reporting). 
However, even if other factors contribute to the reporting of endpoints in advertisements, 
this finding does not change the fact that we identified a possibly biased drug efficacy 
portfolio in advertisements. 
In conclusion, we found that oncology drug advertisements are more likely to 
include statistically significant endpoints than nonsignificant endpoints. This effect was 
most pronounced in advertisements marketed to HCPs. All advertisements relied mostly 
on surrogate endpoints and frequently omitted nonsignificant OS data. Immature OS data 
did not create a barrier to advertising a drug as effective to consumers and HCPs. We 
recommend that advertisements not be aired or printed without clear descriptions of 
patient-important endpoints, such as OS. Further, we recommend that the FDA critically 
review advertisements in the preapproval stage to ensure that patients and physicians are 
not misled (even unintentionally) regarding drug efficacy. We advocate for improved 
patient education of surrogate endpoints because available studies have shown that patients 
may conflate surrogate endpoints with clinically meaningful outcomes.58 At minimum, 
since few, if any, oncology drugs aim to improve quality of life alone, we recommend a 
clear, prominent declaration of whether or not the drug has shown OS improvements. 
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Noninferiority trials compare a new treatment (NT) against an active control (AC) 
and aim to demonstrate that the NT is not worse than the AC, within a certain margin.303 
NTs that demonstrate noninferiority versus an AC usually exhibit a tradeoff: slightly less 
(but acceptable) therapeutic efficacy in exchange for increased safety or decreased cost. 
However, the design, reporting, and interpretation of noninferiority trials has been 
questioned,304–307 and trials that are poorly designed, reported, and interpreted may 
represent a breach of ethical obligations to patients.308 Another consequence may be 
spurious conclusions of noninferiority. 
Basic design characteristics 
and the choice of noninferiority 
margin (i.e., the acceptable amount 
of efficacy lost) are some of the key 
issues in noninferiority trials. Basic 
design characteristics may include 
the choice of type I error rate 
(alpha) and the number of analyses 
run on the primary endpoint. 
Figure 10. Visual representation of the noninferiority margin as it 
relates to the expected effects of new treatments and active controls. 
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Lenient alpha values or alpha values that do not align with the reported confidence intervals 
may compromise noninferiority conclusions.304 Simultaneous intention-to-treat and per 
protocol analyses are encouraged in noninferiority trials309,310 because reporting only 
intention to treat (the gold standard for superiority trials) may bias the results toward 
conclusions of noninferiority. Each of these basic design characteristics is as important to 
robust noninferiority conclusions as the choice of noninferiority margin. The margin 
represents the acceptable loss of efficacy for the NT compared to an AC that is more 
effective but may lack nonefficacy benefits of the NT (Figure 10). If the chosen margin of 
efficacy difference is too wide, then whatever effect the AC previously showed against 
placebo or another historical control may be lost. Even if the margin is appropriate, there 
may be concerns, as evidenced by the approval of lenvatinib for hepatocellular 
carcinoma.311 Lenvatinib showed noninferiority to sorafenib, which had previously shown 
superiority to a placebo; however, it was later found that the clinical trial efficacy of 
sorafenib did not generalize to older patients and patients with worse performance status.312 
Thus, the supposed efficacy of sorafenib, which formed the basis for the chosen 
noninferiority margin, resulted in a conclusion about noninferiority that is not robust. 
Building on recent investigations of noninferiority trials across 
biomedicine304,313,314 in the context of an increasing number of new oncology drug 
approvals based on noninferiority trials, we aimed to determine the robustness of 
noninferiority trial design in cancer medicine. Our investigation had 3 components: (1) 
investigate basic design characteristics, (2) determine the percentage of AC effect 
preserved by the chosen margin, and (3) assess the overall quality of included trials using 
data gathered from components 1 and 2. 
 
Methods 
Our protocol with detailed methods and search strategy is available via the Open 
Science Framework.315 Briefly, we used a PubMed search to collect oncology 
noninferiority trials published in New England Journal of Medicine, The Lancet, Journal 
of Clinical Oncology, Lancet Oncology, JAMA Oncology, Annals of Oncology, Cancer, 
European Journal of Cancer, British Journal of Cancer, and Journal of the National 
Cancer Institute between January 1, 2012, and December 31, 2018. All retrieved studies 
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from our search were exported to Rayyan,256 a web-based platform used to screen studies 
for eligibility. 
All articles were independently screened by 2 masked authors. Studies were 
included if they represented an oncology, noninferiority, phase 3 randomized controlled 
trial (RCT) of an antitumor or adjunct therapeutic (e.g., colony-stimulating factor) 
intervention. We excluded phase 2 studies, studies that only assessed the superiority of an 
intervention, studies that did not evaluate antitumor or adjunct therapeutic interventions, 
studies that used Bayesian methods, and studies that had a design other than an RCT.  
Data extraction was performed independently by 2 masked authors using 2 Google 
Forms. The first form included items related to the basic characteristics and design of the 
noninferiority trial (see our protocol for the full list of items).315 The second form was used 
to extract data from the noninferiority studies that cited previous studies of the AC versus 
a placebo or another control to justify the noninferiority margin. These previous results 
must have been used to justify the noninferiority margin, and they must have tested the 
same AC (including dose and administration procedures) against a placebo or another 
control for the same endpoint used in the noninferiority trial. The following items were 
extracted from the previous AC study into this second form: effect size, confidence 
interval, and P-value. 
If multiple background studies of the AC versus placebo or other control were 
referenced in the noninferiority trial, we followed the algorithm devised by Tsui et al314 to 
select 1 background study because of the inherent difficulties and limitations of attempting 
to generate a single effect size from multiple heterogeneous studies. The algorithm is a set 
of hierarchical criteria, in order of decreasing importance: (1) similarity of AC in the 
noninferiority trial and background study (e.g., dose, regimen); (2) placebo-controlled 
studies preferred over other control studies; (3) similarity of outcome between 
noninferiority trial and background study; (4) higher-order studies preferred over primary 
studies (e.g., meta-analysis over RCT); and (5) more recent study preferred.  
For each noninferiority trial that cited a previous study with data that could be 
extracted into the second Google Form, we calculated the percentage of preserved effect 
(%PE), or the minimum effect of the AC that must be preserved by the NT to conclude 
noninferiority (Figure 10), using a previously described formula.314 The %PE ranged from 
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0% (no different from placebo) to 100% (maximum effect of AC preserved). For absolute 
differences (e.g., percentages), the %PE was calculated as:  
 
%PE = (AC effect + noninferiority margin/AC effect) 
 
For relative differences (e.g., hazard ratio), the %PE was calculated as: 
 
%PE = log(AC effect × noninferiority margin)/log(AC effect) 
 
The AC effect and noninferiority margin had to go in opposite directions. For example, a 
hypothetical 5% increased survival rate (AC vs placebo) and a -2.5% margin are 
compatible, just like a hypothetical hazard ratio of .8 (AC versus placebo) and margin of 
1.2. If a %PE is less than 0% (i.e., negative percent), then the noninferiority margin is too 
wide and the NT is at risk of a “not inferior” conclusion, while actually being worse than 
placebo or another historical control. 
Slightly modifying previous guidance,313 we graded the quality of each 
noninferiority trial based on 4 criteria: (1) whether the margin was justified by previous 
data or clinical reasoning (yes vs no); (2) whether the selected margin could demonstrate 
that the NT preserves at least 50% of the AC effect (yes vs no/not capable of calculating 
%PE); (3) whether the type I error rate was consistent with the level of the confidence 
interval (yes vs no); and (4) how many analyses (e.g., intention to treat, per-protocol) were 
performed on the primary outcome (<2 or ≥2). Studies were graded as excellent (4/4 
criteria), good (3/4), average (2/4), fair (1/4), or poor (0/4). The choice of 50% preserved 
AC effect was chosen since an excellent noninferiority trial achieves the goal of preserving 
a significant portion of the AC effect while also providing nonefficacy benefits. 
The primary outcome of this investigation is the methodological quality of 
oncology noninferiority trials of antitumor or adjunct therapeutic interventions. For our 
quality assessment (using the 4 criteria), we report a sensitivity analysis excluding our 
%PE, owing to poor adherence. We calculated summary statistics using Google Sheets. No 






General Characteristics  
Our database search retrieved 337 
articles, of which 110 were eventually 
included (Figure 11). These 110 articles 
were published most often in Lancet 
Oncology (n = 32), Journal of Clinical 
Oncology (n = 31), and Annals of 
Oncology (n = 17). The funding source 
was most often industry (n = 33), mixed 
(n = 19 with partial industry, n = 12 
without partial industry), and public (n = 24). Protocols were available for 45/110 (40.9%) 
of noninferiority trials. Nonefficacy benefits of the NT were used as rationale in 88/110 
(80.0%) trials, and a total of 103 nonefficacy benefits were cited. The most commonly cited 
NT nonefficacy benefits were fewer adverse events (n = 71), treatment convenience (n = 
12), and cost (n = 10) (Table 9). 
 
Trial Design 
In 18/110 (16.4%) noninferiority trials, the reported confidence interval and 
prespecified alpha value were not aligned. Authors most often used 1-sided alpha values 
(65/110, 59.1%), and the most common alpha value was .05 (34/110, 30.9%). Ten trials 
did not mention the chosen alpha level. No trials used a more favorable alpha level of 
greater than .05 (2-sided equivalent). Two-sided 95% confidence intervals were most often 
reported (78/110, 70.9%). Noninferiority trials most often prespecified 80% power 
(63/110, 57.3%). Primary endpoints were most often surrogate endpoints (e.g., PFS or 
response rate) (75/110, 68.2%) or OS (26/110, 23.6%). Hazard ratios were the most 




Figure 11. Flow diagram of included studies. 
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Characteristic No. (%) 
Journal 
Lancet: Oncology 32 (29.1%) 
Journal of Clinical Oncology 31 (28.2%) 
Annals of Oncology 17 (15.5%) 
The Lancet 15 (13.6%) 
New England Journal of Medicine 12 (10.9%) 
Jama Oncology; Cancer; Journal of National Cancer Institute 1 (0.9%) each 
Funding 
Industry 33 (30.0%) 
Mixed 31 (28.2%) 
 Partial industry 19 (17.3%) 
No industry 12 (10.9%) 
Public (e.g., government) 21.8%) 
Private (e.g., non-profit) 19 (17.3%) 
None 2 (1.8%) 
Not mentioned 1 (0.9%) 
Non-efficacy benefits* 
Fewer adverse events 71 (68.9%) 
Convenience to patient (e.g., easier to administer) 12 (11.7%) 
Lower cost 10 (9.7%) 
Avoid future therapy (e.g., surgery) 3 (2.9%) 
Quality of life improvement* 3 (2.9%) 
Cosmetically better (e.g., for surgical procedures) 2 (1.9%) 
Optimize future therapy; Remove treatment delays 1 (1.0%) each 
Table 9. Characteristics of included noninferiority trials (n = 110). * denominator of 103 for 103 total non-efficacy 
benefits cited; ** QoL coded for studies that mentioned QoL without specifics, e.g., no mention of QoL improvement by 
lowering adverse events 
  
Justification for the noninferiority margin was provided in 71.8% (79/110) of trials. 
Authors most often used previous data as justification for the chosen margin (n = 42), but 
only 40 trials cited a study containing such data. Despite 40 noninferiority trials citing a 
total of 73 potential studies as justification for the noninferiority margin, only 17 studies 
were eligible for calculation of %PE. Fifteen studies were included for calculation of %PE, 
with the remaining 2 eligible studies being passed over based on our decision algorithm 
(see Methods). Of the 15 noninferiority trials for which %PE could be calculated, 10 
(66.7%) were designed to preserve greater than 50% AC effect, 4 (26.7%) were not 
designed to preserve 50% AC effect, and 1 (6.7%) could not calculated because the 
noninferiority hypothesis was to test a difference from zero using a special formula.316 The 
median %PE was 56.8% (interquartile range 26.0%).  
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A total of 166 analyses were conducted for the noninferiority comparisons (e.g., 1 
trial conducted intention-to-treat and per protocol). Half of the included trials (55/110, 
50.0%) conducted only 1 analysis for the primary endpoint, with the most common analysis 
being intention to treat (48/55, 87.3%). Overall, the most common analysis was intention 
to treat (103/166, 62.0%), followed by per protocol (60/166, 36.1%). A total of 122 
noninferiority comparisons (e.g., one NT versus AC) were made in the 110 included 
noninferiority trials. Authors most often concluded that the NT was not inferior to AC 
(70/110, 63.6%). The remaining noninferiority comparisons were either inferior (22/110, 
20.0%), superior (10/110, 9.1%), or inconclusive (20/110, 18.2%) for the NT versus AC.  
 
Quality Judgment 
 Seventy-seven (70.0%) of the 110 noninferiority trials included in the sample were 
scored as average (2/4 criteria; 51/110, 46.4%), fair (1/4 criteria; 22/110, 20.0%), or poor 
(0/4 criteria; 4/110, 3.6%) (Table 9). Only 5 (4.5%) noninferiority trials met all 4 quality 
criteria. Designing the noninferiority trial to preserve 50% of the AC effect was done the 
least often (10/110, 9.1%), with a failure to cite data to allow %PE calculations being the 
main driver of failing to meet this criterion. In a sensitivity analysis removing the %PE 
criterion, the number of excellent-quality noninferiority trials (all 3 remaining criteria) 
increased to 20 (20/110, 18.2%).  
Criteria Met [No. (%)] Not met [No. (%)] 
Margin to 50% preserved effect 10 (9.1%) 100 (90.9%) 
>2 analyses (e.g., ITT and PP) 55 (50.0%) 55 (50.0%) 
Matched alpha and confidence intervals 92 (83.6%) 18 (16.4%) 
Use of clinical judgment or data to justify margin 74 (67.3%) 36 (32.7%) 
Total of criteria met No. (%) 
0/4 4 (3.6%) 
1/4 22 (20.0%) 
2/4 51 (46.4%) 
3/4 28 (25.5%) 
4/4 5 (4.6%) 







We found that oncology noninferiority trials are often of moderate to poor quality 
and often demonstrate key methodological shortcomings. These shortcomings include 
alpha values and confidence intervals that do not match, lack of citations for data that 
justify the chosen noninferiority margin, and prespecification of only 1 analysis (e.g., 
intention to treat only) for the primary endpoint. Altogether, these shortcomings are 
counterbalanced by the clearly delineated nonefficacy benefits expected from the NT and 
strong %PE in the 15 noninferiority trials in which calculating %PE was possible. 
However, the identified methodological shortcomings may lead to spurious conclusions of 
noninferiority that may be due to study design rather than the efficacy of the NT.  
A previous study304 showed that mismatched alpha values and confidence intervals 
(e.g., 2-sided 90% CI and .05 alpha) may result in spurious conclusions of noninferiority. 
In that study, recalculation using normal, more stringent confidence intervals (e.g., 95% 
instead of 90%) changed the conclusions of the noninferiority trial to be unfavorable to the 
NT. For example, if a 90% confidence interval is initially used and the authors conclude 
that the NT is not inferior to the AC by excluding the noninferiority margin, a 95% 
confidence interval may nullify this finding if the margin is included. Our reported rates of 
mismatched alpha values and confidence intervals may be cause for concern regarding the 
strength of oncology noninferiority conclusions—especially in the context of the clinical 
equipoise in sample size estimates and choice of noninferiority margin (i.e., possible 
sample size and margin as small as can be ethically justified) inherent to oncology 
noninferiority trials.317 Moreover, the rate of noninferiority trials that only used intention-
to-treat, which is known to bias a trial toward conclusions of noninferiority,309,310,313 was 
concerning. Thus, for future oncology noninferiority trials, we recommend justifying an 
alpha value and matched confidence interval as well as both intention-to-treat and per 
protocol analyses in a publicly accessible study protocol. 
Designing a noninferiority trial so that some of the AC effect versus placebo or 
another historical control is preserved is fundamentally important.318 If the noninferiority 
margin is too large, a trial can conclude noninferiority while failing to preserve 
effectiveness over placebo or historical control (Figure 10). Thus, it is crucial that authors 
of noninferiority trials start with what effect the AC had over placebo or another control, 
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and choose a clinically acceptable margin. We attempted to calculate the %PE by 
combining the noninferiority margin and AC effect against placebo or historical control 
into a formula previously described.314 Unfortunately, only a small percentage of 
noninferiority trials cited studies that could be used for our calculation. We understand that 
it may be possible to infer expected AC efficacy based on trials of same-class drugs or of 
trials using the same AC for a different endpoint; however, we question the use of single-
arm trials, observational studies, or studies in which no difference from placebo was found. 
Even using trials with different drugs, doses, or endpoints may introduce noise to the 
presumed AC effect that is used as the basis for the noninferiority margin. Encouragingly, 
however, where %PE could be calculated, the noninferiority trials were designed to 
preserve a median of 56.8% of the AC effect. In the future, we recommend that all 
noninferiority trials clearly delineate the justification for the noninferiority margin using 
data and citation where possible and with as much detail as possible if clinical judgment is 
all that is available.  
This study has several key strengths and limitations. With regard to strengths, we 
used double data extraction to minimize bias in retrieved data. We also based our study on 
3 previously published studies, but restricted our analysis to oncology noninferiority trials 
in a 6-year period. Thus, we believe our conclusions to be robust and relevant for the 
oncology community. With respect to limitations, we used very strict criteria for 
calculating %PE, which resulted in only a small subset of noninferiority trials being eligible 
for inclusion. It is likely that many noninferiority margins from our study not subjected to 
the %PE calculation were high quality, but we, and many readers, may be unable to 
confirm. Our inability to calculate %PE for all noninferiority trials also affected our quality 
assessment because 50%PE or more was one criterion. To remedy this limitation, we 
reported sensitivity analyses excluding this criterion.  
In conclusion, we found that many oncology noninferiority trials clearly defined 
the expected nonefficacy benefits of an NT but exhibited some design shortcomings. We 
recommend addressing the following key methodological items in future noninferiority 
trials: (1) alpha values and confidence intervals that match, (2) prespecification of 
intention-to-treat and per protocol analyses for the primary endpoint, and (3) use of data, 
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preferably with a citation, to justify a noninferiority margin that preserves a clinically 
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Concerns are growing about the reproducibility of biomedical research.319,320 Many 
of these concerns stem from research practices that lack transparency, including poor 
reporting of study methodology321 and failing to make study data publicly available.143 As 
a result, efforts to reproduce biomedical research findings have been thwarted.322,323 The 
vast majority of efforts to reproduce research findings have been dedicated to primary 
studies, such as clinical trials, and little effort has been dedicated to reproduce higher levels 
of evidence, such as SRs. The first studies to holistically evaluate the reproducibility of 
SRs and meta-analyses in the biomedical literature found that authors frequently fail to 
employ reproducible research practices.143,324 However, only a small proportion of the SRs 
evaluated in previous investigations were for oncology interventions, leaving unanswered 
questions for researchers in this field, oncologists, and policy makers.  
 For this investigation of the reproducibility of oncology SRs, we identified SRs 
cited in NCCN CPGs. The NCCN set of guidelines are one of many available to 
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oncologists; however, a survey of oncologists showed that NCCN guidelines were more 
likely to influence clinical practice than other popular oncology guidelines325. Further, 
NCCN guidelines cover all blood and solid cancers, thus making them ideal for a broad 
investigation such as this. The primary objective of this investigation is to evaluate the 
reproducibility of meta-analyses in oncology SRs cited by the 49 NCCN guidelines for the 
treatment of cancer by site. The secondary objective is to evaluate whether Cochrane 




 The protocol for this investigation is publicly available via the Open Science 
Framework326. We defined an SR according to the PRISMA for protocols definition: 
articles that explicitly stated methods to identify studies (i.e., a search strategy), explicitly 
stated methods of study selection (e.g., eligibility criteria and selection process), and 
explicitly described methods of synthesis (or other type of summary).327 Since NCCN 
guidelines update regularly throughout each year, all guidelines were manually 
downloaded as PDFs on May 6, 2018 to avoid citations being added to the guideline during 
the course of our investigation.328 To identify SRs we manually screened the reference lists 
and Discussion narratives of all NCCN CPGs for the treatment of cancer. We extracted all 
references with “systematic review”, “meta-analysis”, “metaanalysis”, and any references 
without the keywords in the title that are discussed as an SR or meta-analysis by guideline 
authors. We also extracted any cited references that were published in the Cochrane 
Database for Systematic Reviews. All extracted references were added to a PubMed 
collection and exported to Rayyan256 for title and abstract screening. 
We screened articles using the liberal acceleration method whereby one author 
(CW) was required to mark a record for inclusion and two authors (CW, MP) were required 
to mark a record for exclusion. Next, two authors (CW, MP) screened the full-text of 
potentially relevant articles for inclusion. Key inclusion criteria were SRs published in 
2011 or later with at least one meta-analysis that included at least one randomized-
controlled trial. We chose to include only SRs published after 2011 to allow time for uptake 
of the 2009 PRISMA Statement. Thus, all included SRs are accountable to currently 
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accepted reporting quality standards. SRs of individual patient data or of primary studies 
other than clinical trials, network meta-analyses, and pooled analyses of clinical trials were 
excluded. 
To extract data for this study we developed a pilot-tested Google Form based on 
the extraction form used in a similar, previous study143. Extracted data items were related 
to the number of meta-analyses reported, reporting of summary statistics for each 
individual study, use of fixed-effect versus random-effect models, interpretation of tests of 
heterogeneity and small-study effects, and types of subgroup and sensitivity analyses 
performed. We extracted data for all meta-analyses, but certain items were dedicated to the 
index meta-analysis, which we defined as the primary meta-analysis for the primary 
endpoint. If there was no primary endpoint mentioned, we used the first reported meta-
analysis as the index meta-analysis and inferred the primary endpoint from there. We 
counted meta-analyses by summing the number of summary effects in forest plots, written 
narrative, and supplemental appendices. Duplicate meta-analytic effects were only counted 
once. We counted subgroup effects that were derived from an analysis of at least two 
studies, as well as the overall summary effect that synthesized all subgroup effects. We 
only counted sensitivity analyses that were expressly described with a summary effect in 
the paper or the supplemental material.  
To be considered reproducible in theory an analysis must have three elements: 1) 
effect estimate and measure of precision (e.g., hazard ratio with 95% confidence interval); 
2) clear list of studies included for each analysis; 3) for subgroup and sensitivity analyses, 
it was clear which studies were included in each group or level. 
Data from all SRs were extracted by CW. A random sample of 15% of the included 
SRs was extracted in duplicate by MP. MV adjudicated discrepancies in the double-
extracted 15% sample. Any item that had at least one discrepancy was reviewed a second 
time in the 85% of other studies by CW. A complete list of items with a discrepancy are 
available, along with our protocol and data, via the Open Science Framework326.   
Summary statistics and measures of central tendency (e.g., median with 
interquartile range (IQR)) were calculated using Microsoft Excel. We planned to use 
STATA 15.1 to calculate risk ratios and 95% confidence intervals for the comparisons 
between Cochrane and non-Cochrane SRs, and between SRs self-reporting use of PRISMA 
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versus not, but owing to disparate numbers of Cochrane and non-Cochrane SRs, we only 
report the comparisons of SRs stratified by PRISMA adherence and year of publication. 
We conducted sensitivity analyses for meta-analyses presented in figures and for those 






We identified 1,124 potential SRs from our survey of the 49 NCCN guidelines for 
the treatment of cancer by site. Five NCCN guidelines did not cite any SRs. An additional 
19 CPGs did not have any SRs that met the inclusion criteria. After removing duplicates 
and screening all articles, 154 SRs were included from 25 guidelines (Figure 12)326. There 
was high agreement between reviewers (94.0%) for studies extracted in duplicate. 
Half of the included SRs were either a 
Cochrane review or mentioned adherence to 
PRISMA (77/154, 50.0%). Eighteen (11.7%) SRs 
were Cochrane SRs, and 60 (39.0%) adhered to 
PRISMA. Of the SRs that received funding, 
public sources (e.g., government) were most 
common (36/78, 46.2%). The SRs included a 
median of 14 (IQR 7.25 - 29.75) meta-analytic 
effect estimates, including those from subgroup 
and sensitivity analysis. Additional 
characteristics of our sample are reported in 
Table 17.  
Only 88 (57.1%) SRs labelled their primary endpoint (Table 18). Thus, we inferred 
the primary endpoint in the remaining 66 SRs from the index (first reported) meta-analysis. 
Seventy-three (47.4%) primary endpoints were all-cause mortality. A median of 8 (IQR 5 
- 12) primary studies with a median 1,914 (IQR 917 - 3,941) patients was included in each 
Figure 12. Flow diagram of included studies. 
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index meta-analysis. Seventy-nine (51.2%) index meta-analyses included a subgroup 
analysis and 54 (35.1%) included a sensitivity analysis.  
 
Reproducible research practices: Overall 
There was a total of 3,696 meta-analytic effect estimates, including subgroup and 
sensitivity analyses in the 154 SRs, but only 2,375 (64.3%) were reproducible in theory. 
All meta-analyses were reproducible in theory in 100 (64.9%) SRs, and in 139 (90.3%) 
SRs there was at least one meta-analysis that could potentially be reproduced. Summary 
statistics (e.g., event rates) for studies included in the index meta-analysis were reported in 
107 (69.5%) SRs, but only 39 (25.3%) mentioned whether or not missing data was imputed 
and included in the index meta-analysis. Missing data was reported to have been imputed 
in 29 of these 39 SRs, but it was not clear which exact data points were imputed in all 29. 
Similarly, only 29 SRs mentioned whether unpublished data were retrieved from primary 
study authors, with 17 affirming that authors were contacted. However, only 3/17 (17.6%) 
were clear about which data were retrieved.  
Eighty-seven (56.5%) SRs generated funnel plots to assess for publication bias, but 
only 49/87 (56.3%) presented the funnel plot in the SR or supplemental appendix.  In many 
SRs the number of studies included in the funnel plot was unclear (28/87, 32.2%). Only 62 
SRs cited the guide they used to interpret their I2 statistic, with the most common guide 
being by Higgins, et al329. Sixty-one (39.6%) authors decided between a random- or fixed-
effects model based on the statistical heterogeneity of the included studies, but 31/61 
(50.8%) did not report the amount of heterogeneity necessary to use a random-effects 
model. 
Random-effects models were used for 91/154 (59.1%) index meta-analyses, but 
specific information about the between-trial variance estimator (e.g., Dersimonian and 
Laird330) were not reported in 45/91 (49.5%). Subgroup analyses were included in 79/154 
(51.3%) index meta-analyses, but only 51/79 (64.6%) were fully reproducible in theory. 
Of the 54 sensitivity analyses that accompanied index meta-analyses, only 34 (63.0%) were 




When considering only the 2,341 of 3,696 meta-analyses that were presented on 
forest plots, we determined that 2,195/2,341 (93.7%) were reproducible in theory, since 
they included numerical point estimates (or event rates conducive to calculating point 
estimates) and a list of included studies. Compared to meta-analyses not published in 
figures (180/1,355), forest-plot-based meta-analyses were more often reproducible in 
theory (uRR 8.4; 95% CI, 7.2 - 9.7). When considering only meta-analyses published as 
supplemental material, we determined that 368/642 (57.3%) were reproducible in theory. 
Compared to main-text meta-analyses (2,007/3,054), supplemental meta-analyses were 
less often reproducible in theory (uRR .74; 95% CI .65 - .86). Both sensitivity analyses are 
unadjusted and should be interpreted with caution, especially the supplemental versus 
main-text analysis, which is likely confounded by forest-plot-based meta-analyses. 
 
Reproducible research practice All (n = 154) PRISMA (n = 60) 
non-PRISMA 
(n = 94) 
Reported the data needed to recreate all meta-analytic effect 
estimates in the SR 100 (64.9%) 36 (60.0%) 64 (68.1%) 
Reported the data needed to recreate the index meta-analytic 
effect estimate 140 (90.9%) 58 (96.7%) 82 (87.2%) 
Reported summary statistics for each individual study in the 
index meta-analysis 107 (69.5%) 42 (70.0%) 65 (69.1%) 
Reported effect estimates and measures of precision for each 
individual study in the index meta-analysis 140 (90.9%) 58 (96.7%) 82 (87.2%) 
Reported that some data in the index meta-analysis had been 
imputed 39 (25.3%) 14 (23.2%) 25 (26.6%) 
 Clear which data were imputed and how 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Reported that some data in the index meta-analysis had been 
obtained from the study author/sponsor 17 (11.0%) 7 (11.7%) 10 (10.6%) 
 Clear which data were obtained 3 (1.9%) 0 (0.0%) 3 (3.2%) 
Reported (or inferred) the type of random-effects method used 
for the index meta-analysis 78/91 (85.7%) 22/43 (51.2%) 24/48 (50.0%) 
Reported the data needed to recreate each subgroup analysis 
for the index meta-analysis 
 
For all subgroup analyses 51/79 (64.6%) 26/40 (65.0%) 25/39 (64.1%) 
For some subgroup analyses 1/79 (1.3%) 0/40 (0.0%) 1/39 (2.6%) 
Not for any subgroup analysis 27/79 (34.2%) 14/40 (35.0%) 13/39 (33.3%) 
Reported the data needed to recreate each sensitivity analysis 
for the index meta-analysis 
 
For all sensitivity analyses 34/54 (63.0%) 12/23 (52.2%) 22/31 (71.0%) 
For some sensitivity analyses 2/54 (3.7%) 2/23 (8.7%) 0/31 (0.0%) 
Not for any sensitivity analysis 18/54 (33.3%) 9/23 (39.1%) 9/31 (29.0%) 
Mention of access to data sets and statistical analysis code 
used to perform analyses 1 (0.6%) 0 (0.0%) 1 (1.1%) 
Table 11. Reproducible research practices of systematic reviews that underpin the National Comprehensive Cancer Network clinical 





Figure 13. Comparison of reproducible research practices in systematic reviews that did and did not report adherence 
to PRISMA guidelines. 
 
 
Figure 14. Comparison of reproducible research practices in systematic reviews before and after uptake of PRISMA 
guidelines.  
 
Stratified analyses of reproducible research practices 
We limit our analysis of Cochrane and non-Cochrane reviews to summary statistics 
owing to large differences in group sample sizes. One of 18 (5.6%) Cochrane SRs and 59 
of 136 (43.4%) non-Cochrane SRs stated that they adhered to PRISMA guidelines. In 16/18 
(88.9%) Cochrane SRs all included meta-analyses were reproducible in theory compared 
to 85/136 (62.5%) non-Cochrane SRs. Regarding sensitivity and subgroup analyses, all 
were reproducible in theory in Cochrane SRs. In non-Cochrane SRs only 29/48 (60.4%) 
with sensitivity analyses and 49/77 (63.6%) with subgroup analyses provided enough 
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information to make these analyses reproducible. All data for comparisons between SRs 
that did and did not mention PRISMA are in Table 11 and Figure 13. Data for our analysis 
by year of publication is shown in Figure 14. 
 
Discussion 
 The results of our investigation demonstrate that reproducible research practices 
are commonly implemented for primary analyses, but far less so for secondary, subgroup, 
and sensitivity analyses. Moreover, figure-based (e.g., forest plot) meta-analyses were far 
more reproducible than other meta-analyses, and our sensitivity analysis shows that the 
main driver of whether a meta-analysis was reproducible or not was based on it being 
published in a forest-plot or not. SRs cited by oncology practice guidelines may represent 
the most important cohort of oncology SRs, since these SRs inform guideline 
recommendations, in some cases. Yet, despite recent improvements in the quality of SRs 
after the publication of the PRISMA statement331, we found that key items were missing 
from oncology meta-analyses, which may hinder their reproducibility. The ability to 
reproduce all meta-analytic effects — even for secondary endpoints, since SRs are not 
powered for one endpoint like clinical trials — is fundamentally important, since scientific 
progress requires trustworthy results. And while the inability to reproduce study findings 
does not mean the study findings are false, it may affect the interpretation of results, 
especially since our study defined “reproducibility” for main effects as the reporting of a 
summary effect, measure of precision, and list of included studies.  
Our findings are comparable to those from a previous, similar study that examined 
the reproducible research practices of a cross-section of SRs and meta-analyses that were 
published in February of 2014143. That study found that 73% of meta-analytic effects were 
reproducible in theory, compared to the 64.3% found in our study. For articles in this study, 
adhering to PRISMA and citing a guide to interpret statistical heterogeneity both seemed 
to improve the reporting of effect estimates and measures of precision for the index meta-
analysis. These effects are either small or imprecise and should be interpreted accordingly. 
This study has several key strengths and limitations. Our sample of 154 is 40% 
larger than the previous study of reproducible research practices and is focused on only 
one area of medicine. Unlike previous investigations of data reporting in SRs43,332–336, we 
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extracted whether data necessary to reproduce meta-analyses (e.g., summary statistics or 
effect estimates) were available from published reports, and whether subgroups or 
sensitivity analyses differed from the index meta-analyses in this regard. Concerning 
limitations, our sample of SRs may not be generalizable to all SRs of oncology 
interventions, because we relied on the citations in NCCN guidelines. It is possible that 
other specialized organizations (e.g., American Society of Hematology for blood cancers) 
cite different SRs. Further, it may be that other SRs of oncology interventions are more or 
less reproducible in theory than those in this study. We used double data extraction for only 
15% of the included studies, which may increase the chance of data extraction errors. 
Despite high percent agreement between authors, in order to mitigate the possibility of 
these errors, we extracted data a second time for all items with a discrepancy and used a 
third-party adjudicator. These quality checks are consistent with previous studies143,337. 
Further, the absence of data to reproduce a meta-analysis effect does not necessarily imply 
it was incorrectly estimated, only that the availability of the data to reproduce may improve 
confidence for some readers in its accuracy.   
In conclusion, we recommend that SR authors incorporate more reproducible 
research practices and expect guideline authors to evaluate whether existing SRs are 
reproducible. We further recommend journals encourage authors to present all meta-
analyses in figures, since standard graphical output for meta-analyses in most statistical 
packages includes a list of included studies and numerical point estimates. In this study, 
these two items alone were necessary to reproduce a summary effect, in theory. A guideline 
development group may downgrade the quality of SR data if they feel that the findings are 
not trustworthy. We further recommend earnest adherence to PRISMA, since many 
reproducible research practices we investigated are addressed therein, indicating that 
authors may incompletely adhere to PRISMA recommendations. Authors should make use 
of data repositories, such as the Open Science Framework, to store data, supplemental 
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SRs combine results from similar, individual studies in an attempt to provide a 
reliable answer to a healthcare question338. Previous SRs have demonstrated benefit to both 
physicians and patients. An iconic example of how SRs have influenced clinical practice 
concerns antenatal corticosteroid use in women at risk for preterm birth71. This SR 
demonstrated a survival benefit for preterm infants and resolved unanswered clinical 
questions, such as the long-term effects of corticosteroids on surviving infants. The authors 
of this SR reported their methodology and conducted their study in a manner that promotes 
reproducibility and trustworthiness. Examples of such practices include publishing the 
search strategy used to identify included studies, assessing the included studies for risk of 
bias, and using robust statistical methods to combine these studies for determining the 
pooled treatment effect. These practices, however, are not common as previous studies 
suggest that SRs often fail to report detailed search strategies or evaluate for risk of bias
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 using valid tools337,339. Such incomplete SR methodology may lead to biased results, the 
consequences of which are far-reaching, including spurious alterations to clinical practice 
and future research questions. These consequences are especially harmful if the SR is cited 
to support CPG)recommendations. 
CPGs are consensus documents developed by a group of experts that are designed 
to guide patient care88. SRs are often used, alongside robust clinical trials, to assign level 
1 evidence to CPG recommendations340. However, for an SR to be a trustworthy and 
accurate source of clinical information, its methods and reporting must first be robust. 
Previous investigations of SRs underpinning CPG recommendations have identified 
suboptimal methodology and reporting43,333,334. Such SRs may be irreproducible, and the 
critical appraisal of their summary effects by CPG development groups may be 
compromised. 
SRs are also critically important to the prevention, diagnosis, and treatment of colon 
and rectal cancer. Currently, colorectal cancer is being diagnosed in patients under age 50 
at an increasing rate341. Even worse, there is evidence that colon cancer in younger patients 
may differ from colon cancer in older adults with respect to clinical presentation, 
pathologic findings, and tumor biology342. Therefore, there is a fundamental need for robust 
research based on rigorous methodology to continue the advancements in understanding 
preventing, diagnosing, and treating colorectal cancer. SRs are likely to play a key role in 
these advancements.  
Therefore, the primary objective of this study is to assess the risk of bias and 
reporting quality in SRs cited in the NCCN guidelines for the treatment of colon (Version 
2.2018)343 and rectal (Version 1.2018)344 cancer, since NCCN guidelines are heavily used 
by physicians to guide patient care325 and SRs are the highest level of medical evidence. 
To do so, we applied the novel Risk of Bias In Systematic Reviews (ROBIS) tool100 and 




In this review, we adhered to PRISMA guidance where possible and applicable327, 
despite this study not being an SR. Our choice to adhere to PRISMA was made because no 
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validated reporting checklist for cross-sectional or meta-epidemiological studies exists. We 
defined an SR according to the PRISMA-P (PRISMA for protocols) definition: articles that 
explicitly stated methods to identify studies (i.e., a search strategy), explicitly stated 
methods of study selection (e.g., eligibility criteria and selection process), and explicitly 
described methods of synthesis (or other type of summary)327. SRs were gathered from a 
previous study whose protocol is available via the Open Science Framework326. To identify 
SRs in the previous study, one author (CW) manually screened the reference list of and 
Discussion (main narrative) section of the NCCN colon and rectal cancer guidelines. 
Keywords searches were conducted for studies referenced as a “systematic review”, “meta-
analysis”, “review”, or “metaanalysis”. Any referenced papers published in the Cochrane 
Database for Systematic Reviews were also extracted. All extracted references were added 
to a PubMed collection and exported to Rayyan256 for title and abstract screening. In 
accordance with the previous study from which our sample is derived, an SR was included 
if it had at least one meta-analysis that included at least one randomized-controlled trial. 
Further, each SR that met these criteria must have been published after 2011 to allow 
uptake of the PRISMA statement (published in 2009). To extract data for this study we 
developed Google Forms based on the ROBIS and PRISMA statements. Two authors 
extracted data in duplicate with masking for ROBIS (CW, LP) and for PRISMA (CW, 
MB). All discrepancies were resolved between the authors, with the availability of a third-
party adjudicator (MV). 
The ROBIS statement assesses whether an SR is at risk of bias based on its methods 
and conduct. ROBIS includes 3 phases: 1) assess relevance (optional), 2) identify concerns 
with the SR process, and 3) judge risk of bias of the SR. We opted to exclude the first phase 
of assessing relevance, since all SRs from the NCCN colorectal guidelines are relevant to 
our research question. In the second phase, signaling questions are asked to guide an 
investigator through 4 bias domains: 1) study eligibility criteria, 2) identification and 
selection of studies, 3) data collection and study appraisal, and 4) synthesis and findings. 
Signaling questions are answered as “yes”, “probably yes”, “no”, “probably no”, and “no 
information”. We followed the guidance of the ROBIS statement manual when answering 
signaling questions. Based on the answers to the signaling questions in each domain, each 
domain is assigned a risk of bias grade. Potential grades include “high”, “low”, or 
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“unclear”. In the third phase, signaling questions are again asked, except these questions 
relate to the overall reliability of the SR findings. If limitations are identified in phase 2, 
SR authors will be required to address these limitations and interpret the findings 
accordingly. Further, SR authors will be required to not emphasize findings based on 
statistical significance alone. After completing phase 3, a summary judgement (e.g., high, 
low, or unclear) regarding the risk of bias for the SR will be rendered. For this study, we 
distinguished between high and unclear risk of bias based on the completeness of SR 
reporting. For example, to be judged high risk of bias, the SR would have to report the use 
of flawed methods, such as a flawed risk of bias scale, use of only one database to gather 
studies, or single-author data extraction. If an SR did not report enough information for us 
to determine whether the methods were at high or low quality, we judged that SR with 
unclear risk of bias. 
Contrary to ROBIS, PRISMA assesses reporting quality, so rather than asking if an 
item was conducted adequately, PRISMA asks whether an item was reported. For example, 
whereas ROBIS may ask about the adequacy and comprehensiveness of the search strategy, 
PRISMA asks if a search strategy was reported. This distinction is important for 
complementing the assessment of risk of bias in SR methodology measured using ROBIS. 
The PRISMA checklist contains 27 items divided into 7 domains: Title, Abstract, 
Introduction, Methods, Results, Discussion, and Funding. For each item, we judged 
whether an SR fully reported what was required by PRISMA and scored each item with a 
1 (Yes – fully reported) or 0 (Not reported or Partially Reported). Our rationale for partial 
reported being grouped with “not reported” is that PRISMA does only asks whether an 
item is mentioned, not that it was methodologically robust. So, failure to completely report 
an item indicates that a key piece of that item is not available to readers. For example, Item 
5 requires SR authors to indicate if a protocol exists and direct readers to it with a citation 
or registration number. Failure to direct readers means readers are unable to access the 
protocol, just as if the SR authors did not mention a protocol at all. After scoring each 
PRISMA item, we summed the adherence across each article and each item. It should be 
noted that PRISMA is not a measurement tool, but a reporting checklist. Despite that fact, 
PRISMA has been used in numerous previous studies as a measurement tool, since no other 
validated option to assess reporting quality exists. 
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We used Google Sheets for all summary statistics and measures of central tendency 
(medians and interquartile ranges (IQR)). 
 
Results 
 Sixty-three SRs (33 Colon, 30 
Rectal) were included in this study 
(Figure 15). The 63 SRs included a 
median of 10 (IQR 7-16) studies and 
a median of 3,160 (IQR 1,270-5,825) 
patients. Twenty-four (38.1%) SRs 
stated that they adhered to PRISMA 
guidelines. The included SRs were 
cited a total of 76 times, 
overwhelmingly for support of NCCN committee recommendations (56/76, 73.7%). SRs 
were also cited as evidence of harm for available therapies (10/76, 13.2%), as evidence that 
contradicts the committee recommendations (5/76, 6.6%), and as background evidence 
where no recommendation was given (5/76, 6.6%). All primary data and the protocol from 
this investigation are available via the Open Science Framework346. 
 Using ROBIS, only 3 (4.8%) SRs were judged with low risk of bias, 35 (55.6%) 
SRs were judged with unclear risk of bias, and 25 (39.7%) SRs were judged with high risk 
of bias (Table 12). Across all SRs, the individual bias domains at the highest risk of bias, 
were domains 1 (protocol and eligibility criteria) and 2 (methods to identify and select 
studies). Twenty-eight (44.4%) SRs were at high risk of bias for domain 1 and 26 (41.3%) 
were at high risk of bias for domain 2. Specific areas of concern in these two domains were 
the lack of information about publication of an SR protocol, language restrictions, choice 
of bibliographic databases, and searches for grey literature. Domains 3 (data collection and 
appraisal) and 4 (synthesis of findings) were predominantly judged as unclear risk of bias, 
corresponding to a frequent lack of critical information that would have aided our 
assessments. Individual study scores are shown in Table 19. 
  








Methods to identify 
and/or select studies 
DOMAIN 3 






Low 6 5 5 4 3 
Unclear 29 32 43 46 35 
High 28 26 15 13 25 
Table 12. Summary of risk of bias judgments for included systematic reviews (n = 63) 
 
Across all studies, the median adherence to PRISMA was 74.1% (IQR 69.2%-
80.0%), corresponding to approximately 20 of 27 items (Table 20). Two items had 100% 
adherence: Item 3 (rationale for SR) and Item 21 (presentation of results with measures of 
precision). Thirteen additional items had adherence greater than 75%, with 7 items 
maintaining adherence greater than 90%. Only 3 items had adherence lower than 25%: 
Item 8 (search strategy), Item 5 (protocol and registration), and Item 4 (provision of PICO-
format research question). There was no difference between SRs that adhered to PRISMA 
(n = 24) and did not adhere to PRISMA (n = 39) in terms of number of fully reported items 
(20 PRISMA vs. 20.5 no PRISMA). 
 
Discussion 
 Our investigation found that SRs cited in colorectal guidelines are frequently at 
unclear or high risk of bias and do not report key SR items that are important for the critical 
appraisal of results. Specifically, that our predominant risk of bias judgement was unclear, 
signals that much of the critical SR methodological items were missing or poorly described. 
Our finding — that SRs adhered to a median of 20/27 PRISMA items — may appear at 
odds with our risk of bias findings. However, the difference in these two findings highlights 
our key takeaway: an SR item may be reported but still represent a flawed method, thus 
placing the SR at risk of bias. Thus, our findings identify two key action items for future 
and ongoing SRs in colorectal cancer: ensure SRs report all items from PRISMA and 
ensure SRs describe methods in enough detail to facilitate critical appraisal of results. 
 Two key examples of how missing or poorly described information may affect the 
critical appraisal of an SR relate to study protocols and risk of bias evaluations. In our 
sample, SRs rarely directed the reader to a publicly available, a priori protocol (2/63, 
3.2%). It has been shown that SRs, like randomized-controlled trials36,136, exhibit 
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significant rates of selective outcome reporting — defined as the selective inclusion, 
omission, or alteration of study outcomes, often due to statistical significance291. Thus, the 
lack of a publicly available protocol leaves the possibility that SR results are published at 
the author's discretion, rather than at the behest of a prespecified protocol. Similarly, a lack 
of detail regarding risk of bias evaluations may compromise the validity of meta-analytic 
effects in an SR. In our study, authors often reported that a risk of bias evaluation was 
conducted (46/63, 73.0%), but further inspection of the risk of bias methods showed that 
many authors used outdated, flawed tools. For example, authors frequently used the Jadad 
scale for assessing risk of bias of included clinical trials. The Jadad scale is notorious for 
its omission of allocation concealment as a bias domain, and according to the Cochrane 
Handbook, use of the Jadad scale is “explicitly discouraged”347. Thus, the use of the Jadad 
scale leaves the possibility that interventional effects shown in the included colorectal SRs 
are confounded by bias that is undetected by SR authors. Furthermore, even if authors used 
Cochrane risk of bias tool, they often reported only judgment for individual risk of bias 
domains, without an accompanying comment that explained the judgment. It has been 
shown previously that authors frequently make erroneous judgments (i.e. judgments that 
were not in line with the accompanying comment) and thus, not in line with 
recommendations available in the Cochrane Handbook348–350. Therefore, inadequate 
reporting of Cochrane risk of bias tool prevents readers to verify accuracy of authors’ 
judgments. 
The cohort of SRs we analyzed are unique since these SRs informed the evidence 
base of NCCN colorectal guidelines. However, this sample of SRs is likely not the only, 
or even the primary, source of evidence for most NCCN recommendations, since the field 
of oncology relies heavily on randomized-controlled trial data. Indeed, the NCCN 
categories of recommendations simply state that “high-level evidence” and “uniform 
NCCN consensus” is necessary to achieve Level 1 evidence status351. Nonetheless, the 
findings from our study warrant concern due to the predominance of unclear or high risk 
of bias judgements and variability in reporting quality. For example, in the NCCN rectal 
cancer guidelines, seven SRs were cited in the discussion of laparoscopy vs. open 
resection352–358. Five of these SRs were at high or unclear risk of bias, while 2 were at low 
risk, including the only Cochrane review. There was no discussion of the risk of bias for 
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any of these SRs. This oversight may be reasonable in this case because of the dearth of 
other data available and cited for laparoscopy, all pointing to a fairly certain conclusion of 
its risks and benefits. Moreover, in this case the low risk of bias SRs had similar findings 
as the high and unclear risk of bias SRs. However, even this scenario highlights an 
important point — risk of bias assessments are crucial to reasoned discussions and serve 
to augment the ongoing, skillful clinical appraisal inherent to CPG panel discussions. In 
this case, where the benefits and risks of laparoscopy are fairly well-established, the harm 
of omitting risk of bias from a CPG discussion may be benign, but for emerging therapies 
with less certain benefit, risk of bias evaluations are necessary because the risk of false 
positive or negative results may have a broad impact of CPG recommendations and clinical 
practice. This study has several key limitations. First, our findings may not be 
generalizable to all colorectal SRs, since we only evaluated SRs cited by the NCCN rather 
than all colorectal SRs available. Next, we discourage the interpretation of our findings to 
mean that NCCN recommendations are at risk of bias, since the NCCN recommendations 
rely on other robust research, such as clinical trials, that we did not include in our 
investigation. Any judgments about the quality of NCCN recommendations would need to 
be supported with thorough assessment of all evidence included and validated tools for 
assessment of clinical guidelines. Moreover, the included NCCN guidelines included 1,698 
total references, so our 63 included SRs represents only a small fraction of the cited 
evidence. Finally, this study is limited by investigating only guidelines written for 
healthcare professionals, rather than NCCN guidelines for patients. In conclusion, our 
investigation of the risk of bias and quality of reporting of SRs referenced by the NCCN 
guidelines for colon and rectal cancer found that SRs are commonly at high risk of bias 
and do not fully report key items. Specifically, we found that an SR item may be mentioned, 
but may report a flawed method or incompletely report all aspects of the item. The 
implication for the treatment and management of colon and rectal cancer, which relies on 
high-quality evidence for demographically diverse patients, is that summary effects may 
not exemplify the trust normally imputed on SRs and meta-analyses. Further, even though 
the objective of our investigation is not to question the strength of NCCN guideline 
recommendations, our findings may be of concern to oncologists who heavily rely on 
NCCN recommendations. The NCCN developers use what literature is available to 
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formulate recommendations, and thus, we recommend more stringent SR methodology and 
reporting be enforced in journal publications. When readers or guideline developers 
encounter a biased SR, we recommend careful critical appraisal of the results and 
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Robust, clearly reported CPGs are essential for evidence-based clinical practice. 
The Institute of Medicine recognizes CPGs as necessary reference material for physicians 
seeking to optimize patient care.88 CPGs are capable of increasing the quality of patient 
care and improving patient outcomes359, but the adoption of low-quality guidelines may 
result in widespread use of ineffective treatments, inefficient practices, and harm to 
patients360,361. Even though they are an essential resource, CPGs have historically exhibited 
low-quality reporting.362 The ramifications of low reporting quality in CPGs are broad, but 
most pressing is the lack of a distinction between poor methods and poorly reported 
methods. In practice, the two may be indistinguishable. For example, if CPG developers 
perform a narrow, inadequate search of the literature, their subsequent recommendations 
may not be reproducible or trustworthy. Similarly, if the CPG developers do not report 
their search strategy, the question remains as to whether the recommendations are 
trustworthy. The quality of CPG reporting is as important as its methodological quality.
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In oncology, new drug approvals may result in rapid changes to patient care.  
Articulating the available evidence, its strength, and its limitations to physicians is vital. 
The NCCN — arguably the premier guideline organization in the United States363 — has 
a policy to update their CPGs “at least annually.”44 This policy of annual updates highlights 
the urgent need for clear reporting of current and future CPGs.  
Two popular instruments exist for assessing the quality of CPGs in healthcare: The 
Reporting Items for practice Guidelines in HealThcare (RIGHT) statement94 and the 
Appraisal of Guidelines for Research and Evaluation (AGREE) II instrument95. The 
AGREE-II instrument includes items related to the methodological (e.g., quality of search 
strategy, inclusion of stakeholder preferences) and reporting quality of CPGs, whereas the 
RIGHT statement focuses solely on reporting quality (e.g., providing a summary of 
recommendations, disclosure of funding source). Neither was created as a handbook for 
developing guidelines. According to the RIGHT Statement authors, the RIGHT Statement 
is not designed to assess the inherent quality of a guideline.94 Rather, the RIGHT Statement 
is designed to complement tools that are designed to assess the inherent quality of a 
guideline, such as the AGREE-II instrument.  
Given the comprehensiveness and importance of the NCCN CPGs to oncology 
practice363, the aim of this investigation is to highlight the strengths and weaknesses in the 
reporting of NCCN guidelines. By doing so, we aim to improve the delivery of oncology 
evidence to oncologists and improve patient care. In this study we applied the RIGHT 
Statement and AGREE-II instrument to 49 NCCN guidelines for the treatment of cancer 
by cancer site.  
 
Methods 
A version of this manuscript is available as a preprint via bioRxiv364. Since NCCN 
guidelines update frequently throughout a calendar year, we downloaded the PDF of all 49 
NCCN treatment guidelines on March 21, 2018 from the NCCN website under the heading 
“NCCN Guidelines for the Treatment of Cancer by Site”. To be included in this study, a 
guideline must have a written Discussion section, which is the equivalent to the guideline 
narrative. Prior to data extraction, CW, CC, and DT reviewed the RIGHT statement and 
AGREE-II instrument manuals to become familiar with the checklist items.94,95 We met 
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and devised a Google Form for both tools. CW, CC, and DT extracted data for all items 
from each tool independently, while masked to each other’s decisions. Since the NCCN 
does not detail their full methods in each CPG, and provides a full explanation of many 
aspects of their methods on their website (www.nccn.org), we extracted data from the CPG 
and website policy documents. Any discrepancies in data extraction were resolved via 
consensus discussion. After extraction and validation of all Google Form responses, we 
exported these responses to a Google Sheet. We used this Google Sheet to calculate 
summary statistics. We correlated the RIGHT and AGREE-II scores using Stata 15.1 and 
the commands pwcorr, for a Pearson’s r, and graph twoway scatter for a two-way scatter 
plot. Raw AGREE-II scores were used, rather than scaled scores, with a maximum value 
of 161 (23 items, 7-point Likert scale) indicating a judgement of perfect methodological 
quality across all domains for a CPG. 
The design of the RIGHT Statement parallels other statements and reporting 
guidelines, such as CONSORT for clinical trials or PRISMA for SRs, and consists of a 35-
item checklist and an Explanation and Elaboration document.94. For each of the items we 
assigned a numeric score of 1 (full adherence), 0.5 (partial adherence), or 0 (no adherence). 
An example of partial adherence may be if a guideline provides a partial explanation of 
cancer epidemiology, explaining only the prevalence and incidence of the disease. Full 
explanation includes a description of prevalence/incidence, morbidity, mortality, and 
burden (including financial). We present summary data using the described scoring 
convention for each of the 35-items. Rather than dichotomizing the data in an attempt to 
separate CPGs into high, medium, or low reporting quality groups, we present data as 
continuous and out of the maximum possible score of 35. This decision was made because 
there is no guidance for what constitutes high, medium, or low-quality reporting quality in 
CPGs. 
The AGREE-II instrument is organized differently, and consists of 23 items divided 
into 6 domains, with each item scored on a 1 (strongly disagree) to 7 (strongly agree) 
Likert-type scale. In accordance with the AGREE-II manual,95 we calculated a scaled 
domain score for each domain for each CPG. The scaled domain score is calculated as 
follows: 
(𝑂𝑏𝑡𝑎𝑖𝑛𝑒𝑑	𝑆𝑐𝑜𝑟𝑒	 − 	𝑀𝑖𝑛𝑖𝑚𝑢𝑚	𝑆𝑐𝑜𝑟𝑒) 	÷	 (𝑀𝑎𝑥𝑖𝑚𝑢𝑚	𝑆𝑐𝑜𝑟𝑒	 − 	𝑀𝑖𝑛𝑖𝑚𝑢𝑚	𝑆𝑐𝑜𝑟𝑒) 
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The scaled domain score can be converted to an average rating (1 to 7 scale) by multiplying 
the scaled domain score by 7. The obtained score is calculated for each domain and is the 
sum of all rater scores in that domain. The minimum score is calculated by multiplying the 
minimum item score (1, strongly disagree), the number of raters (3, in this study), and the 
number of items in the domain. The maximum score is calculated similarly, but substitutes 
the maximum item score (7, strongly agree) for the minimum item score. Lastly, we made 
a consensus judgement about whether the CPG should be used in practice or not based on 
the 6 scaled domain scores for each CPG. We based our judgement of each NCCN CPG 
off the AGREE-II manual, which suggests answering whether a CPG should be used with 
“yes”, “yes with modifications”, or “no”. We rendered our judgements by looking at the 
full scope of domain scores, rather than using dichotomous decision rules. The rationale 
for this decision was that each domain has been shown to independently associated with 
CPG quality365 Our primary objective was to assess CPG scores on the RIGHT statement 
and AGREE-II instrument. Since all NCCN guidelines were published after the RIGHT 
statement and AGREE-II instrument were published, they are all eligible for analysis. As 
neither the RIGHT statement or AGREE-II instrument can judge the clinical usefulness of 
a guideline, our study is designed to only focus on the methodological and reporting quality 
of each guideline. 
 
Results 
 We identified 49 NCCN CPGs for the treatment of cancer by site. The Uveal 
Melanoma CPG was excluded because the Discussion section (the narrative section of 
NCCN guidelines) was under development and not written. All of our data, including data 
for each individual item on the RIGHT statement and AGREE-II instrument, are publicly 
available via the Open Science Framework366. 
 
RIGHT Statement  
The NCCN guidelines were largely homogenous, and many key methodological 
items were reported clearly in policy documents on the NCCN website. Table 13 shows 
each NCCN guideline and its adherence to all RIGHT statement items. Notable strengths 
of the NCCN CPGs were the reporting of conflicts of interest for all authors (items 19a and 
126 
 
19b), complete description of pertinent subgroups (item 7b), and the clarity of CPG 
recommendations (item 13a). Notable deficiencies were the description of stakeholder 
involvement (e.g., patient views and preferences) [item 14a], the cost and resource 
implications of therapies (item 14b), which outcomes were prioritized when formulating 
recommendations (item 10b), and the approach to assess the certainty of the quality of 
evidence (item 12).  
 
AGREE-II 
Table 14 shows the scaled domain scores for each NCCN CPG. Using the AGREE-
II instrument we were able to assess CPG scores in six domains, each essential to a 
methodologically robust CPG. No guideline scored extremely low for any domain. The 
fourth domain (Clarity of Presentation) and sixth domain (Editorial Independence) scored 
the highest, overall. The Clarity of Presentation domain asks whether the recommendations 
are specific and unambiguous, if alternative treatment options were mentioned, and if the 
key recommendations are easily identifiable. The sixth domain asks questions about the 
influence of the funding source on CPG development and whether conflicts of interest were 
disclosed. The lowest, individual domain score was 36.1% in the Applicability domain for 
the Acute Lymphoblastic Leukemia CPG. This score indicates that average score (1 to 7 
scale) for this domain was approximately 2.5. With respect to overall domain scores across 
all guidelines, the Stakeholder Involvement domain scored the lowest with an average 
score of 48.6% (e.g., 3.4 out of 7). The Stakeholder Involvement domain asks questions 
related to the description of guideline development members, the incorporation of target 
population views and preferences, and the identification of target users of the guidelines.  
Correlation of RIGHT and AGREE-II scores 
There was a small, negative correlation between RIGHT and AGREE-II scores (r 
= -.25). The negative correlation is likely driven by the 4 guidelines that adhered to only 
19/35 (54.2%) of RIGHT items, while maintaining relatively high AGREE-II scores. 
Overall, most data clustered between RIGHT scores of 19.5 - 20.5 and AGREE-II scores 
of approximately 105-115. Visual inspection of our data shows that many CPGs had 












(n = 8) 
Evidence 
(n = 5) 
Recommendations 
(n = 7) 
Quality 
assurance 




4.0 6.5 1.5 3.5 1.0 4.0 21 (60.0%) 
Acute Myeloid 
Leukemia 4.0 5.0 1.5 3.5 1.0 4.0 
19.5 
(55.7%) 
Amyloidosis 5.0 5.0 1.5 3.5 1.0 4.0 20.5 (58.6%) 
Anal 5.0 5.0 1.5 3.5 1.0 4.0 20.5 (58.6%) 
B-Cell 4.0 6.0 1.5 3.5 1.0 4.0 20.5 (58.6%) 
Basal Cell 4.0 5.0 1.5 3.5 1.0 4.0 19.5 (55.7%) 
Bladder 4.0 5.0 1.5 3.5 1.0 4.0 19.5 (55.7%) 
Bone 4.0 5.0 1.5 3.5 1.0 4.0 19.5 (55.7%) 
Breast 4.5 5.0 1.5 3.5 1.0 4.0 20 (57.1%) 




4.0 5.0 1.5 3.5 1.0 4.0 19.5 (55.7%) 
Chronic Myeloid 




System 5.0 5.0 1.5 3.5 1.0 4.0 
20.5 
(58.6%) 
Colon 5.0 5.0 1.5 3.5 1.0 4.0 20.5 (58.6%) 
Cutaneous B-Cell 4.0 3.5 1.5 3.5 1.0 4.0 18 (51.4%) 
Dermato-
Protruberans 4.0 5.0 1.5 3.5 1.0 4.0 
19.5 
(55.7%) 
Esophageal 4.0 5.0 1.5 3.5 1.0 4.0 19.5 (55.7%) 
Gastric 5.0 5.0 1.5 3.5 1.0 4.0 20.5 (58.6%) 
Hairy Cell 5.0 5.0 1.5 3.5 1.0 4.0 20.5 (58.6%) 
Head/Neck 4.0 4.0 1.5 3.5 1.0 4.0 18.5 (52.9%) 
Hepatobiliary 4.0 5.0 1.5 3.5 1.0 4.0 19.5 (55.7%) 
Hodgkin 4.0 5.5 1.5 3.5 1.0 4.0 20 (57.1%) 
Kaposi 4.0 5.0 1.5 3.5 1.0 4.0 19.5 (55.7%) 
Kidney 4.0 5.0 1.5 3.5 1.0 4.0 19.5 (55.7%) 
Myelodysplastic 
Syndrome 4.5 5.0 1.5 3.5 1.0 4.0 
20 
(57.1%) 
Melanoma 5.0 5.0 1.5 3.5 1.0 4.0 20.5 (58.6%) 
Merkel 4.5 5.0 1.5 3.5 1.0 4.0 20 (57.1%) 
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Mesothelioma 4.0 5.0 1.5 3.5 1.0 4.0 19.5 (55.7%) 
Myeloproliferative 
Neoplasms 4.0 5.0 1.5 3.5 1.0 4.0 
19.5 
(55.7%) 
Myeloma 4.0 5.0 1.5 3.5 1.0 4.0 19.5 (55.7%) 
Neuroendocrine 4.0 5.0 1.5 3.5 1.0 4.0 19.5 (55.7%) 
Non-small cell 
lung 4.0 5.0 1.5 3.5 1.0 4.0 
19.5 
(55.7%) 
Occult primary 4.0 5.5 1.5 3.5 1.0 4.0 20 (57.1%) 
Ovarian 4.0 5.0 1.5 3.5 1.0 4.0 19.5 (55.7%) 
Pancreatic 4.0 5.0 1.5 3.5 1.0 4.0 19.5 (55.7%) 
Penile 5.0 5.0 1.5 3.5 1.0 4.0 20.5 (58.6%) 
Prostate 4.0 6.0 1.5 3.5 1.0 4.0 20.5 (58.6%) 
Rectal 4.0 5.0 1.5 3.5 1.0 4.0 19.5 (55.7%) 
Sarcoma 4.0 5.0 1.5 3.5 1.0 4.0 19.5 (55.7%) 
Squamous cell 4.5 5.0 1.5 3.5 1.0 4.0 20 (57.1%) 
Small cell lung 4.0 4.0 1.5 3.5 1.0 4.0 18.5 (52.9%) 
T-Cell 5.0 6.0 1.5 3.5 1.0 4.0 21.5 (61.4%) 
Testicular 4.0 5.0 1.5 3.5 1.0 4.0 19.5 (55.7%) 
Thymus 5.0 5.0 1.5 3.5 1.0 4.0 20.5 (58.6%) 
Thyroid 4.0 5.0 1.5 3.5 1.0 4.0 19.5 (55.7%) 
Uterine 4.0 5.0 1.5 3.5 1.0 4.0 19.5 (55.7%) 
Vulvar 5.0 5.0 1.5 3.5 1.0 4.0 20.5 (58.6%) 
Waldenstrom 4.0 5.0 1.5 3.5 1.0 4.0 19.5 (55.7%) 
Table 13. Adherence to RIGHT statement items overall and in each domain for all NCCN guidelines.  
 
Certain outliers are visible in the scatter plot, which have been labelled with the 
CPG name. Notable outliers are the guidelines for Merkel Cell Carcinoma and Primary 
Cutaneous B-Cell Lymphoma. The Merkel Cell Carcinoma guideline scored lowest on 
AGREE-II, but average on RIGHT. This guideline was judged to score relatively low on 
three methodological domains: Stakeholder Involvement, Rigor of Development, 
Applicability. None of these items had direct overlap with RIGHT statement items, so the 
Merkel Cell Carcinoma guideline was still capable of achieving an average score in terms 
of reporting quality. On the other hand, the Primary Cutaneous B-Cell Lymphoma 
129 
 
guideline scored lowest on the RIGHT statement, but above average on AGREE-II. In 
absolute terms, the Primary Cutaneous B-Cell Lymphoma guideline only scored 2 items 
lower than most other guidelines. 
 




Leukemia 77.8% 42.6% 61.8% 85.2% 36.1% 94.4% 
Acute Myeloid 
Leukemia 79.6% 38.9% 59.0% 87.0% 40.3% 94.4% 
Amyloidosis 42.6% 50.0% 57.6% 74.1% 48.6% 94.4% 
Anal 72.2% 37.0% 54.9% 81.5% 40.3% 94.4% 
B-Cell 74.1% 50.0% 56.9% 81.5% 52.8% 94.4% 
Basal Cell 77.8% 53.7% 61.8% 85.2% 62.5% 94.4% 
Bladder 74.1% 42.6% 57.6% 90.7% 51.4% 94.4% 
Bone 77.8% 51.9% 67.4% 85.2% 59.7% 94.4% 
Breast 79.6% 50.0% 70.8% 79.6% 62.5% 94.4% 
Cervical 68.5% 51.9% 63.9% 87.0% 63.9% 94.4% 
Chronic Lymphocytic 
Leukemia 83.3% 51.9% 57.6% 83.3% 65.3% 94.4% 
Chronic Myeloid 
Leukemia 70.4% 40.7% 65.3% 87.0% 45.8% 94.4% 
Central Nervous 
System 77.8% 53.7% 58.3% 81.5% 66.7% 94.4% 
Colon 83.3% 42.6% 61.1% 70.4% 51.4% 94.4% 
Cutaneous B-Cell 63.0% 50.0% 43.8% 77.8% 61.1% 94.4% 
Dermato-Protruberans 77.8% 50.0% 65.3% 88.9% 63.9% 94.4% 
Esophageal 81.5% 50.0% 66.0% 87.0% 63.9% 94.4% 
Gastric 66.7% 40.7% 61.1% 83.3% 50.0% 94.4% 
Hairy Cell 70.4% 42.6% 63.9% 85.2% 50.0% 94.4% 
Head/Neck 74.1% 51.9% 65.3% 81.5% 65.3% 94.4% 
Hepatobiliary 77.8% 48.1% 64.6% 83.3% 59.7% 94.4% 
Hodgkin 70.4% 42.6% 68.1% 87.0% 52.8% 94.4% 
Kaposi 70.4% 48.1% 63.9% 83.3% 54.2% 94.4% 
Kidney 74.1% 53.7% 61.8% 85.2% 65.3% 94.4% 
Myelodysplastic 
Syndrome 63.0% 40.7% 43.8% 68.5% 40.3% 94.4% 
Melanoma 72.2% 51.9% 62.5% 81.5% 61.1% 94.4% 
Merkel 68.5% 48.1% 65.3% 85.2% 61.1% 94.4% 
Mesothelioma 81.5% 40.7% 62.5% 87.0% 51.4% 94.4% 
Myeloproliferative 
Neoplasms 79.6% 53.7% 59.0% 85.2% 55.6% 94.4% 
Myeloma 70.4% 53.7% 66.7% 87.0% 63.9% 94.4% 
Neuroendocrine 74.1% 46.3% 67.4% 87.0% 69.4% 94.4% 
Non-small cell lung 77.8% 51.9% 66.7% 87.0% 63.9% 94.4% 
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Occult primary 74.1% 51.9% 66.0% 87.0% 63.9% 94.4% 
Ovarian 85.2% 51.9% 62.5% 87.0% 61.1% 94.4% 
Pancreatic 74.1% 51.9% 66.7% 85.2% 65.3% 94.4% 
Penile 72.2% 53.7% 68.1% 87.0% 63.9% 94.4% 
Prostate 81.5% 46.3% 67.4% 85.2% 56.9% 94.4% 
Rectal 70.4% 53.7% 63.9% 87.0% 66.7% 94.4% 
Sarcoma 75.9% 53.7% 61.8% 87.0% 58.3% 94.4% 
Squamous cell 74.1% 53.7% 66.7% 85.2% 62.5% 94.4% 
Small cell lung 70.4% 42.6% 50.7% 85.2% 48.6% 94.4% 
T-Cell 75.9% 44.4% 62.5% 85.2% 50.0% 94.4% 
Testicular 74.1% 53.7% 64.6% 87.0% 69.4% 94.4% 
Thymus 77.8% 46.3% 64.6% 87.0% 52.8% 94.4% 
Thyroid 63.0% 53.7% 64.6% 87.0% 68.1% 94.4% 
Uterine 74.1% 53.7% 64.6% 87.0% 61.1% 94.4% 
Vulvar 79.6% 42.6% 63.9% 85.2% 51.4% 94.4% 
Waldenstrom 74.1% 55.6% 66.0% 87.0% 61.1% 94.4% 
Average Scaled 
Domain Score 73.9% 48.6% 62.4% 84.4% 57.5% 94.4% 
Table 14. AGREE-II scores, using scaled percent adherence, in all domains and overall across all guidelines.  
 
Discussion 
 In this investigation we found that NCCN CPGs demonstrate key strengths and 
weaknesses with respect to the reporting of key items essential to CPGs. For example, the 
NCCN CPGs require conflicts of interest disclosure, clearly describe all pertinent 
subgroups, and delineate key recommendations. On the other hand, the NCCN CPGs did 
not consistently describe how patient values and preferences were incorporated into 
recommendations, the financial burden of the recommendations, or describe the approach 
used to assess the certainty of the evidence underpinning the recommendations. The NCCN 
guidelines were incredibly uniform in how they are reported and conducted, which resulted 
in similar (or identical, in the case of the RIGHT statement) scores for most CPGs. This 
uniformity is reflected in the scatter plot. Across all NCCN guidelines, certain items, such 
as providing a summary of recommendations, were always reported. On the other hand, 
some items, such as describing the approach to assessing the certainty of the evidence, were 
never reported. The slight variations in AGREE-II scores for identical RIGHT scores is a 
product of 1-7 Likert scale format, which allows more variation in judgements than the 
RIGHT statement scoring system of full, partial, or no adherence. In light of the uniformity 
131 
 
of our data, our findings should be interpreted to mean that there are significant 
shortcomings in the reporting and development of NCCN guidelines, but all of these 
shortcomings could be addressed at once by updating the central NCCN policies and 
procedures. 
 Nonetheless, compared to other CPGs scored with the AGREE-II instrument, those 
published by the NCCN appear to have as good or stronger methodological quality365,367–
369. A recent evaluation in JAMA Internal Medicine of CPGs for the pharmacologic 
management of noncommunicable diseases in primary care found that three CPG 
characteristics are associated with high quality CPGs: greater than 20 authors, development 
at a government institution, and reported funding370. The NCCN is a non-profit 
organization and their CPGs are developed by a team of volunteers from member 
institutions and no external funding is received to develop the CPGs. All guidelines all 
have greater than 20 authors. So, the findings of this recent evaluation in JAMA Internal 
Medicine seem in line with our findings that NCCN CPGs are of comparable or higher 
methodological quality than other biomedical CPGs. However, the reporting quality of 
biomedical CPGs has been evaluated far less, owing to the fact that the RIGHT statement 
is the only available tool and was published in 2017. Only one study was identified which 
used the RIGHT Statement371. This lone study evaluated 539 CPGs in traditional Chinese 
medicine, finding that 17 of 35 (48.6%) RIGHT Statement were reported less than 10% of 
the time. In comparison, our study found that only 9 items were never fully reported. In an 
effort to provide the highest-quality recommendations to physicians for the treatment of 
different cancers, we encourage continued improvements to the NCCN guidelines. The 
AGREE-II instrument95 was developed to assess CPG quality in six, equally essential 
domains ranging from describing the purpose of the CPG to the applicability of the CPG 
recommendations. We found that they scored well enough to continue being recommended 
in clinical practice, but key methodological items were not reported, thus highlighting areas 
where the delivery of oncology evidence can be improved. Since we assigned summary 
judgements related to the recommended use of NCCN CPGs in clinical practice in a 
continuous manner, each judgement of “Yes, with modifications” should be interpreted 
continuously. Since no two CPGs were scored identically for all 6 domains, each judgment 
of “yes, with modifications” should signal different improvements are needed in different 
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orders of magnitude. Through applying the RIGHT Statement, which was created to be 
used alongside the AGREE-II instrument, we confirmed that improvements in the reporting 
of several key items would strengthen the impact of NCCN CPGs by increasing the clarity 
and comprehensiveness of the recommendations.  
 None of the NCCN CPGs described the process by which patient values and 
preferences were solicited and incorporated into the guideline recommendations, nor do 
they adhere to an accepted framework for grading the quality of evidence. The primary 
reason for incorporating patient values and preferences into CPG recommendations is that 
recommendations that are aligned with patient values may be more easily adopted and 
implemented372–374. Until recently, there were no firmly established processes for including 
patient values and preferences in CPG recommendations. To address this gap, the GRADE 
(Grading of Recommendations Assessment, Development and Evaluation) working group 
created the GRADE Evidence-to-Decision (EtD) framework373. Previously, the GRADE 
approach has been used to assess the quality and certainty of evidence underpinning CPG 
recommendations. The NCCN CPGs do not currently use the GRADE approach, or any 
similar framework, rather they seem to rely on guideline development member assessments 
of the quality of evidence. The NCCN members assess the quality of evidence over certain 
domains, but in an effort to improve the objectivity, applicability, and comparability of 
NCCN recommendations, we recommend adopting the GRADE approach. Concurrent 
adoption of the GRADE EtD framework would ensure the incorporation of patient values 
and preferences in all recommendations. 
 Additional, minor adjustments to the reporting of NCCN CPGs would improve the 
delivery of oncology evidence. First, stating key research questions that formed the basis 
for treatment recommendations in PICO (Population, Intervention, Comparator, Outcome) 
format would guide physicians through the purpose and scope of the guideline80,375,376. Due 
to how comprehensive the NCCN CPGs are, it may be that listing all PICO-format 
questions is not practical. Should this be the case, we recommend including a section in 
the CPG that clearly describes the scope, limitations, and gaps in the NCCN 
recommendations. A second, related adjustment includes listing the outcomes that were 
most important when developing the CPG recommendations. For example, if efficacy 
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outcomes are the primary basis for the recommendations, or recommending one treatment 
over another, physicians would benefit from that understanding. 
This study has key strengths and limitations. With respect to strengths, we used two 
formally published and peer-reviewed tools to assess the quality of reporting and 
methodological rigor of NCCN guidelines. We further used 3 data extractors to mitigate 
bias in our data analysis. Each author underwent identical, comprehensive training to 
ensure competency prior to data extraction. With respect to limitations, our assessment of 
methodological quality may be limited by a lack of reporting. In other words, simply 
because someone was not reported as having been done, does not mean it was not done. 
For example, it is possible that the views of patients were sought in the formulation of the 
guidelines, but if this was not reported or described, we were forced to assign a low score 
this AGREE-II item low. 
In conclusion, we simultaneously recommend the continued use of NCCN CPGs to 
guide oncologists in patient care and efforts to improve the weaknesses we identified in 
this study. Each guideline contained strengths and weaknesses, and improving the 
weaknesses will enhance the applicability and comparability of the recommendations. We 
have outlined key recommendations that would improve the completeness of reporting and 
increase transparency. These recommendations include the adoption of the GRADE and 
GRADE-EtD approach, describing key questions in PICO format, and sorting which 
outcomes were important when developing recommendations. We believe that adopting 
these recommendations will not only improve the NCCN CPGs, but oncology clinical care 





DISCUSSION AND CONCLUSION 
 
The aforementioned 10 studies investigated various forms of bias, transparency, 
and reproducibility in oncology clinical trials, SRs, and CPGs. All studies involved top-
ranked journals, prestigious CPGs, or highly-regarded studies. Key results from each 
study are summarized in Table 15. In-depth discussions and conclusions were included in 
prior chapters, which leaves room for a discussion of how all these studies fit together 
and how the results may be interpreted together to improve the rigor and reproducibility 
of cancer medicine evidence. In particular, the various forms of bias and irreproducibility 
that have been discussed likely contribute to hype, financial toxicity, and other practices 
that do not align with what patients may expect from their oncologist. Namely, patients 
likely expect impartiality and strong critical appraisal from their oncologist and from the 
oncologists who recommend medications. Based on the results presented above, it is 
likely that an oncologist’s ability to make evidence-based decisions is more difficult in 
light of various forms of bias, lack of transparency, and lack of understanding inherent to 
the design, conduct, and reporting of oncology research. In other words, the state of 
oncology research is such that if one wants to offer strong critical appraisal, they will 
likely meet roadblocks — known and unknown — that make their pursuit more difficult. 
First, it is prudent to discuss clinical trials, since trials are the most important 
primary study in oncology. Like all medical research, oncology research contains barriers 
to fully trustworthy, translatable results. Such barriers may be likened to “random error”, 
while other barriers, based on the results presented in this dissertation, are more 
systematic. Namely, the high prevalence of conflicts of interest with the pharmaceutical 
industry is more likely to be a systematic error in oncology research than a random one. 
Chapter V shows that approximately 75% of included oncologist-authors had financial  
135 
 
relationships with industry and that approximately 40% of those authors did not disclose 
all of their conflicts of interest. The pattern that emerged from that data is one of 
inattention to detail, rather than overt deception.  After all, these authors are likely aware 
of the Open Payments database , so if these authors were trying to hide their financial 
relationships, they would be unable to do that job well.  
Chapter & Brief Title Key results 
III. Reporting guidelines in 
oncology journals 
16/21 journals use CONSORT; 16/21 journals mention trial registration 
Journal mention of CONSORT increased use of CONSORT, although the effect 
was imprecise 
Mentioning trial registration did not seem to affect trial registration rates 
IV. Reporting of oncology 
trial interventions 
Reporting of trials leading to FDA-approval is largely homogeneous, with key 
deficits 
Targeted focus on the details of trial centers, intervention administrators, and 
compliance assessments would improve the reporting and translation of trial 
findings 
V. Financial conflicts of 
interest in trials 
Oncology trial authors often have high-dollar, undisclosed conflicts of interest 
NEJM, Lancet Oncology, and Lancet Haematology had the highest proportion of 
authors with undisclosed conflicts of interest 
VI. Spin in trials 
46/124 clinical trials had spin in the abstract, most often in the conclusions by 
ignoring overall survival data 
There was no difference in the rate of spin when overall survival was a primary or 
secondary endpoint, indicating that spin is used for different reasons across trials 
VII. Interim analyses 
Interim analyses with surrogate endpoints are overwhelmingly statistically 
significant, while final results with overall survival are more often nonsignificant 
Interim analyses generate more hype and attention than final analyses 
Many interim analyses use surrogate endpoints that are not valid predictors of 
survival 
VIII. Selective outcome 
reporting in advertisements 
Advertisements often exclude unfavorable secondary outcomes, while including 
favorable ones 
Advertisements often air or print before final overall survival data is published 
Advertisements may contribute to hype and biased prescribing of drugs based on 
preliminary data alone 
IX. Quality of noninferiority 
trials 
Poor design and methods were common in included trials 
Notably, confidence intervals and P-values were not consistent, justification for the 
margin was absent, and per-protocol analyses were omitted 
X. Reproducibility of 
oncology meta-analyses 
Only approximately 65% of meta-analyses were reproducible at face value 
The majority of non-reproducible meta-analyses were presented in table form, 
rather than figures 
Key omissions included how missing and unpublished data were handled, what 
summary statistic was used, 
XI. Risk of bias and reporting 
quality in systematic reviews 
Only 3 colorectal systematic reviews were at low risk of bias 
Bias was most common in protocols, eligibility, and study identification domains 
Overall, adherence to PRISMA was good, with no difference between reviews that 
mentioned and did not mention PRISMA, indicating well-defined standards for 
reporting throughout the systematic review community 
XII. Reporting and quality of 
practice guidelines 
NCCN guidelines have strong guidance for conflicts of interest, clearly describe 
recommendations, and clearly define important subgroups 
These guidelines lack involvement of patient stakeholders, consideration of cost, 
and a clear description of how uncertainty was adjudicated in the evidence base 




Trying to explain the inattention in disclosing conflicts of interest is difficult, but 
it is likely that journal response to undisclosed conflicts of interest contributes to author 
inattention. Despite journals having access to the same data we used to check the 
disclosure accuracy, Chapter V shows that authors consistently did not disclose all 
conflicts, and complete accuracy was not verified. No public corrections had been made 
to disclosures at the time of our study. Many even believe that close working 
relationships with industry are advantageous for patients and physicians alike235. Drug 
firms have a near-monopoly on clinical trials now because of the immense global cost to 
bring a drug to market. Oncologists who publish these trials often see an increase in the 
amount of money they receive as a result of their financial relationships, per our 
preliminary findings in Chapter V.  This system creates numerous incentives for key 
opinion leaders in oncology to praise any positive finding, because one’s career and 
financial status advances as more trials are published.  
For oncologists who see patients, rather than only conducting clinical trials, there 
is ample evidence that financial relationships with industry affect physician behavior. The 
strongest evidence worth discussing is from the National Bureau of Economic Research, 
whose 2020 publication using Medicare Part D data showed that physicians who receive 
money from industry for a drug are more likely, for a time after receiving money, to 
prescribe that drug compared to unpaid physicians154. The efficacy of the drug for which 
payment was received did not explain the differential prescription. Over time, if paid 
physicians remained unpaid, their prescribing habits fell back in line with physicians who 
had been unpaid all along. Other relational and prescribing habits were also observed that 
could add to the deleterious effects on patients. The drug firms were found to change 
their advertising and payment campaigns to physicians when generic drug competition 
began, by advertising new formulations, such as an extended-release version of the 
branded drug. Altogether, payments from industry, even in the form of food or drug 
samples, are likely to benefit oncologists in clinical practice just like they do clinical 
trialists. In addition, these payments to physicians are not benign for patients and likely 
contribute to financial toxicity and strain on the healthcare economy.  
 Financial conflicts of interest do not only affect the interpretation, critical 
appraisal, and translation of clinical trials to patient care: they also affect CPGs. A 
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seminal paper in oncology research was published in 2016 and described the extensive 
conflicts of interest held by oncologists-authors of NCCN guidelines. These guidelines, 
as previously mentioned, are the most widely recognized and influential guidelines in the 
United States. These guidelines made zero mention of patient values and preferences 
when formulating guideline recommendations which is problematic for several reasons. 
First, at face value, this strategy is unlikely to result in recommendations that align with 
what patients want. Second, the omission of patient values and preferences means that the 
only potential external influences on oncologist-authors are ones from their social and 
academic circles, which is composed of drug firm sponsors and fellow authors who likely 
have strong ties to drug firms. Last, patients with cancer have to navigate financial6, 
physical377, social378, and psychological harms379 in the face of a potentially terminal 
disease. With rapid development of novel cancer therapeutics, the toxicity profile of 
standard cancer therapy has dramatically changed and the messaging around these 
changes is that the new drugs are less toxic when in fact the toxicities are just different. 
Older cancer therapies were administered in cycles, with off weeks scheduled in advance 
where patients would not receive any medications. The weeks with medication were 
difficult, sometimes requiring proactive hospitalization to combat expected harms380. 
Older chemotherapy regimens were more likely to cause higher-grade toxicities381, but 
were given in cycles, rather than continuously. Novel cancer treatments have lesser-grade 
toxicity profiles, but are sometimes given daily, which raises the question of which is 
preferable: higher-grade toxicity less often or lower-grade toxicities daily? The decision 
and cost considerations may be different for individuals, but no such preferences were 
considered in NCCN guidelines. This omission appears ominous when one considers that 
the new medications that are often favored in the NCCN guidelines are ones for which 
oncologist-authors have received extensive payments from drug firms and cost 
significantly more for patients and the healthcare economy.  
The NCCN guidelines are unique in that they are one of 5 guidelines that 
comprise the Centers for Medicare and Medicaid services (CMS) compendium, which 
means that anything recommended in the NCCN guidelines — FDA-approved or not — 
must be reimbursed by CMS89. This creates a strong incentive for a company’s drug to be 
included in the NCCN guidelines. Given what is known about financial relationships with 
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industry and changes in prescribing practices, it is no wonder that a recent analysis of 
NCCN guidelines found that NCCN guidelines recommended a cohort of 47 novel drugs 
for 113 indications when only 69 indications were approved by the FDA48. Such “off-
label” recommendations give patients and oncologists more treatment options, which is a 
strategy lauded by the FDA3, but may decrease the value of each drug on average. To 
understand this over-recommendation and why it is unlikely to help patients, it is 
important to understand how oncology trials are designed. It is common for an oncology 
trial to have 2 primary endpoints: a surrogate endpoint and clinical endpoint. The trial is 
designed to accrue patients and outcome events until both endpoints are fully powered, 
but the surrogate endpoint accrues events faster, resulting in data that is mature more 
quickly. These mature data are then published and generate much hype, attention, and 
acclaim for authors. This phenomenon is described in Chapter VII. The reason this 
strategy took hold in oncology research is because of the long-recognized problem that 
patients are dying from terminal cancer every day, and that clinical trials take years. This 
traditional delay from preclinical tests to three phases of clinical trials to market 
authorization is designed by the FDA to protect patients from unsafe or ineffective drugs. 
This delayed regulatory pathway came under scrutiny during the AIDS epidemic in the 
1990s when patients were dying rapidly, with promising drugs available, but not studied 
to the satisfaction of the regulatory agencies382. The solution was to create a novel 
regulatory pathway — Accelerated Approval — where drugs that were reasonably likely 
to predict clinical benefit, based on data from surrogate endpoints, could be approved for 
market use383. The caveat is that these drugs would have to show clinical benefit in a 
follow up trial within 3 years. A recent analysis of oncology drugs showed that early 
publications with surrogate endpoint data are only 11 months faster on average than trials 
that waited for OS data57. Those 11 months are meaningful, but a far-cry from the multi-
year estimates many advocates of surrogate endpoints tout. This 11-month estimate is 
low enough that it raises questions about whether an unintentional loophole was created 
by the FDA. After accelerated approval, the 3-year countdown for drug firms to submit 
confirmatory data with OS to the FDA starts. If the average trial is only delayed by OS by 
11 months, that means some drugs may remain on the market for 2 additional years 
before submitting OS data, which if negative may result in removal of market 
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authorization. Constant and careful review of FDA drug policy is necessary to ensure that 
the system works in the best interests of patients, rather than drug firms.  
It is plainly clear that surrogate endpoints are often poor predictors of patient-
centered endpoints. This data is based on multiple SRs and meta-analyses that studied the 
correlation of surrogate endpoint with OS and quality of life results61,62,64. Despite that, 
surrogate endpoints are used by the FDA and relied upon by NCCN guideline authors to 
approve or recommend novel drugs for patient care. As shown in Chapter VII the 
oncologists hype early results with only surrogate endpoint data, as it may be a widely 
held belief that surrogate endpoints are truly meaningful. It is possible that these 
surrogate endpoints are favored by the drug firms as well. After all, it is known that 
surrogate endpoints do not predict clinical benefit, but positive surrogate endpoint results 
is the key to market approval and recommendation by the FDA and NCCN, which can 
result in billion-dollar profits in a matter of years384. Drugs are rarely removed from the 
market for failing to demonstrate clinical benefit after accelerated approval, but even if 
they were, the three-year window in which drug firms must present confirmatory data to 
the FDA is enough time to make a profit on the drug. As a result, there is no incentive for 
for-profit drug firms to avoid surrogate endpoints when designing their trials. This system 
also makes it difficult for everyday oncologists to be skeptical in their clinical practice 
about new treatments. In a hypothetical scenario where an oncologist chose to not 
prescribe a novel therapy to a patient who dies because of his or her belief that surrogate 
endpoint data is not sufficient, the malpractice lawsuit would focus on the fact that the 
experts in the field — authors of NCCN guidelines — recommended the drug. The social 
pressure to conform is likely immense, and surrogate endpoints present one of the most 
challenging problems in oncology research  
In addition to the problems that surrogate endpoints present to physicians in terms 
of being a barrier to independent critical appraisal and pursuits of maximal clinical 
benefit, surrogate endpoints present a problem for patients as well. It is unlikely that 
patients fully understand the difference between a surrogate endpoint and a clinical 
endpoint. This belief is based on a recent SR of patient values and preferences in regards 
to surrogate endpoints in cancer drug data58 which found inconclusive results, due to 
inaccuracies in how the authors of included studies described surrogate endpoints to 
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patients. If the authors were not able to define a surrogate endpoint to patients, it is 
unlikely that patients could define these endpoints themselves. This represents a barrier in 
oncology research to patient health literacy and self-efficacy. Some have called for a 
renaming of some surrogate endpoints, like PFS385 which is a composite endpoint of time 
to tumor growth by 20%, development of new tumor lesions, or death — whichever 
occurs first114. Unsurprisingly, the former two items occur more quickly than the latter 
one, which means that PFS is hardly a measure of survival at all. In the aforementioned 
SR of 15 investigations of patient values and preferences toward surrogate endpoints, 
oncologists omitted the following items to patients: 1) that PFS may not predict OS 
(10/15), 2) that progression may not affect how you feel (10/15), and 3) that progression 
does not mean treatment is needed (14/15). Data from patients in these studies is likely 
wasted because it fails to capture opinions that are meaningful, since the opinions were 
based on a faulty definition of the endpoint. 
Beyond clinical trials in journals and guidelines, oncology drug advertisements 
are a significant barrier to proper critical appraisal for patients and physicians. In Chapter 
VIII we describe how oncology advertisements selectively reported their efficacy 
endpoints based on statistical significance. The implication is that mostly positive results 
are being conveyed to patients and physicians in advertisements. Our findings fit within 
what is known about potential harms of drug advertisements, which include potentially 
misleading patients,282,283 exaggeration of drug benefits,284,285 omissions regarding quality 
of life,286 and increased healthcare spending279,280. Empirical data for how advertisements 
affects physicians is unclear, but from what is known about how interactions with 
industry affect physician behavior, it is within reason to believe that misleading 
advertisements will similarly affect physician behavior. The strategy for these 
advertisements appears to be to fully accrue patient data for a surrogate endpoint, submit 
for FDA Accelerated Approval, receive said approval, and market the drug based on the 
preliminary data which is overwhelmingly favorable. A significant proportion of 
advertisements reviewed did not mention OS or were made public while OS data was 
accruing. As mentioned above, patients may not know the difference between a surrogate 
endpoint and a clinical endpoint, while doctors may be swayed because these 
advertisements are a form of industry interaction. The selective outcome reporting 
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evident in these advertisements follows what has been shown in previous work on breast 
cancer-related toxicities185 and oncology trials as a whole189. Selective outcome reporting 
is one form of misinterpretation of research findings that is endemic to medical research 
and oncology research alike. 
There are other ways in which authors of oncology trials spin their research 
findings to misrepresent what was found. We studied this in a cohort of 124 oncology 
clinical trials that measured both a surrogate endpoint and OS. This study confirmed that 
oncology trial authors misrepresent their research findings, even in major oncology 
journals that exert a strong influence on clinical practice. How spin was used by authors 
in the included studies indicates one worrisome conclusion: oncology trial authors 
emphasize OS or surrogate endpoints - whichever is most favorable. The evidence for 
this is that when OS was a primary endpoint, spin was more common when the data were 
unfavorable. On the other hand, when a surrogate endpoint was the primary endpoint, 
spin was almost always used to ignore fully-mature, nonsignificant OS data. These 
oncology trials enroll patients until the surrogate endpoint and OS are fully powered, so 
the use of “primary” and “secondary” endpoint is different than in other forms of research 
where only the primary endpoint is the basis for the sample size calculation. In reality, 
these trials have 2 primary endpoints, one of which they call secondary, and when that 
“secondary” endpoint is not favorable, they dismiss that data in the abstract. This would 
not be impactful if the “secondary endpoint” that they were dismissing was a surrogate 
endpoint or something else that is of little clinical importance to patients. Given that there 
are 2 endpoints in oncology that truly matter to patients — OS and quality of life — it is 
worrisome that a pattern has emerged in oncology research where publication in a top-tier 
journal is possible without patient-centered data. This is akin to a cardiology trial 
dismissing unfavorable results for major adverse cardiac events to highlight that 
symptomatic angina was improved. Angina is important, like delayed tumor growth is 
important, however if patients were queried, one will expect that they care more about 
living longer and living better, which is best accomplished by reducing risk of heart 
attack, stroke, and death386. Spin, if it continues to pervade the oncology literature, will 
not only affect perceptions of oncology drug efficacy52, but also continue to indicate that 
there is no clear mechanism to curtail the number of drugs that are approved for market 
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use off surrogate endpoints that fail to demonstrate commensurate benefits in patient-
centered endpoints203. Such a bias in oncology research will have downstream effects on 
patient care.  
Biases previously discussed have been long-standing issues in oncology research. 
The increasing popularity of noninferiority trials presents new issues for oncology 
research. Based on our analysis, there is a lack of understanding of what constitutes a 
rigorous noninferiority clinical trial. In many ways, traditional knowledge about clinical 
trials is flipped for noninferiority trials. In particular, the intention-to-treat analysis may 
actually introduce bias, rather than prevent it387. One-sided P values may be used to 
determine statistical significance, which may create asymmetry if the width of the two-
sided confidence intervals used for hazard ratios is not carefully reviewed. However, the 
design item with the most potential for harm is the noninferiority margin. These margins 
are meant to preserve a portion of the active control effect, such that the new treatment is 
still moderately effective while offering other benefits, like lower cost or toxicity388. 
Concerns about inappropriate noninferiority margins were discussed in the approval of 
lenvatinib, whose margin at face value may have seemed appropriate if one did not 
critically appraise the trial on which the margin was based311. Such an example, discussed 
at length in Chapter IX, highlights the fact that the effect of bias on the practice of 
medicine can multiply as future research is conducted.  
Meta-analyses have been the prototypical example of how bias and lack of rigor 
can ripple through multiple generations of research studies. The catch-phrase for how 
meta-analyses can multiply bias is “garbage in, garbage out”389. It is possible that even if 
risk of bias evaluations are conducted for primary studies in SRs, that primary studies 
could be biased. For example, risk of bias evaluations may fail to capture the problems 
that plague sorafenib for the treatment of hepatocellular carcinoma312, such as the fact 
that the trial’s inclusion criteria did not match real-world patients who are older, more 
sick, and less physically capable312. Additional concerns arise from the SR itself, rather 
than the included trials. In Chapter XI we describe how the SRs cited by NCCN 
guidelines were explicitly at high risk of bias or under suspicion for bias due to lack of 
clear reporting of methodological items. Specifically, basic principles for good science 
were not followed like publication of a protocol and broad database searches. The latter 
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omission means that the sample of studies included in the SR may be biased toward a 
more favorable effect, given what is known about published studies and statistical 
significance78. The former omission is a barrier to critical appraisal and the 
reproducibility of oncology SRs. The inability for independent oncologists to verify the 
rigor of SRs is worrisome, and this worry is compounded by the fact that all the SRs we 
evaluated were cited by the NCCN guidelines. Recall, the NCCN guidelines are the 
premier set of oncology guidelines in the United States and are one of the five 
compendium guidelines for the Centers for Medicare and Medicaid services. 
Irreproducible SRs force implicit trust of the findings presented and from what is known, 
these findings are potentially skewed. 
To reproduce an SR is theoretically much easier than a clinical trial. To fully 
reproduce a clinical trial, one would have to re-enroll a new set of patients and recreate 
the same conditions as the original trial. For an SR, one would only have to 
independently search for studies, extract data, and synthesize results. Some of these steps 
may be skipped if the search strategy is robust at face value and data are fully available. 
Reproducing the synthesis of findings, called computational reproducibility390, requires at 
minimum the event rates and sample size to be presented in a meta-analysis. By these 
numbers, one can calculate effect sizes, then reproduce the model characteristics 
specified by the study authors. We found in Chapter X that even this low-level version of 
reproducibility was not feasible in a significant portion of meta-analyses included in SRs 
cited by NCCN guideline authors. Data were made publicly available once, and protocols 
were rare, confirming what was found in Chapter XI. Moreover, key methodological 
items that would be necessary knowledge if one were to go through the process of 
reproducing database searches and data extraction were missing. In other words, while 
words were written to describe the SR and meta-analytic methods, these studies were 
really a black box, where the process of how the final results were calculated is unknown. 
If data were available, this would not be a concern because availability of data is a crucial 
step to allow the inference of how data extraction was conducted. However, as previously 





What can be done in the future to improve the rigor and reproducibility of 
oncology research? Based on the findings presented in this dissertation, advancements in 
5 areas are proposed. 
First, the easiest way to start re-structuring oncology research to work in the best 
interest of patients is to commit to improved reporting practices and transparency in 
clinical trials, SRs, and CPGs. Chapters III and IV describe how there are gaps in journal 
policies for submitting authors to follow reporting guidelines. CONSORT guidelines, for 
clinical trials, have been shown to increase the completeness of clinical trial reporting in 
major medical journals,391 and many aspects of CONSORT have now woven themselves 
into medical research practices. For example, the simple addition of “randomized 
controlled trial” to the title of papers has improved the indexing of clinical trials, which 
facilitates more robust SRs and meta-analyses392. Other CONSORT items, like 
publication of a protocol and statistical analysis plan are commonplace now. CONSORT 
was so successful in highlighting good and bad reporting practices that researchers 
eventually developed the TIDieR checklist to narrow the reporting focus on trial 
interventions206. Our analysis of oncology trials using the TIDieR checklist found that the 
major important components of interventions were described well, but items that would 
facilitate translation to all types of oncology practices were absent. Evidence suggests a 
difference in patient outcomes between academic centers where clinical trials are 
conducted216, and community oncology clinics, where the majority of oncology care 
takes place217,218. Small shifts in how protocols are structured to better report trial 
methods would allow oncologists and other researchers an insight into what differences 
may be contributing to different outcomes for patients treated outside a clinical trial. 
Altogether, none of the aforementioned improvements in reporting will be as influential 
in shifting the landscape of oncology research as advancements in open data. The open 
science movement has advocated for publicly-available, open data to improve the 
reproducibility and translation of clinical evidence to practice132. Much of the trial data in 
oncology is proprietary and owned by pharmaceutical companies who sponsor trials. 
While these companies offer access to data through an application, significant barriers 
exist to being approved and using the data393. The goal of open data is not to simply hunt 
down errors that led to false results, but also to allow for better meta-analyses based on 
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individual patient data that are tailored to specific populations that one sees on a daily 
basis. If a global trial is majority white individuals from the USA and UK, an Indian 
oncologist may wish to exclude these patients to determine the effect size on those 
individuals in his/her country. Without open data, there will continue to be a reliance on 
what is believed to be true, rather than a more precise estimate based on data with a 
narrow focus.  
Second, oncology research must expand its focus on patient values. A recent 
analysis of the mean survival gain of oncology interventions found a 2.1-month average 
increase116. In such cases where the OS benefit is low or zero, quality of life becomes the 
default patient important endpoint to which trial sponsors and regulatory agencies can 
turn to determine if a drug improves patient outcomes. Multiple studies suggest that the 
prevalence of favorable quality of life results in cancer clinical trials ranges from 40-
50%394,395. Unfortunately, a recent retrospective study of cancer drugs approved by the 
European Medicines Agency found that only 7/68 (10.3%) approved drugs between 2009 
and 2013 had favorable quality of life data at the time of market approval395. Even worse, 
an analysis of quality of life assessments found that quality of life is often only measured 
during the time the intervention is given in the clinical trial setting, rather than until 
patient death396. This same study showed that most studies reporting quality of life until 
death showed that the intervention had worse quality of life than the control. It may be 
that the details of how long we measure quality of life can be set aside for now, since the 
logical first step is increasing oncologist reliance on quality of life as an outcome of 
interest for patient care. Our analysis of the reporting of NCCN guidelines showed that 
no explicit inclusion of patient-values and preferences was identified. A recent SR found 
that oncologist consideration of patient values and preferences was a facilitator of shared 
decision making, while poor physician communication was a barrier397. Given the NCCN 
guidelines’ reputation for guiding the oncology community, it is recommended that 
leadership in patient-centered care begin at the NCCN guideline level. These guidelines 
may begin by consulting patients, patient advocates, and psycho-oncology specialists to 
determine whether recommended treatments align with patient values related to efficacy, 
cost, and toxicity.  
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Third, it is important that oncologists are clear and precise when they discuss drug 
efficacy. Surrogate endpoints measure drug activity, such as whether a drug can 
temporarily slow tumor growth114. These surrogate endpoints do not measure survival, 
and their inability to reliably predict survival demonstrates how many factors — cancer-
related and not — contribute to a patient’s survival. When oncologists recommend a drug 
in a guideline based on surrogate endpoint data, there needs to be an understanding that 
this data is not final, and that there is likely a significant degree of imprecision to be 
expected with respect to patient outcomes. No such nuance is conveyed by key opinion 
leaders in oncology, as evidenced by the degree of hype and attention that surrogate 
endpoint results obtain versus the subsequent OS (Chapter VII). There is no strong 
evidence that patients understand the difference between PFS and OS58. The over-
reliance on surrogate endpoints is not solely the fault of oncologists themselves. The drug 
firms who sponsor clinical trials make full use of the FDA’s accelerated approval system. 
The majority of new drugs receive initial approval from a surrogate endpoint, and this 
proportion is increasing3. In the first three years of market approval, many of these drugs 
will garner million, even billion, dollar profits for the drug firms398. In the worst-case 
scenario, where the FDA revokes market authorization based on insufficient confirmatory 
data, drug firms who obtain accelerated approval will still be profitable. The system, 
which began as a way to give patients access to novel drugs for a disease with no 
available treatments, is now being used to give patients additional treatment options that 
are costlier than ever, with no known benefit on survival or quality of life.  
Fourth, the oncology profession must disincentivize financial relationships with 
drug firms and reward divestiture. The evidence that FCOI acutely affects physicians 
prescribing habits is overwhelming154,223,399. These habits shift toward more costly drugs 
with unclear advantages. For some medical treatments, these shifts are less meaningful, 
and may not result in much harm to patients or strain on the healthcare economy. For 
example, there is flexibility in which long-acting inhalers to prescribe to a patient, and 
costs are not much different400. Cancer drugs may vary in price by tens of thousands of 
dollars and may have very different toxicity profiles. Patients with cancer are a 
vulnerable population who may be facing imminent death, body changes, and other 
psychosocial harms401. Thus, external influences that affect medical decision making 
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become less ethical and more harmful. Efforts to mitigate FCOI require reforms at 
multiple levels. Journals and CPG organizations must enforce FCOI policy and adhere to 
best practices88. Institutions must reward unbiased scientific practice402. Until the patient 
is the only external influence that affects clinical decision making, oncology research and 
practice may fail to capture patient values and preferences for cancer treatment.  
 
Overall, there have been a number of significant advances in the treatment of 
cancer in the United States and around the globe. Identification of novel mechanisms or 
signaling pathways and drugs that target those mechanisms or pathways have resulted in 
dozens of new therapies for patients in previous decades. Knowing the true effect that 
these interventions have on patient outcomes is contingent on the rigor and 
reproducibility of oncology evidence. Whether the oncology community continues to 
reinforce a commitment to robust critical appraisal of new evidence is contingent on its 
ability to remain unbiased from external influences, such as financial relationships with 
drug firms. Improvements in research reporting, data availability, selection of trial 
endpoint, solicitation of patient values, and drug approval regulations will all be critical 
to the future success of oncology research. The success of cancer treatment should not be 
measured by the number of treatment options or degree of hype around novel therapies, 
but rather by whether patients are informed, understood, and empowered to trust that 
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Table 16. Additional characteristics of included clinical trials. 
Characteristic No. (%) 
Journal 
New England Journal of Medicine 40 (41.7%) 
Lancet: Oncology 23 (24.0%) 
Journal of Clinical Oncology 12 (12.5%) 
Lancet 8 (8.3%) 
Blood 4 (4.2%) 
Leukemia 2 (2.1%) 
Lancet: Haematology 2 (2.1%) 
JAMA Oncology 2 (2.1%) 
Haematologica 2 (2.1%) 
European Journal of Cancer 1 (1.0%) 
Funding Source 
Industry 83 (86.5%) 
Mixed 
Partial industry 9 (9.4%) 
No industry 1 (1.0%) 
Public 2 (2.1%) 
Private 1 (1.0%) 
Group assignment 
Randomized 60 (62.5%) 
Single arm 32 (33.3%) 
Nonrandomized (2+ arms) 4 (4.2%) 
Blinding 
Double blind 28 (29.2%) 
Open label 68 (70.8%) 
Trial phase 
1 9 (9.4%) 
1/2 (combined) 5 (5.2%) 
2 26 (27.1%) 
3 56 (58.3%) 
Hypothesis 
Superiority 57 (59.4%) 
Non-inferiority 3 (3.1%) 




Table 17.. General characteristics of systematic reviews underpinning the NCCN guidelines. 
Characteristic No. (%), All = 154 
Year of Publication 
 
2011 11 (7.1%) 
2012 31 (20.1%) 
2013 29 (18.8%) 
2014 22 (14.3%) 
2015 41 (26.6%) 
2016 15 (9.7%) 
2017 4 (2.6%) 
2018 1 (0.6%) 
Median number of meta-analyses 14 (IQR 7.25 - 29.75) 
Any subgroup analyses reported 96 (62.3%) 
Any sensitivity analyses reported 66 (42.9%) 
Sources of Funding 
 
Public (e.g., government) 36 (23/.3%) 
Private (e.g., foundation) 14 (9.1%) 
Hospital 10 (6.5%) 
Industry 5 (3.2%) 
None 76 (49.4%) 
No statement 23 (14.9%) 
Number of Cochrane reviews 18 (11.7%) 
Number that adhered to PRISMA 60 (39.0%) 
186 
 
Table 18. Characteristics of each index meta-analysis. 
Characteristic All = 154 PRISMA (n = 60) 
non-PRISMA 
(n = 94) 
Type of outcome    
 
All-cause mortality 73 (47.4%) 29 (48.3%) 44 (46.8%) 
Comorbid event 21 (13.6%) 7 (11.7%) 14 (14.9%) 
Recurrence of disease or therapy 10 (6.5%) 4 (6.7%) 6 (6.4%) 
Disease response 10 (6.5%) 3 (5.0%) 7 (7.4%) 
Cause-specific mortality 8 (5.2%) 4 (6.7%) 4 (4.3%) 
Composite endpoint which includes mortality 8 (5.2%) 1 (1.7%) 7 (7.4%) 
Length of hospital stay or operative time 6 (3.9%) 4 (6.7%) 2 (2.1%) 
Patient-reported outcome 6 (3.9%) 0 (0.0%) 6 (6.4%) 
Other physician assessed endpoint 12 (7.8%) 8 (5.2%) 4 (4.3%) 
Described primary endpoint 88 (57.1%) 31 (51.7%) 57 (60.6%) 
Median included studies 8 (IQR 5 - 12) 8 (IQR 5 - 11.25) 7 (IQR 4 - 12) 
Median included patients 1,914 (IQR 917 - 3,941) 
1896 (IQR 
965 - 3883) 
1932 (IQR 891 
- 3958) 
Effect measure  
 
Hazard ratio 58 (37.7%) 23 (38.3%) 35 (37.2%) 
Odds ratio 40 (26.0%) 14 (23.3%) 26 (27.7%) 
Risk ratio 35 (22.7%) 14 (23.3%) 21 (22.3%) 
Event rate 9 (5.8%) 3 (5.0%) 6 (6.4%) 
Mean difference 7 (4.5%) 5 (8.3%) 2 (2.1%) 
Response rate or median survival 3 (1.9%) 1 (1.7%) 2 (2.1%) 
Standardized mean difference 2 (1.3%) 0 (0.0%) 2 (2.1%) 
Random-effects model used 91 (59.1%) 43 (71.7%) 48 (51.1%) 
Reported a subgroup analysis 79 (51.3%) 40 (66.7%) 39 (41.5%) 
Reported a sensitivity analysis 54 (35.1%) 23 (38.3%) 31 (33.0%) 
187 
 
















Ahmad, 2013 Unclear Unclear Unclear High Unclear 
Amelung, 
2015 High Unclear High Unclear High 
Ardekani, 201 Unclear Unclear Unclear High Unclear 
Arezzo, 2013 Low Unclear Low Low Low 
Belum, 2013 High High High Unclear High 
Berry, 2015 Unclear Unclear Unclear High Unclear 
Böckelman, 
2015 Unclear Unclear Unclear Unclear Unclear 
Botrel, 2016 Unclear Unclear Unclear Unclear Unclear 
Bujko, 2015 High High Unclear Unclear High 
Chang, 2015 High High Unclear High High 
Chung, 2011 Low High High Unclear Unclear 
Ciliberto, 
2012 High High Unclear High High 
Dahabreh, 
2011 Low High Unclear Unclear Unclear 
Dai, 201 High High Unclear Unclear High 
Di, 2013 High High Low High High 
Elwood, 2016 Low Low Unclear Unclear Unclear 
Filippo, 2015 High High High High High 
Guo, 2016 High High High Unclear High 
Hofheinz, 
2016 High High Unclear High High 
Huang, 2014 Unclear Unclear Unclear Unclear Unclear 
Huang, 2014 Unclear Unclear Unclear Unclear Unclear 
Jiang, 2015 High High Low Unclear High 
Kidane, 2015 Unclear High Unclear Unclear Unclear 
Lim, 2016 High Unclear Unclear High High 
Liu, 2014 High High Unclear High High 
Lu, 2015 High Unclear Unclear Unclear Unclear 
Lv, 2013 Unclear Unclear Unclear Unclear Unclear 
Macedo, 
2012 Unclear Unclear High Unclear Unclear 
Matsuda, 
2015 Unclear Unclear Unclear High Unclear 
Mirnezami, 
2013 High Unclear Unclear Unclear Unclear 
Ohtani, 2012 Unclear High Unclear Unclear Unclear 
Petersen, 
2012 Unclear Unclear Unclear Unclear Unclear 
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Petrelli, 2012a High High Unclear Unclear High 
Petrelli, 2012b Unclear High Unclear Unclear Unclear 
Petrelli, 2013 High High Unclear Unclear High 
Pietrantonio, 2015 High Unclear Unclear Unclear Unclear 
Pita-Fernández, 2015 Unclear Unclear Unclear Unclear Unclear 
Qu, 2015 Unclear High High Unclear High 
Rahbari, 2012 Unclear Unclear Unclear Unclear Unclear 
Rahbari, 2013 Unclear Unclear Unclear High Unclear 
Ranpura, 2011 High Unclear High Unclear Unclear 
Rokkas, 2016 High High Unclear Unclear High 
Rondelli, 201 Unclear Unclear High Unclear Unclear 
Rowland, 2015 Unclear Unclear Unclear High Unclear 
Sajid, 201 Unclear High High Unclear High 
Schiphorst, 2015 High High Unclear Low High 
Segelov, 2014 Unclear Low Unclear Low Unclear 
Sorich, 2015 High Unclear Unclear Low Unclear 
Theophilus, 2014 Unclear Unclear Unclear Unclear Unclear 
Trastulli, 2012 Unclear Unclear Low Unclear Unclear 
Vennix, 2014 Low Low Unclear Unclear Low 
Wang, 2015 High High Unclear Unclear High 
Wen, 2013 Unclear Unclear Unclear Unclear Unclear 
Whitlock, 201 Low Low Low Unclear Low 
Wu, 2012 Unclear High High Unclear High 
Xiong, 2012 Unclear Unclear Unclear Unclear Unclear 
Xu, 2017 High High High Unclear High 
Zarak, 2015 High High High Unclear High 
Zhang, 2012 High Unclear High Unclear High 
Zhang, 2014 Unclear Unclear Unclear Unclear Unclear 
Zhang, 2015 Unclear Unclear Unclear Unclear Unclear 
Zhao, 2016 High Low Unclear Unclear Unclear 
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Table 20. Adherence to PRISMA items for all individual studies. 
Study Mention adherence to PRISMA PRISMA Adherence (n/N, %) 
Ahmad, 2013 Yes 17/27 63.00% 
Amelung, 2015 Yes 23/27 85.20% 
Ardekani, 201 Yes 19/27 70.40% 
Arezzo, 2013 Yes 26/27 96.30% 
Belum, 2013 No 13/25 52.00% 
Berry, 2015 No 20/27 74.10% 
Böckelman, 2015 No 20/27 74.10% 
Botrel, 2016 No 23/27 85.20% 
Bujko, 2015 No 16/27 59.30% 
Chang, 2015 No 23/27 85.20% 
Chung, 2011 No 18/27 66.70% 
Ciliberto, 2012 No 16/25 64.00% 
Dahabreh, 2011 No 22/27 81.50% 
Dai, 201 No 20/27 74.10% 
Di, 2013 No 19/25 76.00% 
Elwood, 2016 Yes 22/27 81.50% 
Filippo, 2015 Yes 19/27 70.40% 
Guo, 2016 No 17/25 68.00% 
Hofheinz, 2016 Yes 17/27 63.00% 
Huang, 2014 Yes 19/27 70.40% 
Huang, 2014 No 16/25 64.00% 
Jiang, 2015 Yes 22/27 81.50% 
Kidane, 2015 No 23/27 85.20% 
Lim, 2016 No 22/27 81.50% 
Liu, 2014 Yes 21/27 77.80% 
Lu, 2015 Yes 19/27 70.40% 
Lv, 2013 No 21/27 77.80% 
Macedo, 2012 No 19/27 70.40% 
Matsuda, 2015 Yes 20/27 74.10% 
Mirnezami, 2013 Yes 20/27 74.10% 
Ohtani, 2012 Yes 16/25 64.00% 
Petersen, 2012 Yes 20/27 74.10% 
Petrelli, 2012a Yes 23/27 85.20% 
Petrelli, 2012b No 20/25 80.00% 
Petrelli, 2013 No 19/27 70.40% 
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Petrelli, 2015 No 17/25 68.00% 
Pietrantonio, 2015 No 19/27 70.40% 
Pita-Fernández, 2015 Yes 20/27 74.10% 
Qu, 2015 No 15/25 60.00% 
Rahbari, 2012 Yes 24/27 88.90% 
Rahbari, 2013 Yes 21/27 77.80% 
Ranpura, 2011 No 21/27 77.80% 
Rokkas, 2016 Yes 21/27 77.80% 
Rondelli, 201 Yes 22/27 81.50% 
Rowland, 2015 No 20/27 74.10% 
Sajid, 201 No 20/27 74.10% 
Schiphorst, 2015 No 21/27 77.80% 
Segelov, 2014 Yes 18/27 66.70% 
Sorich, 2015 No 20/27 74.10% 
Theophilus, 2014 No 20/27 74.10% 
Trastulli, 2012 No 20/27 74.10% 
Vennix, 2014 No 22/27 81.50% 
Wang, 2015 Yes 23/27 85.20% 
Wen, 2013 No 21/27 77.80% 
Whitlock, 201 No 17/27 63.00% 
Wu, 2012 No 19/27 70.40% 
Xiong, 2012 No 20/25 80.00% 
Xu, 2017 Yes 22/25 88.00% 
Zarak, 2015 No 16/27 59.30% 
Zhang, 2012 No 16/25 64.00% 
Zhang, 2014 No 17/27 63.00% 
Zhang, 2015 No 21/27 77.80% 
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